

CTAD

2025

Clinical Trials on Alzheimer's Disease

December 1-4, 2025
San Diego, CA, United States



FINAL PROGRAM*

* Subject to change.

Montpellier '08 • Las Vegas '09 • Toulouse '10 • San Diego '11 • Monte Carlo '12 • San Diego '13
Philadelphia '14 • Barcelona '15 • San Diego '16 • Boston '17 • Barcelona '18 • San Diego '19 • Virtual '20
Boston '21 • San Francisco '22 • Boston '23 • Madrid '24

www.ctad-alzheimer.com
Email: ctad@ant-congres.com

JPAD
THE JOURNAL
OF PREVENTION
OF ALZHEIMER'S
DISEASE



TABLE OF CONTENTS

Organizing & Scientific Committees	03
Lifetime Achievement Award	04
Keynotes	05
Program at a glance	06
Scientific sessions	07
Monday, December 1	07
Tuesday, December 2	09
Wednesday, December 3	15
Thursday, December 4	20
Poster Presentations	26
Biotech Showcase Session Details	87
Early Career Investigator Showcase Details	90
Practical Details	93

CTAD Organizing Committee and Scientific Committee

Susan ABUSHAKRA (San Francisco, United States); Paul AISEN (San Diego, United States)*; Rebecca E. AMARIGLIO (Boston, United States); Patricia ANDREWS (Nashville, United States); Sandrine ANDRIEU (Toulouse, France)*; Davide ANGIONI (Toulouse, France); Laura D. BAKER (Winston-Salem, United States); Randall J. BATEMAN (St. Louis, United States); Karim BENNYS (Montpellier, France); Ram BISHNOI (Tampa, United States); Kaj BLENNOW (Molndal, Sweden); Merce BOADA (Barcelona, Spain); Marc CANTILLON (Livingston, United States); Maria CARRILLO (Chicago, United States); Mathieu CECCALDI (Marseille, France); Suzanne CRAFT (Winston-Salem, United States); Lucia CRIVELLI (Buenos Aires, Argentina); Jeffrey CUMMINGS (Las Vegas, United States); Steven DEKOSKY (Gainesville, United States); Michael C. DONOHUE (San Diego, United States); Rachelle DOODY (Houston, United States); Bruno DUBOIS (Paris, France); Howard FELDMAN (San Diego, United States); Howard FILLIT (New York, United States); Nick FOX (London, UK); Kristian Steen FREDERIKSEN (Copenhagen, Denmark); Giovanni B. FRISONI (Brescia, Italy); Serge GAUTHIER (Montreal, Canada); Joshua GRILL (Los Angeles, United States); Michael GRUNDMANN (San Diego, United States); Harald HAMPEL (Nutley, United States); Oskar HANSSON (Lund, Sweden); Tobias HARTMANN (Homburg, Germany); Jakub HORT (Prague, Czech Republic); Takeshi IWATSUBO (Tokyo, Japan); Frank JESSEN (Cologne, Germany); Ara KHACHATURIAN (Washington DC, United States); Zaven KHACHATURIAN (Washington DC, United States); Miia KIVIPELTO (Stockholm, Sweden); Yan LI (St. Louis, United States); Jorge J. LLIBRE GUERRA (St. Louis, United States); Constantine G. LYKETSOS (Baltimore, United States); Gad A. MARSHALL (Boston, United States); Adam MECCA (New Haven, United States); Lefkos T. MIDDLETON (London, UK)*; José Luis MOLINUEVO (Valby, Denmark); Kyra O'BRIEN (Philadelphia, United States); Claire PAQUET (Paris, France); Robert PERNECZKY (Munich, Germany); Ronald PETERSEN (Rochester, United States); Elif PINAR COSKUN (Lexington, United States); Michael S. RAFII (San Diego, United States); Rema RAMAN (San Diego, United States); Craig W. RITCHIE (Edinburgh, UK); Robert RISSMAN (San Diego, United States); Marwan SABBAGH (Phoenix, United States); Stephen SALLOWAY (Providence, United States); Pascual SANCHEZ-JUAN (Madrid, Spain); Nikolaos SCARMEAS (New York, United States); Rachel SCHINDLER (New York, United States); Philip SCHELTENS (Amsterdam, NL); Lon SCHNEIDER (Los Angeles, United States); Eric SIEMERS (Indianapolis, United States); Sietske SIKKES (Amsterdam, The Netherlands); Yong SHEN (Hefei, China); Jiong SHI (Hefei, China); Irina SKYLAR-SCOTT (Stanford, United States); Heather SNYDER (Chicago, United States); Maria SOTO (Toulouse, France); Reisa SPERLING (Boston, United States)*; Yaakov STERN (New York, United States); Duygu TOSUN (San Francisco, United States); Jacques TOUCHON (Montpellier, France)*; Maileen ULEP (Las Vegas, United States); Wiesje van Der FLIER (Amsterdam, The Netherlands); Christopher H. VAN DYCK (New Haven, United States); Bruno VELLAS (Toulouse, France); Prashanthi VEMURI (Rochester, United States); Michael W. WEINER (San Francisco, United States)* Donna M. WILCOCK (Indianapolis, United States); Bengt WINBLAD (Stockholm, Sweden); Kirsten WRIGHT (Portland, United States); Jin-Tai YU (Shanghai, China)

*Organizing Committee Member

CTAD 2025

Lifetime Achievement Award

This year the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research, is awarded to Takeshi Iwatsubo MD, PhD in recognition for his pioneering work in Alzheimer's Disease neuroimaging and neuropathology.



Takeshi IWATSUBO

Director of the National Institute of Neuroscience, National Center of Neurology and Psychiatry, Professor of the University of Tokyo.

Chairman of the Japan Society for Dementia Research.

Biography

Trained as a neurologist and neuropathologist, Dr. Iwatsubo has contributed to the study of human neurodegenerative diseases, particularly Alzheimer's and Parkinson's, using multidisciplinary approaches. He demonstrated that Ab42 is the initial species deposited in senile plaque amyloid, elucidated the process of γ -secretase complex formation, and identified phosphorylated α -synuclein as a component of Lewy bodies. He was the Principal Investigator of the Japanese AD Neuroimaging Initiative (J-ADNI) and the Japanese Trial Ready Cohort for Prevention of Alzheimer's Disease (J-TRC), and currently is the PI of the Japanese Registry for AD-DMT. He is the recipient of the MetLife Award for Medical Research (2008), AAIC Lifetime Achievement Award (2010), the Potamkin Prize (2012), and the Medal with Purple Ribbon from the Japanese government (2024).

CTAD 2025

Keynotes



Next Generation Anti-Amyloid Therapies... Shuttling Past the ARIA Risk

Ronald B. DeMattos, PhD, Senior Vice President and Chief Scientific Officer for Neurobiology, Eli Lilly and Company – Indianapolis, IN (United States)

Ronald B. DeMattos, Ph.D. is a Senior Vice President and Chief Scientific Officer for Neurobiology at Eli Lilly. Dr. DeMattos received his doctorate in molecular and cellular biochemistry (SUNY – Stony Brook, 1998) and performed a post-doctoral fellowship at Washington University School of Medicine (Holtzman Lab). Dr. DeMattos joined Eli Lilly in 2002 and has since held multiple scientific positions within Neuroscience Discovery over the last 20+ years. He discovered and developed numerous compounds that progressed to clinical studies in Alzheimer's disease patients, including Solanezumab, Donanemab (FDA-approved Kisunla), and Remternetug (Phase-3 ongoing). He currently leads multiple discovery projects while managing the Indianapolis Neurodegeneration Discovery group, whose mission is to develop novel first-in-class therapies for neurodegeneration and Alzheimer's disease.



Enhancing Participation of Representative Populations in Alzheimer Disease Clinical Trials

Sid O'Bryant, PhD, Principal Investigator of the Health & Aging Brain Study, The University of North Texas Health Science Center at Fort Worth – Fort Worth, TX (United States)

Dr. Sid O'Bryant is the principal investigator of the Health & Aging Brain Study – Health Disparities (HABS-HD), the most comprehensive study of Alzheimer's disease among the three largest racial/ethnic groups in the U.S. ever conducted: African Americans, Hispanics, and non-Hispanic whites. The goal of HABS-HD is to understand the life-course factors—including biological, sociocultural, environmental, and behavioral—that influence Alzheimer's disease risk in later life. This work aims to create population-specific precision-medicine approaches to treat and prevent Alzheimer's disease. Dr. O'Bryant is also a global expert in using blood-based biomarkers to develop precision-medicine strategies for diagnosing and treating Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease in adults with Down Syndrome.



From Real World Data to Clinical Trials: The Case for Investigating Semaglutide in Alzheimer's Disease

Peter Johannsen, MD, PhD, International Medical Vice President, Novo Nordisk, Copenhagen (Denmark)

Dr. Peter Johannsen is a board-certified neurologist with more than 30 years' experience in cognitive neurology and Alzheimer's trials. He joined Clinical Drug Development at Novo Nordisk in 2020. Dr. Johannsen is scientifically responsible for Novo Nordisk's neurology development programs, including Alzheimer's disease. He previously served as senior consultant neurologist at the Memory Clinic, Rigshospitalet, and the National Danish Dementia Research Centre, Copenhagen University Hospital, Denmark, gaining extensive experience from clinical trials in Alzheimer's disease from first-in-human to Phase III. He has published over 100 scientific papers and given more than 300 lectures on Alzheimer's disease treatment. He also served as vice-chairman of the Danish Alzheimer Association and as a board member of the European Alzheimer's Disease Consortium (EADC).

Program at a glance

ALL SESSIONS WILL TAKE PLACE IN THE SAPPHIRE BALLROOM – LEVEL 4

● Monday, December 1

- 3:30 p.m. CTAD25 Welcome Ceremony
- 3:50 p.m. CTAD Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research
- 4:00 p.m. **Introductory Lecture:** Alzheimer's Therapeutics: Past, Present, Future
- 4:20 p.m. **LATE BREAKING COMMUNICATIONS**
- 5:35 p.m. **SYMPOSIUM 1:** Trontinemab's path to Phase III – From proof-of-concept in the ongoing Brainshuttle™ AD study to the pivotal studies TRONTIER 1 and TRONTIER 2 in people with early-stage symptomatic Alzheimer's disease
- 6:15 p.m. **KEYNOTE 1:** Enhancing Participation of Representative Populations In Alzheimer Disease Clinical Trials
- 6:45 p.m. CTAD WELCOME RECEPTION with the Support of the Alzheimer's Association • Sapphire Foyer – Level 4

● Tuesday, December 2

- 7:35 a.m. **POSTER WALKING TOUR** • Indigo Ballroom – Level 2
- 8:35 a.m. **LATE BREAKING SYMPOSIUM 1:** The Global Neurodegeneration Proteomics Consortium: additional insights into ApoE, cellular aging clocks from the V1 Harmonized Dataset, and what's coming in V2
- 9:15 a.m. **KEYNOTE 2:** From Real World Data to Clinical Trials: The Case for Investigating Semaglutide in Alzheimer's Disease.
- 9:40 a.m. **ORAL COMMUNICATIONS**
- 10:25 a.m. **COFFEE BREAK AND POSTER SESSION** • Indigo Ballroom – Level 2 (Biotech Showcase Session 1 & Early Career Investigators Showcase Session 1)
- 11:00 a.m. **SYMPOSIUM 2:** The U.S. POINTER Trial: Imaging, neurovascular, and sleep outcomes
- 11:40 a.m. **LATE BREAKING COMMUNICATIONS**
- 12:40 p.m. **LUNCH ON YOUR OWN**
- 1:30 p.m. **COFFEE BREAK IN THE POSTER HALL** • Indigo Ballroom – Level 2
- 1:40 p.m. **ORAL COMMUNICATIONS**
- 3:10 p.m. **ROUNDTABLE 1:** Charting the Path Forward for Combination Therapy in Alzheimer's Disease: Challenges, Considerations, and Collaborative Solutions
- 3:50 p.m. **COFFEE BREAK AND POSTER SESSION** • Indigo Ballroom – Level 2 (Biotech Showcase Session 2 & Early Career Investigators Showcase Session 2)
- 4:20 p.m. **LATE BREAKING COMMUNICATIONS**
- 5:35 p.m. **ROUNDTABLE 2:** CTAD China Clinical Trials Roundtable
- 6:05 p.m. **End of the Conference Day**

● Wednesday, December 3

- 7:30 a.m. **POSTER WALKING TOUR** • Indigo Ballroom – Level 2
- 8:30 a.m. **LATE BREAKING COMMUNICATIONS**
- 9:30 a.m. **KEYNOTE 3:** Next Generation Anti-Amyloid Therapies... Shuttling Past the ARIA Risk
- 9:55 a.m. **ORAL COMMUNICATIONS**
- 10:55 a.m. **COFFEE BREAK AND POSTER SESSION** • Indigo Ballroom – Level 2 (Biotech Showcase Session 3 & Early Career Investigators Showcase Session 3)
- 11:25 a.m. **ORAL COMMUNICATIONS** – Emerging Solutions: Novel Approaches to Treating Alzheimer's Disease
- 12:35 p.m. **LUNCH ON YOUR OWN**
- 1:15 p.m. **COFFEE BREAK IN THE POSTER HALL** • Indigo Ballroom – Level 2
- 1:30 p.m. **SYMPOSIUM 3:** ALZNET: First Look at Real-World Use of Novel Alzheimer's Disease Therapies in the United States
- 2:10 p.m. **LATE BREAKING COMMUNICATIONS**
- 3:10 p.m. **LATE BREAKING SYMPOSIUM 2:** Lecanemab Subcutaneous Formulation for Treatment Initiation in Early Alzheimer's Disease: Optimizing Patient Care with a Potential New Option
- 3:50 p.m. **COFFEE BREAK AND POSTER SESSION** • Indigo Ballroom – Level 2 (Biotech Showcase Session 4 & Early Career Investigators Showcase Session 4)
- 4:20 p.m. **ORAL COMMUNICATIONS**
- 5:05 p.m. **TOPLINE PHASE 3 RESULTS: SYMPOSIUM 4: TOPLINE RESULTS** from Evoke and Evoke+: Two Phase 3 Randomized Placebo-Controlled Trials of Semaglutide in Participants with Early-Stage Symptomatic Alzheimer's Disease
- 5:45 p.m. **End of the Conference Day**

● Thursday, December 4

- 7:30 a.m. **POSTER WALKING TOUR** • Indigo Ballroom – Level 2
- 8:30 a.m. **LATE BREAKING COMMUNICATIONS**
- 9:00 a.m. **ORAL COMMUNICATIONS** – AD CLINICAL TRIALS – PHASE 1
- 10:30 a.m. **COFFEE BREAK AND POSTER SESSION** • Indigo Ballroom – Level 2 (Biotech Showcase Session 5)
- 11:00 a.m. **SYMPOSIUM 5:** Advancing the Science of Recruitment for Preclinical Alzheimer's Disease Clinical Trials
- 11:40 a.m. **ORAL COMMUNICATIONS**
- 12:25 p.m. **LUNCH ON YOUR OWN**
- 1:10 p.m. **COFFEE BREAK IN THE POSTER HALL**
- 1:25 p.m. **LATE BREAKING COMMUNICATIONS**
- 2:25 p.m. **ORAL COMMUNICATIONS**
- 3:55 p.m. **COFFEE BREAK AND POSTER SESSION** • Indigo Ballroom – Level 2 (Biotech Showcase Session 5)
- 4:30 p.m. **ORAL COMMUNICATIONS**
- 6:00 p.m. **End of the CTAD Conference**

Monday, December 1

ALL SESSIONS WILL TAKE PLACE IN THE SAPPHIRE BALLROOM – LEVEL 4

3:30 p.m.
3:50 p.m.

CTAD25 Welcome Ceremony

Paul Aisen, USC-ATRI - San Diego (United States) and Jacques Touchon, Montpellier University - Montpellier (France)

3:50 p.m.
4:00 p.m.

CTAD Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research

Presented to Takeshi Iwatsubo MD, PhD in recognition for his pioneering work in Alzheimer's Disease Neuroimaging and Neuropathology.

4:00 p.m.
4:20 p.m.

Introductory Lecture: Alzheimer's Therapeutics: Past, Present, Future

Paul Aisen, USC-ATRI - San Diego (United States)

4:20 p.m.
5:35 p.m.

LATE BREAKING COMMUNICATIONS

Moderators: Niklas Mattson-Carlsson, Lund University – Lund (Sweden) and Takeshi Iwatsubo, Tokyo University -Tokyo (Japan)

4:20 p.m.

LB1 – Plasma Biomarkers To Identify and Predict Early Amyloid Accumulation in Cognitively Unimpaired Individuals: Enrichment for Stratified Early-Stage Prevention Trials

Niklas Mattsson-Carlsson¹, Shoren Janelidze¹, Erik Stomrud¹, Sebastian Palmqvist¹, Oskar Hansson¹
¹Lund University - Lund (Sweden)

4:35 p.m.

LB2 – Anti-tau therapeutic antibody, etalaneug, reduces the novel biomarker plasma Emtbr tau243 in patients with DIAD

Kristin Wildsmith¹, Kanta Horie^{1,2}, Peter Boyd³, Erica Andreozzi¹, Randall Bateman², Jin Zhou², Larisa Reyderman¹
¹Eisai Inc. - Nutley (United States), ²Washington University School of Medicine - St. Louis (United States), ³Eisai Europe Ltd. - Hatfield (United Kingdom)

4:50 p.m.

LB3 – Modulation of the p75 neurotrophin receptor in a phase 2a Alzheimer's disease trial reduces plasma p-tau217, engages the synaptic proteome, and preserves visuospatial cognition

Frank Longo¹
¹Pharmatrophix - Menlo Park (United States) ²University of Gothenburg - Gothenburg (Sweden), ³Lund University - Lund (Sweden)

5:05 p.m.

LB4 – Diagnostic Performance of the FDA-cleared Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio Thresholds for the Detection of Amyloid Pathology

Alicia Algeciras-Schimmich¹, Susan Ashrafzadeh Kian¹, Ramiro Eduardo Rea Reyes², Daniel Figdore¹, Brian Burkett¹, Derek Johnson¹, Hugo Botha¹, Stuart McCarter¹, Gregory Day³, Jonathan Graff-Radford¹, Henrik Zetterberg², Joshua Bornhorst¹, Sterling Johnson², Ronald Petersen¹, Vijay Ramanan¹
¹Mayo Clinic - Rochester (United States), ²Wisconsin Alzheimer's Disease Research Center - Wisconsin (United States), ³Mayo Clinic - Jacksonville (United States)

5:20 p.m.

LB5 – Clinical, Safety, and Biomarker Outcomes From a Post Treatment Observational Extension of the Phase 2 PROSPECT-ALZ Study of Ceperognastat in Early Symptomatic Alzheimer's Disease

Leanne Munsie¹, Adam Fleisher¹, Michele Mancini¹, Jiaying Guo¹, Hugh Nuthall¹, Diana Otero Svaldi¹, Vikas Kotari¹, Mike Hutton¹, Dustin J. Mergott¹, Mark Mintun¹, Oskar Hansson¹
¹Eli Lilly and Company - Indianapolis (United States)

Monday, December 1

ALL SESSIONS WILL TAKE PLACE IN THE SAPPHIRE BALLROOM – LEVEL 4

5:35 p.m.
6:15 p.m.

SYMPOSIUM 1

Trontinemab's path to Phase III – From proof-of-concept in the ongoing Brainshuttle™ AD study to the pivotal studies TRONTIER 1 and TRONTIER 2 in people with early-stage symptomatic Alzheimer's disease

Chair: Reisa Sperling, *Brigham and Women's Hospital - Massachusetts General Hospital - Boston (United States)*

Presentation 1: Brainshuttle™ AD: New interim results of a randomized, placebo-controlled Phase Ib/IIa proof-of-concept study with trontinemab, a novel anti-amyloid monoclonal bispecific antibody for the treatment of Alzheimer's disease

Luka Kulic, *F. Hoffmann-La Roche Ltd - Basel (Switzerland)*

Presentation 2: TRONTIER 1 and 2: Rationale and design of two identical Phase III trials to assess the efficacy and safety of trontinemab in early symptomatic Alzheimer's disease

Catherine Mummery, *Queen Square Institute of Neurology, UCL – London (United Kingdom)*

Presentation 3: The TRAVELLER master pre-screener protocol: An approach to reduce participant burden and broaden access to clinical trials in Alzheimer's disease

Christopher Lane, *Roche Products Ltd - Welwyn Garden City (United Kingdom)*

6:15 p.m.
6:40 p.m.

KEYNOTE 1

Enhancing Participation of Representative Populations in Alzheimer Disease Clinical Trials

Sid O'Bryant, *The University of North Texas Health Science Center at Fort Worth – Fort Worth, TX (United States)*

Introduction: Howard Feldman, *University of California San Diego, La Jolla (United States)*

6:45 p.m.
7:45 p.m.

CTAD WELCOME RECEPTION with the Support of the Alzheimer's Association



Tuesday, December 2

ALL SESSIONS WILL TAKE PLACE IN THE SAPPHIRE BALLROOM – LEVEL 4

7:35 a.m.
8:35 a.m.

POSTER WALKING TOUR • *Indigo Ballroom – Level 2*

8:35 a.m.
9:15 a.m.

LATE BREAKING SYMPOSIUM 1

The Global Neurodegeneration Proteomics Consortium: additional insights into ApoE, cellular aging clocks from the V1 Harmonized Dataset, and what's coming in V2

Chair: Farhad Imam, *Gates Ventures – Seattle (United States)*

Presentation 1: Proteomic signatures of the APOE ϵ 4 and APOE ϵ 2 genetic variants and Alzheimer's disease
Niklas Mattsson-Carlsson, *Lund University – Lund (Sweden)*

Presentation 2: Plasma Proteomics Identifies Early-Life Differences in APOE e4/e4 Individuals Related to Key AD Biological Pathways
Erik C. B. Johnson, *Emory University – Atlanta (United States)*

Presentation 3: Cellular Aging Signatures in the Plasma Proteome Record Aging and Neurodegeneration
Daisy Yi Ding, *Stanford University – Stanford (United States)*

9:15 a.m.
9:40 a.m.

KEYNOTE 2

From Real World Data to Clinical Trials: The Case for Investigating Semaglutide in Alzheimer's Disease

Peter Johannsen, *Novo Nordisk - Copenhagen (Denmark)*

Introduction: **Bruno Vellas**, *IHU HealthAge, Toulouse (France)*

9:40 a.m.
10:25 a.m.

ORAL COMMUNICATIONS

Moderators: **Elif Pinar Coskun**, *University of Kentucky – Lexington, KY (United States)* and **Reisa Sperling**, *Harvard Medical School, Brigham and Women's Hospital – Boston, MA (United States)*

9:40 a.m.

OC1 – The effect of herpes zoster vaccination at different stages of the dementia disease course: Implications for defining the study population of clinical trials

Min Xie¹, Markus Eytting¹, Christian Bommer¹, Haroon Ahmed², Pascal Geldsetzer¹

¹Stanford University – Stanford (United States), ²Cardiff University – Cardiff (United Kingdom)

9:55 a.m.

OC3 – Biological staging of Alzheimer's disease using blood-based biomarkers

Gemma Salvadó^{1,2}, Kanta Horie^{3,4,5}, Nicholas Barthélemy^{3,4}, Suzanne E. Schindler^{4,6}, Shorena Janelidze¹, Anna Orduña Dolado¹, Divya Bali¹, Erik Stomrud^{1,7}, Niklas Mattsson-Carlsson^{1,8,9}, Sebastian Palmqvist^{1,7}, Jacob W. Vogel¹⁰, Randall J. Bateman^{3,4,6,11}, Rik Ossenkoppele^{1,12,13}, Oskar Hansson¹

¹Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, - Lund (Sweden), ²BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain), ³The Tracy Family SILQ Center, Washington University School of Medicine - St Louis (United States), ⁴Department of Neurology, Washington University School of Medicine - St Louis (United States), ⁵Eisai Inc. - Nutley (United States), ⁶Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine - St Louis (United States), ⁷Memory Clinic, Skåne University Hospital - Malmö (Sweden), ⁸Wallenberg Center for Molecular Medicine, Lund University - Lund (Sweden), ⁹Department of Neurology, Skåne University Hospital - Lund (Sweden), ¹⁰Department of Clinical Sciences Malmö, SciLifeLab, Lund University - Lund (Sweden), ¹¹Hope Center for Neurological Disorders, Washington University School of Medicine - St Louis (United States), ¹²Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc - Amsterdam (Netherlands), ¹³Amsterdam Neuroscience, Neurodegeneration - Amsterdam (Netherlands)

10:10 a.m.

OC4 – The SMART-HS Study: A Targeted Therapeutic Strategy for LATE Disease

E. Pinar Coskun¹, Ahmed Bahrani¹, Lauren Bojarski¹, Justin Barber¹, Danica Coy¹, Emily Smith¹, Molly Harper¹, Alexandra Curtis¹, Erin Abner¹, Brian Gold¹, Linda Van Eldik¹, Peter Nelson¹, Gregory Jicha¹

¹University of Kentucky - Lexington (United States)

Tuesday, December 2

ALL SESSIONS WILL TAKE PLACE IN THE SAPPHIRE BALLROOM – LEVEL 4

10:25 a.m.
11:00 a.m.

COFFEE BREAK AND POSTER SESSION (Indigo Ballroom – Level 2)

 **Biotech Showcase Session 1 – Artificial Intelligence and Digital Innovation** (details P.87)

 **Early Career Investigators Showcase Session 1 – Translational Therapeutics and Clinical Innovation** (details P.90)

11:00 a.m.
11:40 a.m.

SYMPOSIUM 2

The U.S. POINTER Trial: Imaging, neurovascular, and sleep outcomes

Chair: Susan Landau, UC Berkeley - Berkeley (United States)

Presentation 1: U.S. POINTER Trial Outcomes: Results of the Imaging Ancillary Study

Susan Landau, UC Berkeley - Berkeley (United States)

Presentation 2: POINTER-NV: Results of the U.S. POINTER Neurovascular Ancillary Study

Tina E. Brinkley, Wake Forest University School of Medicine - Winston-Salem (United States)

Presentation 3: POINTER-zzz: Results of the U.S. POINTER Sleep Ancillary Study

Laura D. Baker, Wake Forest University School of Medicine - Winston-Salem (United States)

11:40 a.m.
12:40 p.m.

LATE BREAKING COMMUNICATIONS

Moderators: Laura D. Baker, Wake Forest University School of Medicine - Winston-Salem (United States) and Laia Montoliu-Gaya, University of Gothenburg - Gothenburg (Sweden)

11:40 a.m.

LB6 – Immunoassay-based p-tau205 is a biomarker of Tau-PET abnormality: a cross-sectional and longitudinal study

Juan Lantero-Rodriguez¹, Shorena Janelidze², Sebastian Palmqvist², Luisa Sophie Braun-Wohlfahrt¹, Jakub Vavra¹, Niklas Mattsson-Carlgrén², Erik Stomrud², Henrik Zetterberg¹, Kaj Blennow¹, Oskar Hansson², Gemma Salvadó², Laia Montoliu-Gaya¹

¹University of Gothenburg - Gothenburg (Sweden), ²Lund University - Lund (Sweden)

11:55 a.m.

LB7 – Lumipulse plasma p-tau217/Aβ42 ratio: Accuracy across the spectrum of Alzheimer's disease neuropathologic changes

Stamatia Karagianni^{1,2}, Alexis Moscoso^{1, 2, 3}, Martijn Van Essen⁴, Ismini Mainta⁵, Valle Camacho⁶, Omar Rodríguez-Fonseca⁷, Andrés Perissinotti^{8, 9}, Michel J. Grothe^{10, 11, 12}, Valentina Garibotto^{5, 12}, Michael Schöll^{1, 2, 4, 13}

¹Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg - Gothenburg (Sweden), ²Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg - Gothenburg (Sweden), ³Nuclear medicine department and Molecular Imaging Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Travesía da Choupana s/n - Santiago De Compostela (Spain), ⁴Department of Neuropsychiatry, Sahlgrenska University Hospital - Gothenburg (Sweden), ⁵Division of Nuclear Medicine, Geneva University Hospitals - Geneva (Switzerland), ⁶Department of Nuclear Medicine, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona - Barcelona (Spain), ⁷Nuclear Medicine Department, Lucus Augusti University Hospital (HULA) - Lugo (Spain), ⁸Nuclear Medicine Department, Hospital Clínic Barcelona - Barcelona (Spain), ⁹Biomedical Research Networking Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), ISCIII - Barcelona (Spain), ¹⁰Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Instituto de Salud Carlos III - Madrid (Spain), ¹¹Reina Sofía Alzheimer's Centre, CIEN Foundation, ISCIII - Madrid (Spain), ¹²Faculty of Medicine, University of Geneva and Center for Biomedical Imaging (CIBM) - Geneva (Switzerland), ¹³Dementia Research Centre, Institute of Neurology, University College London - London (United Kingdom)

12:10 p.m.

LB08 – Untargeted proteomics and machine learning reveal novel biomarker candidates capturing diverse perturbed pathways in Alzheimer's disease in an African American cohort

Lindsey Kuchenbecker^{1, 2}, Kevin Thompson³, Cheyenne Hurst¹, Yen-Ning Huang^{4, 5}, Michael Heckman⁶, Minerva M. Carrasquillo¹, Andrew Saykin^{4, 7, 8}, John Lucas⁹, Floyd Willis¹⁰, Gregory Day¹¹, Neill Graff-Radford¹¹, Nilufer Ertekin-Taner^{11, 1}, Kwangsik Nho^{12, 7, 13}, Krishna Kalari¹⁴

¹Department of Neuroscience, Mayo Clinic - Jacksonville (United States), ²Center for Clinical and Translational Science, Mayo Clinic - Rochester (United States), ³Department of Quantitative Health Sciences, Mayo Clinic - Rochester (United States), ⁴Center for Neuroimaging, Department of Radiology and Imaging Sciences, Indiana University School of Medicine - Indianapolis (United States), ⁵Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine - Indianapolis (United States), ⁶Department of Quantitative Health Sciences, Mayo Clinic - Jacksonville (United States), ⁷Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine - Indianapolis (United States), ⁸Department of Medical and Molecular Genetics, Indiana University School of Medicine - Indianapolis (United States), ⁹Department of Psychiatry and Psychology, Mayo Clinic - Jacksonville (United States), ¹⁰Department of Family Medicine, Mayo Clinic - Jacksonville (United States), ¹¹Department of Neurology, Mayo Clinic - Jacksonville (United States), ¹²Indiana University School of Medicine - Indianapolis (United States), ¹³School of Informatics and Computing, Indiana University - Indianapolis (United States), ¹⁴Mayo Clinic - Jacksonville (United States)

12:25 p.m.

LB09 – Neuropathological insights into the effects of aducanumab on patients with Alzheimer's disease

Lindsay A. Welikovich^{1, 2}, Derek H. Oakley^{1, 2}, Rachel E. Bennett^{1, 2}, Alberto Serrano-Pozo^{1, 2}, Haoyang Zhu¹, Nancy Ruiz-Urbe^{1, 2}, Theodore J. Zwan^{1, 2}, Donald S. Marks³, Stephen Salloway⁴, Charles Bernick⁵, David Greeley⁶, Thierry Bussiere⁷, Edward D. Plowey⁷, C. Dirk Keene⁸, Bradley T. Hyman^{1, 2}

¹Massachusetts General Hospital - Boston (United States), ²Harvard Medical School - Boston (United States), ³Headlands Research Eastern MA - Plymouth (United States), ⁴Warren Alpert Medical School of Brown University - Providence (United States), ⁵Cleveland Clinic Lou Ruvo Center for Brain Health - Las Vegas (United States), ⁶Kingfisher Cooperative, LLC - Spokane (United States), ⁷Biogen - Cambridge (United States), ⁸University of Washington - Seattle (United States)

12:40 p.m.
1:20 p.m.

LUNCH ON YOUR OWN

1:20 p.m.
1:40 p.m.

COFFEE BREAK IN THE POSTER HALL (Indigo Ballroom – Level 2)

1:40 p.m.
3:10 p.m.

ORAL COMMUNICATIONS

Moderators: Sandrine Andrieu, IHU HealthAge and INSERM – Toulouse, (France) and Mark Espeland, Wake Forest University School of Medicine – Winston Salem, NC (United States)

1:40 p.m.

OC5 – The Effects of Lecanemab Treatment on Soluble CSF A β Protofibrils in Clarity AD

Kanta Horie¹, Akihiko Koyama¹, Pallavi Sachdev¹, Kazuyoshi Shuta², Kazuhiro Tahara², Michio Kanekiyo¹, Shobha Dhadda¹, Larisa Reyderman¹, Steven Hersch¹, Michael Irizarry¹, Lynn Kramer¹

¹Eisai Inc. - Nutley (United States), ²Eisai Co., Ltd. - Tsukuba (Japan)

1:55 p.m.

OC6 – Impact of a 10-Year Multidomain Lifestyle Intervention on Long-Term Risks for Cognitive Impairment: The Look AHEAD Program

Mark Espeland¹, Rebecca Neiberg¹, Haiying Chen¹, Stephen Rapp¹, Bonnie Sachs¹, Chinedu Udeh-Momoh¹, Laura Baker¹, Kathleen Hayden¹, Denise Houston¹, Jose Luchsinger², Rena Wing³, Sevil Yasar⁴, Lynne Wagenknecht¹

¹Wake Forest University School of Medicine - Winston Salem (United States), ²Columbia University Irving Medical Center - New York (United States), ³The Miriam Hospital - Providence (United States), ⁴Johns Hopkins School of Medicine - Baltimore (United States)

2:10 p.m.

OC7 – Outcomes from the BetterBrains Trial, a multi-domain, person-centred, dementia risk factor management randomised controlled trial to prevent cognitive decline

Emily Rosenich¹, Darshini Ayton¹, Stephanie Pirota¹, Hannah Cummins¹, Maya Norfolk¹, Nawaf Yassi², Shantha Rajaratnam¹, Richard Sinnott², Matthew Pase¹, Amy Brodtmann¹, Ashley Bush³, Leonid Churilov², Anna Barker¹, Paul Maruff⁴, Yen Ying Lim¹

¹Monash University - Melbourne (Australia), ²University of Melbourne - Melbourne (Australia), ³Florey Institute - Melbourne (Australia), ⁴Cogstate Ltd - Melbourne (Australia)

Tuesday, December 2

ALL SESSIONS WILL TAKE PLACE IN THE SAPPHIRE BALLROOM – LEVEL 4

2:25 p.m.

OC8 – Quantifying tau knockdown in individuals with Alzheimer’s Disease receiving intrathecal tau MAPT antisense oligonucleotide NI0752 using Stable Isotope Labelling Kinetics (SILK) – interim analysis of a phase 1B randomised, double-blinded, placebo-controlled, multicentre trial

Aram Aslanyan^{1,2}, Chihiro Sato^{3, 4}, Donald Elbert⁵, Catherine Mummery^{1, 2}, Nupur Ghoshal³, Eric Mcdade³, Randall Bateman^{3, 4, 6}, **Ross Paterson**^{1, 2, 4, 7}

¹Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London - London (United Kingdom), ²National Hospital for Neurology and Neurosurgery - London (United Kingdom), ³Department of Neurology, Washington University School of Medicine in St Louis - St. Louis (United States), ⁴The Tracy Family Stable Isotope Labeling Quantitation Center, Washington University School of Medicine, Washington University in St. Louis - St. Louis (United States), ⁵Department of Neurology, University of Washington - Seattle (United States), ⁶Dominantly Inherited Alzheimer Network, Washington University in St. Louis - St. Louis (United States), ⁷Darent Valley Hospital - Dartford (United Kingdom)

2:40 p.m.

OC9: Insights into Clinical Trial Recruitment: An Analysis of Prescreening Data from the AHEAD Study

Dylan Kirn^{1,2}, Shunran Wang³, Karin Ernstrom³, Joshua D. Grill^{4,5}, Gustavo Jimenez-Maggiora³, Doris Molina-Henry³, Paul Aisen³, Reisa Sperling^{1, 2}, Rema Raman³

¹Department of Neurology, Brigham and Women’s Hospital - Boston (United States), ²Department of Neurology, Massachusetts General Hospital - Boston (United States), ³Alzheimer’s Therapeutic Research Institute, University of Southern California - San Diego (United States), ⁴Institute for Memory Impairments and Neurological Disorders, University of California Irvine - Irvine (United States), ⁵Department of Psychiatry and Human Behavior, University of California Irvine - Irvine (United States)

2:55 p.m.

OC10: Results from the open-label extension period of TOGETHER, a Phase II study evaluating efficacy, safety and tolerability of bepranemab in prodromal–mild Alzheimer’s disease

William Byrnes¹, Irene Rebollo Mesa², Tim Buchanan³, Bart Van Den Steen³, Hans Van Tricht³, Katie Taiyari⁴, Omobola Famodimu⁵, Jos Bloemers⁶, **Saori Shimizu**⁷, Ute Massow⁸, Ralph P. Maguire³, Colin Ewen⁴

¹UCB - Raleigh (United States), ²UCB - Madrid (Spain), ³UCB - Braine-L’alleud (Belgium), ⁴UCB - Slough (United Kingdom), ⁵UCB - Oakville (Canada), ⁶UCB - Breda (Netherlands), ⁷UCB - Brussels (Belgium), ⁸UCB - Monheim Am Rhein (Germany)

3:10 p.m.

3:50 p.m.

ROUNDTABLE 1

Charting the Path Forward for Combination Therapy in Alzheimer’s Disease: Challenges, Considerations, and Collaborative Solutions

Chair: Howard Fillit, Alzheimer’s Drug Discovery Foundation - New York City (United States)

Presentation 1: Add-On Combination Therapy with Monoclonal Antibodies: Implications for Drug Development

Jeffrey Cummings, Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, UNLV - Las Vegas, (United States)

Presentation 2: Considerations in the Development and Use of Biomarkers for Combination Therapy in Alzheimer’s Disease

Suzanne Schindler, Knight Alzheimer’s Disease Research Center, Washington University School of Medicine – St. Louis (United States)

Discussion: Jeffrey Cummings (Moderator)¹, Suzanne Schindler², Howard Fillit³, Diana Gallagher⁴, Fred Grossman⁵

¹Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada at Las Vegas, Las Vegas, NV (United States); ²Department of Neurology, Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, St. Louis, MO (United States); ³Alzheimer’s Drug Discovery Foundation, New York, NY (United States); ⁴Biogen, Cambridge, MA (United States); ⁵Coya Therapeutics, Philadelphia, PA (United States)

Tuesday, December 2

ALL SESSIONS WILL TAKE PLACE IN THE SAPPHIRE BALLROOM – LEVEL 4

3:50 p.m.
4:20 p.m.

COFFEE BREAK AND POSTER SESSION (*Indigo Ballroom – Level 2*)

 **Biotech Showcase Session 2 – Digital and Neurotechnology-Based Biomarkers and Therapeutics**
(*details P.87*)

 **Early Career Investigators Showcase Session 2 – Biomarkers and Mechanisms of Frailty and Cognitive Decline** (*details P.90*)

4:20 p.m.
5:35 p.m.

LATE BREAKING COMMUNICATIONS

Moderators: Marwann Sabbagh, Barrow Neurological Institute – Phoenix, AZ (United States) and Jacques Touchon, Montpellier University – Montpellier (France)

4:20 p.m.

LB10 – Pharmacokinetic / pharmacodynamic relationship of the gamma-secretase modulator nivegacator in presymptomatic carrier participants of the PSEN1 E280A mutation

Agnès Poirier¹, Enrique Gaspar¹, Dominik Lott¹, Stella Yilmaz¹, Tianxu Yang², Agnès Portron¹, Kalbinder Mahil³, Tayo Bodede³, David Aguillón⁴, David Gordon⁵, Robert Alexander⁵, Thomas Mueggler¹, Stefan Sturm¹, Rosanna Tortelli¹, Irene Gerlach¹

¹F. Hoffmann-La Roche Ltd - Basel (Switzerland), ²F. Hoffmann-La Roche Ltd, Roche China Holding - Shanghai (China), ³Roche Products Ltd, Welwyn Garden City - Welwyn (United Kingdom), ⁴Grupo de Neurociencias de Antioquia, Facultad de Medicina, Universidad de Antioquia - Medellín (Colombia), ⁵Banner Alzheimer's Institute - Phoenix (United States)

4:35 p.m.

LB11 – Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer's Disease Patients

Marwan Sabbagh¹, Audrey Gabelle², Timo Grimmer³, Juan Carlos Lopez-Talavera⁴, David Gould⁴, Wolfgang Liedtke⁴, William Chezem⁴, Kun Jin⁴, Christopher Missling⁴

¹Barrow Neurological Institute - Phoenix (United States), ²University of Montpellier - Montpellier (France), ³Technical University of Munich, School of Medicine and Health, TUM University Hospital - Munich (Germany), ⁴Anavex Life Sciences - New York (United States)

4:50 p.m.

LB12– Plasma brain derived p-Tau217 outperforms other p-Tau biomarkers in identifying abnormal brain amyloid burden and predicts faster cognitive decline

Joyce Ruifen Chong¹, Saima Hilal¹, Narayanaswamy Venketasubramanian², Michael Schöll³, Kaj Blennow³, Nicholas J. Ashton³, Henrik Zetterberg³, Christopher P. Chen¹, Mitchell Kim Peng Lai¹

¹National University of Singapore - Singapore (Singapore), ²Raffles Hospital - Singapore (Singapore), ³University of Gothenburg - Gothenburg (Sweden)

5:05 p.m.

LB13 – Benefit Continues to Accumulate When Treatment is Continued Beyond Plaque Clearance– Estimating Accumulated or Maintained Treatment Benefit in the CLARITY AD and TRAILBLAZER-ALZ2 Trials

Suzanne Hendrix¹, John Whetten¹, Kent Hendrix¹, Sam Dickson¹

¹Pentara Corporation - Salt Lake City (United States)

5:20 p.m.

LB14 – The value of earlier initiation of anti-amyloid therapy for AD

Jack M. Chapel^{1,2}, Bryan Tysinger^{1,2}, Hossein Pourmand^{1,2}, Paul Aisen^{1,3}, Dana Goldman^{1,2}

¹University of Southern California - Los Angeles (United States), ²USC Schaeffer Institute for Public Policy & Government Service - Los Angeles (United States), ³USC Alzheimer's Therapeutic Research Institute - San Diego (United States)

5:35 p.m.
6:05 p.m.

ROUNDTABLE 2

CTAD CHINA CLINICAL TRIALS ROUNDTABLE

Chairs: Jiong Shi, The First Affiliated Hospital of USTC – Hefei (China), Jeffrey Cummings, UNLV, Las Vegas (United States), Jacques Touchon, University of Montpellier (France), Bruno Vellas, IHU HealthAge, Toulouse (France)

Presentation 1: Clinical Trials in the Chinese Population and Large-Scale clinical cohorts

Jiong Shi, The First Affiliated Hospital of USTC – Hefei (China)

Presentation 2: Shanghai Action to Prevent the Elderly from Dementia SHAPE: a Funnel-like Stratified Process

Xia Li, Alzheimer's Disease and Related Disorders Center, Jiao Tong University, Shanghai (China)

Discussion: Clinical Trials in the Chinese Population and Large-Scale clinical cohorts and the AD alliance

Jiong Shi, The First Affiliated Hospital of USTC, Hefei (China)

Yong Shen, USTC. Hefei (China)

Yi Tang, Xuanwu Hospital, Capital Medical University, Beijing (China)

Xia Li, Shanghai Jiao Tong University, Shanghai (China)

Zao Han, Shanghai Medical Innovation and Development Foundation -Shanghai (China)

6:05 p.m.

END OF THE CONFERENCE DAY

7:30 a.m.
8:30 a.m.

POSTER WALKING TOUR • Indigo Ballroom – Level 2

8:30 a.m.
9:30 a.m.

LATE BREAKING COMMUNICATIONS

Moderators: Clive Ballard, University of Exeter – Exeter (United Kingdom) and Jorge Llibre-Guerra, Washington University St. Louis – St. Louis, MO (United States)

8:30 a.m.

LB15– Alzheimer's Disease blood biomarkers measured through remote capillary sampling correlate with cognitive performance in older adults

Anne Corbett¹, Millie Sander¹, Nicholas Ashton², Hanna Huber², Freya Bateman¹, Clive Ballard¹

¹University of Exeter - Exeter (United Kingdom), ²University of Gothenberg - Gothenberg (United Kingdom)

8:45 a.m.

LB16 – Stage-specific prognostic roles of plasma biomarkers in Alzheimer's Disease

Daeun Shin¹, Jun Pyo Kim¹, Hyemin Jang², Jihwan Yun³, Eun Hye Lee⁴, Heekyung Kang¹, Sohyun Yim¹, Heekyung Park¹, Sunghyun Kim¹, Henrik Zetterberg⁵, Kaj Blennow⁵, Duk L Na¹, Hee Jin Kim¹, Sookyoung Woo¹, Sang Won Seo¹

¹Samsung Medical Center - Seoul (Korea, Republic of), ²Asan Medical Center - Seoul (Korea, Republic of), ³Kyung Hee University Hospital - Seoul (Korea, Republic of), ⁴Indiana Alzheimer Disease Research Center - Indianapolis (United States), ⁵University of Gothenburg - Gothenburg (Sweden)

9:00 a.m.

LB17 – Multi-biomarker Plasma Clocks for Predicting Alzheimer Disease Symptom Onset

Kellen Petersen¹, Chengjie Xiong¹, Yan Li¹, Marta Milà-Alomà², Duygu Tosun², Benjamin Saef¹, Leslie Shaw³, Jeffrey Dage⁴, Henrik Zetterberg⁵, David Holtzman¹, John Morris¹, Randall Bateman¹, Anthony Bannon⁶, William Potter⁷, Suzanne Schindler¹

¹Washington University in St. Louis - St. Louis (United States), ²University of California San Francisco - San Francisco (United States), ³University of Pennsylvania University in St. Louis - Philadelphia (United States), ⁴Indiana University School of Medicine - Indianapolis (United States), ⁵University of Gothenburg - Gothenburg (Sweden), ⁶AbbVie - Chicago (United States), ⁷Philadelphia (United States)

9:15 a.m.

LB18 – Longitudinal associations between Plasma p-tau217 and amyloid PET

Mahnaz Shekari¹, Duygu Tosun², Suzanne E Schindler^{3,4}, Jeff L Dage^{5,6}, Shaw Leslie⁷, William J Jagust¹, Susan M Landau¹

¹Helen Wills Neuroscience Institute, University of California, Berkeley- Berkeley (United States), ²Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco (United States), ³Department of Neurology, Washington University School of Medicine, St. Louis (United States), ⁴Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine - St. Louis (United States), ⁵Indiana Alzheimer's Disease Research Center, Indianapolis, IN, USA - Indianapolis (United States), ⁶Department of Neurology, Indiana University School of Medicine - Indianapolis (United States), ⁷Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania - Philadelphia (United States)

9:30 a.m.
9:55 a.m.

KEYNOTE 3

Next Generation Anti-Amyloid TherapiesShuttling Past the ARIA Risk

Ronald B. DeMattos, Eli Lilly and Company – Indianapolis, IN (United States)

Introduction: Reisa Sperling, Brigham and Women's Hospital - Massachusetts General Hospital - Boston (United States)

9:55 a.m.
10:55 a.m.

ORAL COMMUNICATIONS

Moderators: Marisa Denlinger, Banner Sun Health Research Institute – Sun City, AZ (United States) and Mike Weiner, UCSF – San Francisco, CA (United States)

9:55 a.m.

OC11: Combining endogenous CSF MTBR-tau243 and plasma pTau217 enhances prediction of continuous regional tau PET burden in amyloid-positive early Alzheimer's disease

Viswanath Devanarayan¹, Thomas Doherty², Erica Andreozzi¹, Kristin Wildsmith¹, Pallavi Sachdev¹, Kanta Horie¹, Arnaud Charil¹, Harald Hampel¹, Lynn Kramer¹, Shobha Dhadda¹, Michael Irizarry¹

¹Eisai Inc. - Nutley (United States), ²Eisai Inc. - Hatfield (United Kingdom)

10:10 a.m.

OC12: Brain volume changes with gantenerumab: relationship with amyloid removal

Matteo Tonietto¹, Erica Silvestri^{1,2}, Christopher Belder^{3,4}, Frederik Barkhof^{3,5}, Nick Fox³, Janice Smith⁶, Gregory Klein¹

¹Neuroscience and Rare Diseases, Roche Pharma Early Research and Development, F. Hoffmann-La Roche Ltd - Basel (Switzerland), ²A*P Consulting Ltd - Sandwich (United Kingdom), ³Dementia Research Centre, UCL Queen Square Institute of Neurology - London (United Kingdom), ⁴Department of Neurology, Royal Adelaide Hospital and Queen Elizabeth Hospital - Adelaide (Australia), ⁵Department of Radiology & Nuclear Medicine - Amsterdam (Netherlands), ⁶Roche Products Ltd - Welwyn Garden City (United Kingdom)

10:25 a.m.

OC13: Head-to-head comparison of SWI and T2*-weighted gradient echo MRI sequences to detect ARIA-H in the TRAILBLAZER-ALZ 6 trial of donanemab

Diana Svaldi¹, Alessandro Biffi¹, Hong Wang¹, Emel Serap Nery¹, Chuning Gao¹, Ming Lu¹, Emily Collins¹, Karolina Feakins¹, Sergey Shcherbinin¹, Dawn Brooks¹, John Sims¹

¹Eli Lilly and Company - Indianapolis (United States)

10:40 a.m.

OC14: Longitudinal trajectories of plasma p tau217 in cognitively unimpaired older adults using a fully automated platform

Marisa N. Denlinger¹, Sterling C. Johnson², Alpna Singh¹, Taina Marques¹, Rachael E. Wilson², Ramiro E. Rea Ryes², Antoine Leuzy¹, Valentina Ghisays³, Robert C. Alexander³, Reisa A. Sperling⁴, Keith A. Johnson⁵, Paul A. Aisen⁶, Jessica B. Langbaum³, Eric M. Reiman³, Nicholas J. Ashton³

¹Banner Sun Health Research Institute - Sun City (United States), ²Wisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison - Madison (United States), ³Banner Alzheimer's Institute - Phoenix (United States), ⁴Department of Neurology, Massachusetts General Hospital, Harvard Medical School, - Boston (United States), ⁵Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital - Boston (United States), ⁶Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States)

10:55 a.m.

11:25 a.m.

COFFEE BREAK AND POSTER SESSION (*Indigo Ballroom – Level 2*)

 **Biotech Showcase Session 3 – Blood-Based Diagnostics and Biomarkers** (*details P.88*)

 **Early Career Investigators Showcase Session 3 – Digital Health and New Tools for Early Detection** (*details P.91*)

11:25 a.m.

12:35 p.m.

ORAL COMMUNICATIONS – Emerging Solutions: Novel Approaches to Treating Alzheimer's Disease

Introduction by Chair: Howard Fillit, Alzheimer's Drug Discovery Foundation, New York, NY (United States)

11:35 a.m.

OC15: Protein-based Diagnosis and Analysis of Co-Pathologies Across Neurodegenerative Diseases: Large-Scale AI-Boosted CSF and Plasma Proteomic Classifier

Ying Xu^{1,2}, Daniel Western^{1,2}, Gyujin Heo^{1,2}, Kwangsik Nho³, Hamilton Oh⁴, Yike Chen^{1,2}, Menghan Liu^{1,2}, Katherine Gong¹, Agustin Ruiz^{5,2}, Maria Victoria Fernández^{6,1}, David Bennett^{7,6,8}, Tony Wyss-Coray⁹, Muhammad Ali^{1,2}, Carlos Cruchaga^{1,2}

¹Department of Psychiatry, Washington University School of Medicine - St Louis (United States), ²NeuroGenomics and Informatics Center, Washington University School of Medicine - St Louis (United States), ³Indiana University School of Medicine - Indianapolis (United States), ⁴Icahn School of Medicine at Mount Sinai - New York (United States), ⁵Ace Alzheimer Center Barcelona - Barcelona (Spain), ⁶CIBERNED, National Institute of Health Carlos III - Madrid (Spain), ⁷Rush Alzheimer's Disease Center, Rush University Medical Center - Chicago (United States), ⁸Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center, - San Antonio (United States), ⁹Wu Tsai Neurosciences Institute, Stanford University - California (United States)

11:50 a.m.

OC16: Identifying and stratifying Alzheimer's disease using circular RNA biomarkers in blood

Bridget Phillips^{1, 2, 3}, Jessie Sanford^{1, 2, 3}, Devin Dikec^{1, 2, 3}, Menghan Liu^{1, 2, 3}, Matt Johnson^{1, 2, 3}, John Budde^{1, 2, 3}, John Morris^{4, 5, 6}, Nikolaos Mellios⁷, Alison Goate⁸, Alan Renton⁸, Dominantly Inherited Alzheimer Network Consortia⁹, Richard Perrin^{4, 5, 6}, Laura Ibanez^{1, 2, 4}, Carlos Cruchaga^{2, 1, 3}

¹Department of Psychiatry, Washington University School of Medicine - St. Louis (United States), ²NeuroGenomics and Informatics Center, Washington University School of Medicine - St. Louis (United States), ³Hope Center for Neurological Disorders, Washington University School of Medicine - St. Louis (United States), ⁴Department of Neurology, Washington University School of Medicine - St. Louis (United States), ⁵Department of Pathology and Immunology, Washington University School of Medicine - St. Louis (United States), ⁶Knight Alzheimer Disease Research Center, Washington University School of Medicine - St. Louis (United States), ⁷Circular Genomics Inc - San Diego (United States), ⁸Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai - New York (United States), ⁹Dominantly Inherited Alzheimer Network (DIAN) - St. Louis (United States)

12:05 p.m.

OC17: Large-scale Plasma Proteomic Profiling Unveils Diagnostic Biomarkers and Pathways for Alzheimer's Disease

Heo Gyu Jin¹, Ying Xu¹, Jigyasha Timsina¹, Daniel Western¹, Carlos Cruchaga¹

¹Washington University - Saint Louis (United States)

12:20 p.m.

OC18: Biomarkers Associated with Response to Treatment of Early Stage AD with Pepinemab, Anti-SEMA4D Blocking Antibody

Maurice Zauderer¹, Elizabeth Evans¹, Terrence Fisher¹, Vikas Mishra¹, Leslie Balch¹, Elaine Gersz¹, John Leonard¹, Crystal Mallow¹, Anton Porsteinsson², Raymond Turner³, John Huffaker⁴

¹Vaccinex, Inc. - Rochester (United States), ²University of Rochester - Rochester (United States), ³Georgetown University - Washington, DC (United States), ⁴Neuropsychiatric Research Center - Southwest Florida (United States)

12:35 p.m.

1:15 p.m.

LUNCH ON YOUR OWN

1:15 p.m.

1:30 p.m.

COFFEE BREAK IN THE POSTER HALL (Indigo Ballroom – Level 2)

1:30 p.m.

2:10 p.m.

SYMPOSIUM 3

ALZNET: First Look at Real-World Use of Novel Alzheimer's Disease Therapies in the United States

Chair: Reisa Sperling, Brigham and Women's Hospital - Massachusetts General Hospital - Boston (United States)

Presentation 1: ALZNET: An Update on Registry Growth and Collaborations

Maria C. Carrillo, Alzheimer's Association - Chicago (United States) on behalf of the ALZ-NET Study Team

Presentation 2: The ALZ-NET patient population: Demographics, Genetics and Biomarker Testing

Gil D. Rabinovici, Memory and Aging Center, UCSF - San Francisco (United States) on behalf of the ALZ-NET Study Team

Presentation 3: Longitudinal assessment of clinical and safety outcomes in participants receiving beta-amyloid targeting monoclonal antibodies: Real world therapy data from ALZ-NET

Michael S. Rafii, USC-ATRI - San Diego (United States) on behalf of the ALZ-NET Study Team

2:10 p.m.

3:10 p.m.

LATE BREAKING COMMUNICATIONS

Moderators: Apostolos Manolopoulos, National Institute on Aging – NIH – Bethesda, MD (United States) and Rema Raman, Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States)

2:10 p.m.

LB19 –Foundation models for the early detection of Alzheimer's using cell-free DNA

Ravi Solanki¹, Ivan Koychev², Jonathan Wan², Pouya Niki², Christoforos Nalmpantis², Javkhan-Ochir Ganbat², Donal Byrne², Henrik Zetterberg³, Masud Husain⁴, Sofia Toniolo⁴, Ivan Koychev²

¹Prima Mente - San Francisco (United States), ²Prima Mente - London (United Kingdom), ³University of Gothenburg - Molndal (Sweden), ⁴University of Oxford - Oxford (United Kingdom)

2:25 p.m.

LB20 – Performance of blood-based Screening algorithm for Predicting AD Pathology and Baseline Characteristics of Participants in a Phase 2 trial of Etanercept and Concurrent Lecanemab.

Thomas Doherty¹, Devanarayan Viswanath², Zhou Jin², Wildsmith Kristin², Charil Arnaud², Pinner Kate¹, Li David², Sachdev Pallavi², Reyderman Larisa², Shobha Dhadha², Michael Irizarry²

¹Eisai Limited - Hatfield (United Kingdom), ²Eisai Inc. - Nutley (United States)

2:40 p.m.

LB21 – Estimating The 10-Year Time-Savings Benefits of Lecanemab Treatment

John Whetten¹, Sam Dickson¹, Garrett Duncan¹, Suzanne Hendrix¹, Katherine Youmans-Kidder², Daryl Jones²

¹Pentara Corporation - Millcreek (United States), ²Eisai Inc. - Nutley (United States)

2:55 p.m.

LB22 – Neuron-derived extracellular vesicle-associated proBDNF and Complex V predict resilience to cognitive impairment

Apostolos Manolopoulos¹, Roxanna Korologou-Linden², Maja Mustapic¹, Francheska Delgado-Peraza¹, Pamela Yao¹, Geraint Price², Andrei Popescu³, Zoi Alexopoulou³, Janaky Coomaraswamy⁴, Janice Wong⁵, Gallen Triana-Baltzer⁶, Gerald Novak⁵, Oliver Robinson², Lefkos Middleton², Dimitrios Kapogiannis¹

¹Laboratory of Clinical Investigation, Intramural Research Program, National Institute on Aging, NIH - Baltimore (United States), ²Ageing Epidemiology Research Unit, School of Public Health, Imperial College London - London (United Kingdom), ³Merck Sharp & Dohme - London (United Kingdom), ⁴Takeda Pharmaceutical Company Ltd. - Cambridge (United States), ⁵Johnson & Johnson - Cambridge (United States), ⁶Johnson & Johnson - San Diego (United States)

3:10 p.m.

3:50 p.m.

LATE BREAKING SYMPOSIUM 2

Lecanemab Subcutaneous Formulation for Treatment Initiation in Early Alzheimer's Disease: Optimizing Patient Care with a Potential New Option

Chair: Sharon Cohen, Toronto Memory Program - Toronto (Canada)

Presentation 1: Rationale and Early Development of Subcutaneous Lecanemab

Larisa Reyderman, Eisai Inc., Nutley (United States)

Presentation 2: Safety Profile of a Subcutaneous Lecanemab Formulation

Michael Irizarry, Eisai Inc., Nutley (United States)

Presentation 3: Potential Benefits of a Subcutaneous Formulation of Lecanemab

Sharon Cohen, Toronto Memory Program - Toronto (Canada)

3:50 p.m.

4:20 p.m.

COFFEE BREAK AND POSTER SESSION (Indigo Ballroom – Level 2)

🍷 Biotech Showcase Session 4 – Multiomics and Precision Diagnostics (details P.88)

🏠 Early Career Investigators Showcase Session 4– Non-Pharmacological and Lifestyle Interventions (details P.91)

4:20 p.m.

5:05 p.m.

ORAL COMMUNICATIONS

Moderators: Paul Aisen, Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego, CA (United States) and Suzanne Schindler, Washington University St. Louis, St. Louis, MO (United States)

4:20 p.m.

OC19: Alpha-Synuclein Detection: A Versatile EV-Based Plasma Assay for Detecting Modified α-Synuclein in Synucleinopathies Without Pre-Enrichment

Carine Lim¹, Hui Ling Ko¹, Brian Minie¹, Nicole Tsang¹, Nicholas Ho¹, Huilin Shao¹, Richard Batrla²

¹Sunbird Bio - Singapore (Singapore), ²Sunbird Bio - Cambridge (United States)

4:35 p.m.

OC20: Population characteristics and implications of implementation strategies for blood-based biomarkers in Alzheimer's disease across healthcare settings: Insights from a prospective, global, multicenter study

Imke Kirste¹, Sayuri Hortsch², Craig Ritchie^{3,4}, Jeffery L. Dage^{5,6,7}, Kristian Steen Frederiksen^{8,9}, Marc Suárez-Calvet¹⁰, ^{11,12} Marwan N. Sabbagh¹³, Clara Quijano-Rubio¹⁴

¹Roche Diagnostics Solutions - Indianapolis (United States), ²Roche Diagnostics GmbH - Penzberg (Germany), ³Scottish Brain Sciences - Edinburgh (United Kingdom), ⁴Department of Medicine, University of St Andrews - St Andrews (United Kingdom), ⁵Department of Neurology, Indiana University School of Medicine - Indianapolis (United States), ⁶Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine - Indianapolis (United States), ⁷Stark Neurosciences Research Institute, Indiana University School of Medicine - Indianapolis (United States), ⁸Danish Dementia Research Centre, Department of Neurology, Copenhagen University Hospital - Rigshospitalet - Copenhagen (Denmark), ⁹Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen - Copenhagen (Denmark), ¹⁰BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain), ¹¹Hospital del Mar Research Institute - Barcelona (Spain), ¹²Servei de Neurologia, Hospital del Mar - Barcelona (Spain), ¹³Department of Neurology, Barrow Neurological Institute - Phoenix (United States), ¹⁴Roche Diagnostics International Ltd - Rotkreuz (Switzerland)

● Wednesday, December 3

ALL SESSIONS WILL TAKE PLACE IN THE SAPPHIRE BALLROOM – LEVEL 4

4:50 p.m.

OC21: Donanemab in Early Symptomatic Alzheimer's Disease: Additional Insights from the TRAILBLAZER-ALZ 2 Long-Term Extension

Jennifer Zimmer

Eli Lilly and Company - Indianapolis (United States)

5:05 p.m.

5:45 p.m.

TOPLINE PHASE 3 RESULTS: SYMPOSIUM 4

TOPLINE RESULTS from Evoke and Evoke+: Two Phase 3 Randomized Placebo-Controlled Trials of Semaglutide in participants with Early-Stage Symptomatic Alzheimer's Disease

Jeffrey L. Cummings¹, Alireza Atri^{2, 3, 4}, Howard H. Feldman⁵, Mary Sano^{6, 7}, Wiesje Van Der Flier^{8, 9}, Henrik Zetterberg¹⁰, Filip K. Knop¹¹, Peter Johannsen¹¹, Teresa León¹¹, Rikke Mortensen Abschneider¹¹, Philip Scheltens^{12, 13}

¹Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, Kirk Kerkorian School of Medicine, University of Nevada Las Vegas - Las Vegas (United States), ²Banner Sun Health Research Institute - Sun City (United States), ³Banner Alzheimer's Institute, - Phoenix (United States), ⁴Brigham and Women's Hospital, Harvard Medical School - Boston (United States), ⁵Alzheimer's Disease Cooperative Study, Department of Neurosciences, University of California San Diego - La Jolla (United States), ⁶Icahn School of Medicine at Mount Sinai - New York (United States), ⁷James J Peters, VAMC - Bronx (United States), ⁸Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC - Amsterdam (Netherlands), ⁹Amsterdam Neuroscience, Neurodegeneration, - Amsterdam (Netherlands), ¹⁰Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg - Mölndal (Sweden), ¹¹Novo Nordisk A/S - Copenhagen (Denmark), ¹²Alzheimer Center, Department of Neurology, Vrije Universiteit Amsterdam - Amsterdam Umc (Netherlands), ¹³EQT Life Sciences - Amsterdam (Netherlands)

5:45 p.m.

END OF THE CONFERENCE DAY

7:30 a.m.
8:30 a.m.

POSTER WALKING TOUR • *Indigo Ballroom – Level 2*

8:30 a.m.
9:00 a.m.

LATE BREAKING COMMUNICATIONS

Moderators: James Doecke, *The Australian e-Health Research Centre, CSIRO - Herston (Australia)* and Gustavo Jimenez-Maggiora, *University of Southern California - San Diego (United States)*

8:30 a.m.

LB23 – Optimizing Blood-Based Alzheimer's Disease Diagnosis: A Multi-Marker pTau-217-Inclusive Approach

Jeremiah Hinson^{1,2}, Johannes Eichner³, Muhammad Ali⁴, Crlos Cruchaga⁴, Timo Wittenberger³, Scott Levin⁵

¹Danaher Diagnostics - Washington, DC (United States), ²Johns Hopkins University School of Medicine - Baltimore, MD (United States), ³GeneData - Basel (Switzerland), ⁴Washington University St. Louis - St. Louis, MO (United States), ⁵Danaher Diagnostics - Washington, DC (United States)

8:45 a.m.

LB24 – pTau217 performance to separate Alzheimer's disease biological stage is not increased by adding demographic or clinical information

James Doecke^{1,2}, Rodrigo Canovas³, Christopher Fowler⁴, Azadeh Feizpour^{4,5}, Vincent Dore^{3,5}, Ziad Saad⁶, Gallen Triana-Baltzer⁶, Manu Vandijck⁷, Gwendlyn Kollmorgen⁸, Clara Quijano-Rubio⁹, Jurgen Fripp¹, Anthony Bannon¹⁰, Paul Maruff¹¹, Christopher Rowe⁵, Colin Masters⁴

¹The Australian e-Health Research Centre, CSIRO - Herston (Australia), ²School of Medical and Health Sciences, Edith Cowan University - Joondalup (Australia), ³The Australian e-Health Research Centre, CSIRO - Parkville (Australia), ⁴The Florey Institute of Neuroscience and Mental Health, the University of Melbourne - Parkville (Australia), ⁵Department of Molecular Imaging & Therapy, Austin Health - Heidelberg (Australia), ⁶Precision Measures, Johnson & Johnson - San Diego (United States), ⁷Fujirebio Europe N.V. - Gent (Belgium), ⁸Roche Diagnostics GmbH - Penzberg (Germany), ⁹Roche Diagnostics International Ltd - Rotkreuz (Germany), ¹⁰Abbvie - North Chicago (United States), ¹¹Cogstate - Melbourne (Australia)

9:00 a.m.
10:28 a.m.

ORAL COMMUNICATIONS – AD CLINICAL TRIALS – PHASE 1 SESSION

Moderators: Miranda E. Orr, *Washington University in St Louis - St. Louis (United States)* and Robert Rissman, *Translational Research Division and Biomarker Laboratory and Biorepository Director, Alzheimer's Therapeutic Research Institute – San Diego (United States)*

9:00 a.m.

LB25 – Phase 1B/2A data from SORT-IN-2: Sortilin inhibition with VES001 in GRN mutation carriers was well-tolerated and elevated plasma and CSF progranulin

Mads Kjolby¹, Nina Schultz¹, Imogen Swift¹, Ditte Mikkelsen¹, Lærke Hedelund Fensbæk¹, Louise Klem¹, Sofie L. Frandsen¹, Ove Pedersen¹, Jacob Falck Hansen¹, Anders Nykjaer¹, Jonathan Rohrer², Harro Seelaar³

¹Vesper Bio - Copenhagen (Denmark), ²University College London - London (United Kingdom), ³Erasmus University Rotterdam - Rotterdam (Netherlands)

9:08 a.m.

LB26 –Phase 1b/2a, 12-month, randomized, double-blind, placebo-controlled study of the safety/tolerability and preliminary evidence of efficacy of a tau anti-sense oligonucleotide in patients with tauopathies.

Lawren Vandevrede¹, Hilary Heuer¹, Courtney Lane-Donovan¹, Peter Ljubenkovic¹, Bruce Miller¹, Julio Rojas¹, Adam Boxer¹

¹Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California San Francisco - San Francisco (United States)

9:16 a.m.

LB27 – BQ-141, a First-in-Class Oral Tau Stabilizer, Robustly Inhibits Tau Spreading and Modulates Translational Biomarkers in a Seed-and-Spread Model

Markus Zweckstetter¹

¹brainQr Therapeutics GmbH - Goettingen (Germany)

9:24 a.m.

OC22: A first-in-human double-blind, placebo-controlled, multiple ascending dose phase 1 study evaluating the safety and pharmacokinetics of PRX005/BMS-986446, a novel anti-MTBR tau monoclonal antibody, in healthy adults and patients with Alzheimer's disease

David P. Walling¹, Ferenc Martenyi², Brian Campbell², Jun Lee², Philip Dolan², Donna Masterman², Chad Swanson², Mark Thomas³, Min Chen³, Aditi Shahane³, Nicholas Colletti³, Nanette Hock³, Ilena George³

¹CenExel - Los Alamitos (United States), ²Prothena - Brisbane (United States), ³Bristol Myers Squibb - Princeton (United States)

9:32 a.m.

OC23: First-in-Human Study of ADEL-Y01, a Monoclonal Antibody Targeting Acetylated Tau (ack280) in the MTBR: Safety and Pharmacokinetics in Healthy Adults and Early Alzheimer's Disease

Min-Seok Kim^{1,2}, Yuna Oh¹, Sungsil Lee³, Kyung-Hoon Hwang¹, Young-Soo Sohn¹, Dong-Sik Jung³, Taeyoung Yoon³, Peter J. Winkle⁴, Seung-Yong Yoon^{1,2}

¹ADEL Institute of Science & Technology (AIST), ADEL, Inc. - Seoul (Republic of Korea), ²Department of Brain Science, Asan Medical Center, University of Ulsan College of Medicine - Seoul (Republic of Korea), ³Oscotec Inc. - Gyeonggi-Do (Republic of Korea), ⁴CenExel ACT - Anaheim (United States)

9:40 a.m.

OC24: Amyloid-related imaging abnormalities in an ongoing Phase 1 study of mivelsiran, an investigational RNA interference therapeutic targeting amyloid precursor protein, in patients with Alzheimer's disease

Neal S. Parikh¹, Sharon Cohen², Sandeep Chaudhari¹, Lynn Farugia¹, Andrew H. Ahn¹, Julia Shirvan¹, Steven M. Greenberg³

¹Alnylam Pharmaceuticals, Inc. - Cambridge (United States), ²Toronto Memory Program - Toronto (Canada), ³Harvard Medical School, Massachusetts General Hospital - Boston (United States)

9:48 a.m.

OC25: Results of a Phase 1, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, and pharmacokinetics of ascending single IV doses of VV7523, a tau-targeting therapeutic, in healthy adult participants

Elena Ratti¹, Monroe Butler¹, Naomi Muse¹, Sarah Piantedosi¹, Thrusha Chauhan¹, Beth Mellen¹, Joydip Kundu¹, Vik Arora¹, Albena Patroneva², Maurice Emery², Raj Rajagovindan¹, Toby Ferguson¹, Alfred Sandrock¹

¹Voyager Therapeutics - Lexington (United States), ²Voyager Therapeutics Contractor - Lexington (United States)

9:56 a.m.

OC26: ABCA1-agonist treatment by CS6253 and effects on plasma total and isoform-specific apolipoprotein E in elderly men and women.

Jan Johansson¹, Bengt Winblad², Henrik Zetterberg³, Jeffrey Cummings⁴, Dobrin Nedelkov⁵, Hussein Yassine⁶

¹Artery Therapeutics, Inc. - San Ramon (United States), ²Karolinska - Stockholm (Sweden), ³Sahlgrenska - Gothenburg (Sweden), ⁴U of Nevada - Las Vegas (United States), ⁵Isoformix Inc. - Sugarland (United States), ⁶USC - Los Angeles (United States)

10:04 a.m.

OC27: Efficacy and safety of xanomeline and trospium chloride for cognitive impairment in Alzheimer's disease (MINDSET-1 and MINDSET-2)

Jeffrey L. Cummings¹, William P. Horan^{2,3}, Dongmei Liu³, Jessica Stanek³, Codrin Lungu³

¹University of Nevada - Las Vegas (United States), ²University of California - Los Angeles (United States), ³Bristol Myers Squibb - Princeton (United States)

10:12 a.m.

OC28: SToMP and STAMINA Clinical Trials of Senolytics in Alzheimer's Disease Treatment and Prevention

Miranda E. Orr, Washington University in St Louis - St. Louis (United States)

10:20 a.m.

OC29: Pleiotropic Effects of the CNS-Selective M1 Muscarinic Agonist NSC001: From Rapid Symptomatic Relief to Long-Term Disease Modification in Alzheimer's Disease (AD)

Manfred Windisch¹, Abraham Fisher²

¹NSC-Therapeutics GmbH - St. Radegund (Austria), ²ADPD - Holon (Israel)

10:30 a.m.
11:00 a.m.

COFFEE BREAK AND POSTER SESSION (Indigo Ballroom – Level 2)

 **Biotech Showcase Session 5 – Next-Generation Therapeutics (details P.89)**

11:00 a.m.
11:40 a.m.

SYMPOSIUM 5

Advancing the Science of Recruitment for Preclinical Alzheimer's Disease Clinical Trials

Chair: Paul Aisen, USC-ATRI - San Diego (United States)

Presentation 1: Impact of upcoming FDA enrollment requirements on recruitment for Alzheimer's disease clinical trials

Lowell Schiller, Schaeffer Institute for Public Policy & Government Service – Washington, DC (United States)

Presentation 2: Recruitment and screening in TRAILBLAZER-ALZ 3: A decentralized study of donanemab in preclinical Alzheimer's disease

Karen C. Holdridge, Eli Lilly & Company – Indianapolis (United States)

Presentation 3: Building a scalable and efficient recruitment funnel for preclinical Alzheimer's disease: The AHEAD 3-45 model

Rema Raman, USC-ATRI, San Diego (United States)

11:40 a.m.
12:25 p.m.

ORAL COMMUNICATIONS

Moderators: [Iwata Atsushi](#), Tokyo Metropolitan Institute for Geriatrics and Gerontology - Tokyo (Japan) and [Heather M. Snyder](#), Alzheimer's Association, Chicago, IL (United States)

11:40 a.m.

OC30: Interim analysis of post-marketing observational study of lecanemab in Japan

[Iwata Atsushi](#)¹, [Sakata Yukinori](#)², [Koizumi Kinuyo](#)², [Endo Akira](#)², [Kuang Weijie](#)², [Sumitomo Kenta](#)², [Ishii Mika](#)²

¹Tokyo Metropolitan Institute for Geriatrics and Gerontology - Tokyo (Japan), ²Eisai Co., Ltd. - Tokyo (Japan)

11:55 p.m.

OC31: Completion of a Phase 2 trial evaluating safety and efficacy of the synaptic regenerative small molecule SPG302 in participants with mild-to-moderate Alzheimer's disease

[Bruce Brew](#)¹, [Lauren Priest](#)², [Aimee Cazyer](#)², [Valerie Bramah](#)³, [Peter Vanderklisch](#)⁴, [Craig Erickson](#)⁴, [Sharron Gargosky](#)⁴, [Stella Saraff](#)⁴

¹St Vincent's Hospital Sydney - Darlinghurst Nsw (Australia), ²Flinders Medical Centre - Bedford Park Sa (Australia), ³Flinders Medical Centre - Darlinghurst Nsw (Australia), ⁴Spinogenix - Los Angeles (United States)

12:10 p.m.

OC32: Breaking barriers in early Alzheimer's disease diagnosis: The power of the in vitro diagnostic Elecsys pT181p immunoassay in a population reflective of real-world clinical practice

[Sayuri Hortsch](#)¹, [David Caley](#)², [Patrick Menzel](#)¹, [Christopher Rowe](#)³, [Mark Rapp](#)⁴, [Dag Aarlsand](#)⁵, [Anna D Burke](#)⁶, [Clara Quijano-Rubio](#)⁷

¹Roche Diagnostics GmbH - Penzburg (Germany), ²Roche Diagnostics Limited - Burgess Hill (United Kingdom), ³Australian Dementia Network Ltd - Melbourne (Australia), ⁴Berman Clinical - New York (United States), ⁵Kings College Hospital - London (United Kingdom), ⁶Barrow Neurological Institute - Phoenix (United States), ⁷Roche Diagnostics International Ltd - Rotkreuz (Switzerland)

12:25 p.m.
1:10 p.m.

LUNCH ON YOUR OWN

1:10 p.m.
1:25 p.m.

COFFEE BREAK IN THE POSTER HALL (Indigo Ballroom – Level 2)

1:25 p.m.
2:25 p.m.

LATE BREAKING COMMUNICATIONS

Moderators: [Denise Faustman](#), Massachusetts General Hospital/Harvard Medical School - Boston (United States) and [Lefkos Middleton](#), Imperial College London, London (United Kingdom)

1:25 p.m.

LB28 – Results of ASURE: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics and Exploratory Activity of TW001 in Patients with Alzheimer's Disease

Ronald Van Der Geest¹, Anastasia Lili¹, Oscar Van Loosbroek¹, Andreia Almeida¹, Frank Ruwe¹, Alina Ciobanu¹, Inez De Greef¹, Charlotte Teunissen², Sietske Sikkes³, Willem De Haan³, Jort Vijverberg³

¹Treeway TW001 AD BV - Tilburg (Netherlands), ²Neurochemistry Laboratory, Department of Laboratory Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC - Amsterdam (Netherlands), ³Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC - Amsterdam (Netherlands)

1:40 p.m.

LB29 – Impact of BCG Immunotherapy on Plasma p-tau217 in Patients with Type 1 Diabetes at Risk of Alzheimer's Disease: A Five-Year, Phase II, Randomized, Controlled Trial

Shiho Hashiguchi¹, Hikaru Hayashi², Nicholas Kartsounis², Daniel Mounier², Serena Bradley², Joan Braley², Hui Zheng², Willem Kühtreiber¹, Denise Faustman¹

¹Massachusetts General Hospital/Harvard Medical School - Boston (United States), ²Massachusetts General Hospital - Boston (United States)

1:55 p.m.

LB30 – Discovery of blood-based microRNAs that characterize Cerebral Amyloid Angiopathy

David Salzman¹, Anthony Bannon²

¹Gatehouse Bio, Inc. - Natick (United States), ²AbbVie - North Chicago (United States)

2:10 p.m.

LB31 – Results of the Phase 2b Trial of Neflamapimod in Dementia with Lewy Bodies

John-Paul Taylor¹, Stephen N Gomperts², Lawrence S Honig³, Niels D Prins⁴, Amanda Gardner⁵, Kelly Blackburn⁵, John Alam⁵, James E Galvin⁶

¹Newcastle University - Newcastle Upon Tyne (United Kingdom), ²Massachusetts General Hospital - Charlestown (United States), ³Columbia University Irving Medical Center - New York (United States), ⁴Brain Research Center - Amsterdam (Netherlands), ⁵CervoMed - Boston (United States), ⁶CervoMed - Boca Raton (United States)

2:25 p.m.

ORAL COMMUNICATIONS

3:55 p.m.

Moderators: Michael Rafii, Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States) and Ruben Smith, Lund University - Lund (Sweden)

2:25 p.m.

OC33: Effects of Semaglutide on Alzheimer's Disease-Related Biological Processes: Results from a Biofluid Biomarker and Multiomics Immunophenotyping Phase 3 Study in Patients with Early Alzheimer's Disease After 12 Weeks of Treatment

Kristian Steen Frederiksen^{1,2}, Marie Aare Bentsen³, Dylan Mathew Belmont-Rausch³, Lisbeth Carstensen³, Brian Cutler⁴, Redwan Farooq⁴, Lea Hildebrandt³, Martí Jiménez-Mausbach³, Peter Johannsen³, Gabriel Martino³, Joseph Poley-Wolf³, Amaya Zaratiegui³, Giovanni B Frisoni^{5,6}, Kathrine E Attfield⁴, Lotte Bjerre Knudsen³

¹Danish Dementia Research Centre, Department of Neurology, Copenhagen University Hospital - Rigshospitalet - Copenhagen (Denmark), ²Department of Clinical Medicine, University of Copenhagen - Copenhagen (Denmark), ³Novo Nordisk - Copenhagen (Denmark), ⁴Oxford Centre for Neuroinflammation, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford - Oxford (United Kingdom), ⁵Geneva Memory Center, Geneva University Hospitals - Geneva (Switzerland), ⁶Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva - Geneva (Switzerland)

2:40 p.m.

OC34: The MultiTEP-based vaccine, AV-1959R, safely elicits high concentrations of antibodies specific to A β 42 protofibrils/fibrils/plaques in vaccinated healthy volunteers.

Michael Agadjanyan¹, Lon Schneider², Alex Grinberg³, Anahit Ghochikyan⁴

¹Nuravax, Inc./Institute for Molecular Medicine - Irvine (United States), ²USC Keck School of Medicine - Los Angeles (United States), ³Arvax, Inc. - Adelaide (Australia), ⁴Institute for Molecular Medicine/Nuravax, Inc. - Huntington Beach (United States)

2:55 p.m.

OC35: Clinical Performance of the Elecsys CSF pTau181/Aβ42 Ratio for Concordance with Tau-PET in Two Independent Cohorts

Ruben Smith¹, Leslie Shaw², Sebastian Palmqvist¹, Niklas Mattsson-Carlgrén¹, Gregory Klein³, Matteo Tonietto³, Clara Quijano-Rubio⁴, Christopher M. Rank⁵, Myrto Andreadou⁴, Samantha C. Burnham⁶, Erik Stomrud¹

¹Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden Memory Clinic, Skåne University Hospital, Malmö, Sweden - Lund, Malmö (Sweden), ²Department of Pathology and Laboratory Medicine and the PENN Alzheimer's Disease Research Center, Center for Neurodegenerative Research, Perelman School of Medicine, University of Pennsylvania, PA, United States - Philadelphia (United States), ³Research and Early Development (pRED), F. Hoffmann-La Roche Ltd, Basel, Switzerland - Basel (Switzerland), ⁴Roche Diagnostics International Ltd, Rotkreuz, Switzerland - Rotkreuz (Switzerland), ⁵Roche Diagnostics GmbH, Penzberg, Germany - Penzberg (Germany), ⁶Eli Lilly and Company, Indianapolis, IN, United States - Indianapolis (United States)

3:10 p.m.

OC36: Biomarkers of Cognitive Performance in Alzheimer's Disease in Adults with Down Syndrome

Jason Russell¹, Zinayida Schlachetzki¹, Alexander Conley², Brian Boyd², Paul Newhouse², Michael Rafii¹

¹Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States), ²Center for Cognitive Medicine, Vanderbilt University Medical Center - Nashville (United States)

3:25 p.m.

OC37: The associations between cognitive deficits and the location of tau tangles and their consistency across clinical and observational datasets

Xingjian Zhang¹, Ritobrato Datta¹, Maggie Fedgchin², Jennifer Bogert³, Janice Wong⁴, David Henley², Gayle Wittenberg², Ziad S. Saad¹

¹Johnson & Johnson - San Diego (United States), ²Johnson & Johnson - Titusville (United States), ³Johnson & Johnson, NJ - Raritan (United States), ⁴Johnson & Johnson - Cambridge (United States)

3:40 p.m.

OC38: Strategies for Increased Representation in Trials from The NIA Health and Aging Brain Study

Charisse Winston, University of Southern California - San Diego (United States)

3:55 p.m.

4:30 p.m.

COFFEE BREAK AND POSTER SESSION (Indigo Ballroom – Level 2)

 **Biotech Showcase Session 6 – Late-Stage Biotech and Industry Innovations (details P.89)**

4:30 p.m.

6:00 p.m.

ORAL COMMUNICATIONS

Moderators: **Lon Schneider**, Keck School Medicine of USC – Los Angeles, CA (United States) and **Jacques Touchon**, Montpellier University – Montpellier (France)

4:30 p.m.

OC39: Estimated budget impact of a screening and treatment program for preclinical Alzheimer's disease in the U.S. over 15 years

Soeren Mattke¹, Jiahe Chen¹, Eric Reiman²

¹University of Southern California - Los Angeles (United States), ²Banner Alzheimer's Institute - Phoenix (United States)

4:45 p.m.

OC40: Long-Term Nicotine Treatment of Mild Cognitive Impairment: The MIND Trial

Paul Newhouse¹, Rema Raman², Brenda Armenta², Michael C. Donohue², Michael S. Rafii², Robert A. Rissman², Edward Levin³, Kenneth Kellar⁴, Andrew Saykin⁵, Julie Dumas⁶, Patricia Andrews¹, Rachel Tyndale⁷, Brian Boyd¹, Paul Aisen²

¹Vanderbilt University Medical Center - Nashville (United States), ²University of Southern California - San Diego (United States), ³Duke University - Durham (United States), ⁴Georgetown University - Washington, Dc (United States), ⁵Indiana University - Indianapolis (United States), ⁶University of Vermont - Burlington (United States), ⁷University of Toronto - Toronto (Canada)

5:00 p.m.

OC41: Impact of Nutrition, Sleep and Physical Activity on Preservation of Intellectual Function in Older Frailty Adults (INSPIOR): A Randomized Controlled Trial

Sakurai Keisuke¹, Izumi Shiraishi¹, Ryo Tanaka¹, Miwa Watanabe¹, Momoko Funakawa¹, Saori Shimada¹, Tomoko Kawaura¹, Toshiyuki Nomura², Fuka Aoki³, Takashi Matsumoto³, Yukihiro Sugawara³, Hiroki Kayama⁴, Joseph Ledsam⁴, Shin'ichi Warisawa¹, Tatsuhiro Hisatsune¹

¹The University of Tokyo - Kashiwa (Japan), ²Mitsui Fudosan, Co., Ltd. - Kashiwa (Japan), ³NH Foods Ltd. - Tsukuba (Japan), ⁴Google - Tokyo (Japan)

5:15 p.m.

OC42: Mapping the Pathogenesis of Alzheimer's Disease in Down Syndrome: Imaging, Fluid Biomarkers, Cognition, and Sex Differences for Clinical Trial Design

Nazek Queder¹, Iris Chiang¹, Andrew Luu¹, Elizabeth Andrews¹, David Keator², Jenna N. Adams³, Lisa Taylor³, Michael Yassa³, Craig Stark³, Mark Mapstone⁴, Elizabeth Head¹

¹Department of Pathology & Laboratory Medicine, University of California, Irvine - Irvine (United States), ²Department of Psychiatry and Human Behavior, University of California, Irvine - Irvine (United States), ³University of California, Irvine - Irvine (United States), ⁴Department of Neurology, University of California, Irvine - Irvine (United States)

5:30 p.m.

OC43: Considerations for Phase 2 Trials of an A β Vaccine, AV-1959R, for Secondary Prevention of Alzheimer's Disease

Lon Schneider¹, Michael Agadjanyan², Anahit Ghochikyan²

¹Keck School of Medicine of USC - Los Angeles (United States), ²Institute for Molecular Medicine - Huntington Beach (United States)

5:45 p.m.

OC44: Tau positron emission tomography harmonization using the CenTauR approach: general conversion equations and external validation

Alexis Moscoso^{1, 2}, Antoine Leuzy^{1, 3}, Lau Raket Lars⁴, Victor L. Villemagne^{5, 6}, Gregory Klein⁷, Matteo Tonietto⁷, Emily Olafson⁸, Ruben Smith^{9, 10}, Fang Xie¹¹, Hartmuth Kolb³, Nadine Tatton¹, Yashmin Karten¹, Christopher C. Rowe^{12, 13}, Oskar Hansson^{9, 10}, Vincent Doré^{12, 14}

¹Critical Path for Alzheimer's Disease (CPAD) Consortium, Critical Path Institute - Tucson (United States), ²Nuclear medicine department and Molecular Imaging Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Travesía da Choupana s/n - Santiago De Compostela (Spain), ³Enigma Biomedical Group - Knoxville (United States), ⁴Eli Lilly and Company - Indianapolis (United States), ⁵Department of Psychiatry, University of Pittsburgh School of Medicine - Pittsburgh (United States), ⁶Department of Molecular Imaging & Therapy, Austin Health - Victoria (Australia), ⁷F. Hoffmann-La Roche Ltd - Basel (Switzerland), ⁸Clinical Imaging Group, Genentech, Inc. - , South San Francisco (United States), ⁹Clinical Memory Research Unit, Department of Clinical Sciences, Lund University - Lund (Sweden), ¹⁰Memory Clinic, Skåne University Hospital - Malmö (Sweden), ¹¹Department of Nuclear Medicine & PET Center, Huashan Hospital, University - Shanghai (China), ¹²Florey Department of Neuroscience, University of Melbourne - Victoria (Australia), ¹³The Australian Dementia Network (ADNeT), The University of Melbourne - Victoria (Australia), ¹⁴Health and Biosecurity Flagship, The Australian eHealth Research Centre, CSIRO - Victoria (Australia)

6:00 p.m.

END OF THE CTAD CONFERENCE



POSTER PRESENTATIONS
presented in San Diego
and available on the CTAD25 Digital
Platform and App

POSTER LIST

MONDAY, DECEMBER 1 (3:00 P.M.) • TUESDAY, DECEMBER 2 (5:30 P.M.)

Clinical Trials: Methodology	P01 to P046	28
Clinical Trials: Results	P047 to P094	34
New Therapies and Clinical Trials	P095 to P123	41
Beyond Amyloid and Tau	P124 to P138	45
Artificial Intelligence in AD Clinical Trials	P140 to P161	47

WEDNESDAY, DECEMBER 3 (7:15 A.M. – 5:30 P.M.)

Clinical Trials: Imaging	P162 to P191	50
Clinical Trials: Biomarkers Including Plasma	P192 to P260	53
Proof of Concept for Alzheimer Drug Development interventions	P261 to P274	62
Translational Research	P275 to P305	64

THURSDAY, DECEMBER 4 (7:15 A.M. – 5:00 P.M.)

Clinical trials: Cognitive and Functional Endpoints	P306 to P327	68
Cognitive Assessment and Clinical Trials	P328 to P349	71
Behavioral Disorders and Clinical Trials	P350 to P352	74
Health Economics and Clinical Trials	P355 to P362	75
Epidemiology and Clinical Trials	P363 to P379	77
Animal Model and Preclinical Trials in AD	P380 to P391	80
Digital Health/ E-Trials	P392 to P409	82
Clinical Trials Early Career Investigator Showcase	PEC001 to PEC008	85

01 ● CLINICAL TRIALS: METHODOLOGY

MONDAY, DECEMBER 1 (3:00 P.M.) – TUESDAY, DECEMBER 2 (5:30 P.M.)

P001 Designing a Trial for LATE (Limbic-predominant Age-related TDP-43 Encephalopathy) with Donepezil: Double-blind Parallel vs Crossover Methodologies with Amyloid Stratification

Presenter: Leila Parand

Leila PARAND, Keith VOSSEL
UCLA, Los Angeles, United States

P002 Instructing Efficient Early Phase Preclinical Alzheimer's Disease Trials

Presenter: Paul R. Gaona Partida

Paul R. GAONA PARTIDA¹, Tselmen ANUURAD², Ian SEQUEIRA³, Em RAGINE⁴, Christopher TURNER⁵, Joshua D. GRILL^{6,7,8,9}, Daniel L. GILLEN^{1,8,10}

¹ Department of Statistics, Donald Bren School of Information and Computer Sciences of University of California Irvine, Irvine, United States, ² Department of Statistics & Data Science, University of California Los Angeles, Los Angeles, United States, ³ Department of Statistics and Applied Probability, University of California Santa Barbara, Santa Barbara, United States, ⁴ Department of Statistics, University of Georgia, Athens, United States, ⁵ Physics and Astronomy Department, Pomona College, Pomona, United States, ⁶ Institute for Memory Impairments and Neurological Disorders University of California Irvine, Irvine, United States, ⁷ Alzheimer's Disease Research Center University of California Irvine, Irvine, United States, ⁸ Department of Neurobiology and Behavior University of California Irvine, Irvine, United States, ⁹ Department of Psychiatry and Human Behavior University of California Irvine, Irvine, United States, ¹⁰ Department of Psychiatry and Human Behavior University of California Irvine, Irvine

P003 CSF cGMP Levels correlates with Alzheimer's Disease Severity in the POLARIS-AD Phase 3 Trial Screening Cohort

Presenter: Tianyang Xi

Sunmin JIN¹, Fred KIM², Vitella FOMENKO², James A ROCK², Jai Jun CHOUNG¹, Tianyang XI²

¹ AriBio Co., Ltd., Seongnam-Si, Republic of Korea, ² AriBio Co., Ltd., San Diego, United States

P004 Learning from failure: investigating reasons for failure of effective treatments identified in a meta-analysis of Alzheimer's disease studies

Presenter: Samuel P. Dickson

Samuel P. DICKSON, Kent HENDRIX, Tyler DUKE, Maxwell J. DICKSON, Craig MALLINCKRODT, Suzanne B. HENDRIX
Pentara Corporation, Salt Lake City, United States

P005 Phase II clinical trial on the effect of urolithin A in Alzheimer's disease

Presenter: Kateřina Veverová

Kateřina VEVEŘOVÁ¹, Jan LACZÓ¹, Shu-Qin CAO², Evandro FEI FANG-STAVEM², Martin VYHNÁLEK³

¹ Memory Clinic, Department of Neurology, Charles University, Second Faculty of Medicine and Motol University Hospital, Prague, Czech Republic, ² Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, Oslo, Norway, ³ Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, Prague, Czech Republic

P006 Characterizing Enrollment Patterns in a Preclinical Alzheimer's Disease Trial

Presenter: Marina Ritchie

Marina RITCHIE¹, Kedir HUSSEN¹, Oliver LANGFORD¹, Johanna JANSEN², Arnav BHATIA³, Doris MOLINA-HENRY¹, Joshua GRILL⁴, Paul AISEN¹, Reisa SPERLING⁵, Shobha DHADDA⁶, Michael IRIZARRY⁶, Rema RAMAN¹

¹ Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United States, ² University of California, Santa Barbara, Santa Barbara, United States, ³ Santa Clara University, Santa Clara, United States, ⁴ University of California, Irvine, Irvine, United States, ⁵ Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, United States, ⁶ Eisai Inc., Nutley, United States

P007 Double 6/18-month Phase III study to reproduce symptomatic and potentially show disease-modifying efficacy of buntanetap in treating Alzheimer's disease

Presenter: Maria Maccacchini

Maria MACCECCHINI¹, Cheng FANG¹, Melissa GAINES¹, Sarah MACALLUM¹, Daniel LASKOWITZ², Martin FARLOW³

¹ Annovis Bio, Malvern, United States, ² Duke University, Durham, United States, ³ Indiana university, Indianapolis, United States

P008 Attitudes Toward the Study Partner Requirement in Alzheimer's Disease Preclinical Trials Among Racially and Ethnically Diverse Populations

Presenter: Yiren Xu

Yiren XU¹, Megan WITBRACHT², Crystal GLOVER^{2,3}, Daniel GILLEN^{1,2}, Joshua GRILL^{2,4,5}

¹ Department of Statistics, University of California, Irvine, Irvine, United States, ² Institute for Memory Impairments and Neurological Disorders UCI MIND, University of California, Irvine, Irvine, United States, ³ Department of Neurology, University of California, Irvine, Irvine, United States, ⁴ Department of Psychiatry & Human Behavior, University of California, Irvine, Irvine, United States, ⁵ Department of Neurobiology and Behavior, University of California, Irvine, Irvine, United States

P009 Alzheimer's Disease Pivotal Trial Design for Zervimesine Following an End of Phase 2 Meeting with FDA

Presenter: Anthony Caggiano

Jennifer IACI¹, Michael GRUNDMAN^{2,3}, Nash HERNANDEZ⁴, Anthony CAGGIANO¹

¹ Cognition Therapeutics, Purchase, Ny, United States, ² Global R&D Partners, San Diego, Ca, United States, ³ University of California, San Diego, La Jolla, Ca, United States, ⁴ GloboScience Inc., Boston, Ma, United States

P010 Pharmacoeconomic Evaluation of Lecanemab for Early Alzheimer's Disease in the Northeast Chinese Population

Presenter: Huayan Liu

Huayan LIU¹, Boru JIN¹, Xue DU¹, Zhuolin JI¹, Lianghao SI²

¹ First Hospital of China Medical University, Shenyang, China, ² Medical Affairs Department, Eisai China Inc., Shenyang, China

P011 Metabotyping Reveals Distinct Gut–Brain Response Profiles to Postbiotic and multi-nutrient Intervention in Older Adults

Presenter: Amanda J Lloyd

Amanda J LLOYD¹, Courtney DAVIES¹, Alexander N W TAYLOR¹, Alina WARREN-WALKER¹, Charly MORGAN¹, Nigel HOLT¹, Denis KAY², Kevin STEPHENS³, Hariom YADAV⁴, Douglas LYNCH⁵, Alison WATSON¹, Laura LYONS¹, Manfred BECKMANN¹

¹ Aberystwyth University, Aberystwyth, United Kingdom, ² Neurodyn Life Sciences Inc, Charlottetown, Canada, ³ Agroceutical Products Ltdc, Glasbury, United Kingdom, ⁴ University of South Florida, Tampa, United States, ⁵ Postbiotics Inc, Winston Salem, United States

P013 The Alzheimer's Disease Diagnosis and Plasma p-tau217 (ADAPT) randomised controlled trial: protocol

Presenter: Joanne Rodda

Ashvini KESHAVAN^{1,2}, Joanne RODDA^{3,4}, Katharine WILTSHIRE^{1,2}, Jemma HAZAN⁵, Tanjil NAWAZ⁶, Charlotte KELHAM⁶, Liz DEANE⁶, Catherine HENDERSON⁷, Raphael WITTENBERG⁷, Melanie HART^{8,9}, Amanda HESLEGRAVE², Henrik ZETTERBERG^{2,10,11,12}, Nicholas FREEMANTLE⁶, Robert HOWARD⁵, Jonathan M. SCHOTT^{1,2}

¹ Dementia Research Centre, UCL Queen Square Institute of Neurology, London, United Kingdom, ² UK Dementia Research Institute at University College London, London, United Kingdom, ³ Kent and Medway NHS Mental Health Trust, Maidstone, United Kingdom, ⁴ Kent and Medway Medical School, Canterbury, United Kingdom, ⁵ UCL Division of Psychiatry, London, United Kingdom, ⁶ Comprehensive Clinical Trials Unit at University College London, London, United Kingdom, ⁷ Care Policy and Evaluation Centre, London School of Economics and Political Science, London, United Kingdom, ⁸ Neuroimmunology and CSF Laboratory, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, United Kingdom, ⁹ Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, United Kingdom, ¹⁰ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden, ¹¹ Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong Special Administrative Region, China, ¹² Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, United States



P014 Clinical research protocol of Lecanemab based on synaptic plasticity for the treatment of early Alzheimer's disease

Presenter: Cuibai Wei

Aidi SHAN¹, Qingyuan SUN¹, Xiaodong HAN¹, Chang XU¹, Qi YAO², Xin WANG¹, Cuibai WEI^{1,3}

¹ Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, China, ² College of Integrated Traditional Chinese and Western Medicine, Changchun University of Chinese Medicine, Changchun, China, ³ Inan Hospital of Xuanwu Hospital, Shandong First Medical University, ²⁵⁰¹⁰², Jinan, China

P015 Open Science: Building an International Data and Specimen Sharing Infrastructure for Alzheimer's Disease Clinical Trials

Presenter: Gustavo Jimenez-Maggiara

Gustavo JIMENEZ-MAGGIORA¹, Aaron SCHULTZ^{2,3}, Michael DONOHUE¹, Hongmei QIU¹, Richard GALLARDO¹, Sara ABDEL-LATIF¹, Robert RISSMAN¹, Reisa SPERLING^{2,3}, Paul AISEN¹

¹ University of Southern California, San Diego, United States, ² Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Massachusetts General Hospital, Boston, United States, ³ Harvard Medical School, Boston, United States

P016 Tau-Predictive Functional Connectome Patterns Predict Clinical Progression and Solanezumab Response in Preclinical Alzheimer's Disease

Presenter: Hamid Abuwarda

Hamid ABUWARDA ^{1,2}, Wen-Xiang TSAI ^{1,3}, Shengxian DING ⁴, Mohamed ELHASSAN ¹, Xilin SHEN ⁵, Yize ZHAO ⁶, Todd CONSTABLE ^{2,7,8}, Carolyn FREDERICKS ^{1,2}

¹ Department of Neurology, School of Medicine, Yale University, New Haven, United States, ² Interdepartmental Neuroscience Program, School of Medicine, Yale University, New Haven, United States, ³ Institute of Brain Science, National Yang Ming Chiao Tung University, Taipei, Taiwan, République de China, ⁴ Department of Biostatistics, School of Public Health, Yale University, New Haven, United States, ⁵ Department of Radiology, School of Medicine, Yale University, New Haven, United States, ⁶ Department of Biostatistics, School of Public Health, Yale University, New Haven, United States, ⁷ Department of Radiology, School of Medicine, Yale University, United States, ⁸ Department of Biomedical Engineering, School of Medicine, Yale University, New Haven, United States

P018 Improving insights on disease modification in Alzheimer's disease by including sequential GSTs in the analysis hierarchy

Presenter: Joshua Christensen

Joshua CHRISTENSEN, Daniel SMITH, Kent HENDRIX, Craig MALLINCKRODT, Suzanne HENDRIX, Samuel DICKSON
Pentara Corporation, Millcreek, United States

P019 ALTITUDE-AD: Recruitment strategies for a global phase 2 trial of sabirnetug in early Alzheimer's disease

Presenter: Robyn Moxon

Robyn MOXON ¹, Alyssa CARROLL ¹, Todd FEASTER ¹, Kathy MARCOZZI PIERCE ¹, Maddelyn HYLAND ¹, Siew TIN GAN ¹, Dung TRINH ², Eric SIEMERS ¹

¹ Acumen Pharmaceuticals, Inc, Newton, Massachusetts, United States, ² Healthy Brain Research, Long Beach, California, United States

P020 Study Design of a Multiple Ascending Intravenous Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics of VY7523 in Participants with Early Alzheimer's Disease

Presenter: Monroe Butler

Monroe BUTLER ¹, Naomi MUSE ¹, Sarah PIANTEDOSI ¹, Thrusha CHAUHAN ¹, Beth MELLEN ¹, Charlotte CHUNG ¹, Raj RAJAGOVINDAN ¹, Vik ARORA ¹, Alben PATRONEVA ², Maury EMERY ², Alfred SANDROCK ¹, Toby FERGUSON ¹, Elena RATTI ¹

¹ Voyager Therapeutics, Lexington, United States, ² Voyager Therapeutics Contractor, Lexington, United States

P021 The PRImus-AD study: design of the phase 2 study treating patients with MCI or mild dementia due to Alzheimer's disease (AD) with the orally available PRI-002

Presenter: Dieter Willbold

Dieter WILLBOLD ^{1,2}, Dagmar JÜRGENS ¹, Tischler GERHARD ³, Brener ALEXANDER ³, Bartsch TINA ³, Kauselmann GUNTHER ¹, Adermann KNUT ¹, Zeiger KATHRIN ³, Kindner KATJA ³, Gabelich JULIE-ANNE ³, Peters OLIVER ⁴

¹ Priavoid GmbH, Düsseldorf, Germany, ² Heinrich Heine University Düsseldorf, Institute of Physical Biology, Düsseldorf, Germany, ³ PRInnovation GmbH, Düsseldorf, Germany, ⁴ Charite, Berlin, Germany

P022 A Phase 3 Clinical Protocol: Placebo-Controlled, Double-Blind, Parallel-Group to Evaluate Safety and Efficacy of NA-831 as Monotherapy and in Combination with Donanemab in Subjects with Early Alzheimer's Disease

Presenter: Lloyd Tran

Lloyd TRAN, Fern VU, Zung TRAN
Biomed Industries, Inc., San Jose, United States

P023 VHB937, a TREM2 stabilizing and activating fully human monoclonal antibody: A Phase 2 study design in Alzheimer's disease and rationale

Presenter: Ana Graf

Ana GRAF ¹, Dominik FEUERBACH ¹, Derya SHIMSHEK ¹, Judit SOVAGO ¹, Gisela PERAUS ¹, Aileen ZHU ², Catherine AGOROPOULOU ¹, Alexandra BOBIRCA ¹, Carmen SERBAN ¹

¹ Novartis Pharma AG, Basel, Switzerland, ² Novartis, Shanghai, China

P025 Has Alzheimer's been defined as a white person's disease? How biomarker-based inclusion criteria may lead to differential access to clinical trials across racial and ethnic groups, an analysis of the Bio-Hermes study

Presenter: Joshua Christensen

Joshua CHRISTENSEN, Suzanne HENDRIX, Garrett DUNCAN, Kent HENDRIX, Samuel DICKSON
Pentara Corporation, Millcreek, United States

P026 Utility of high throughput blood-based p-Tau217, GFAP, NfL and APOE ϵ 4 immunoassays for clinical trials of Alzheimer's disease

Presenter: David Escobar

David ESCOBAR, Elizabeth RAMIREZ, Virginia NYANCHAMA, Navid KOOCHKEK, Mark BLIMLINE, Naveen DAKAPPAGARI
Navigate BioPharma Services, Carlsbad, United States

P027 Incorporating auxiliary information into a continuation decision once a group sequential boundary has crossed into an interim futility stopping set

Presenter: Christina Magana-Ramirez

Christina MAGANA-RAMIREZ, Daniel GILLEN
Department of Statistics, University of California, Irvine, Irvine, United States

P028 Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study

Presenter: J. Nicholas Cochran

Meagan COCHRAN¹, Jada PUGH¹, Tanner COLEMAN¹, S. Quinn JOHNSTON¹, Jared TAYLOR¹, Scott NEWBERRY¹, Whitley KELLEY¹, Lee HOOD², Jennifer LOVEJOY², J. Nicholas COCHRAN¹

¹ HudsonAlpha Institute for Biotechnology, Huntsville, United States, ² Phenome Health, Seattle, United States

P029 Annual Site Coordinator Meetings as a Catalyst for Retention Strategy Development in Alzheimer's Disease Longitudinal Cohort Studies

Presenter: Andrew Mellor

Andrew MELLOR¹, Hannatu AMAZA², Joseph DI BENEDETTO³, Taylor CLANTON¹, Doris MOLINA-HENRY¹, Ozioma OKONKWO², Mónica RIVERA MINDT^{3,4}, Rema RAMAN¹

¹ Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United States, ² Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, United States, ³ Department of Psychology, Latin American and Latino Studies Institute, and African and African American Studies, Fordham University, New York, United States, ⁴ Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, United States

P030 A Single-Center, Retrospective, Rater-Blinded, Crossover Study to Evaluate the Clinical Utility of a Medical Image Analysis Software for Quantitative Analysis of Brain PET Images in Patients with Alzheimer's Disease

Presenter: Jung Yun Seo

Jung Yun SEO¹, Sun Min LEE¹, Kyung Hwa SUN¹, Yong Jin PARK², Su Jin LEE², Young Sil AN², So Young MOON¹

¹ Department of Neurology, Ajou University School of Medicine, Suwon, Republic of Korea, ² Department of Nuclear Medicine and Molecular Imaging, Ajou University School of Medicine, Suwon, Republic of Korea

P031 Many Exciting New Targets for AD... But Do More MOAs Mean More Duplicate Subjects?

Presenter: Thomas Shiovitz

Thomas SHIOVITZ^{1,2}, Chelsea STEINMETZ¹, Brittany STEINMILLER¹, Levi TROUT¹

¹ CenExel CTSdatabase, LLC, Sherman Oaks, United States, ² CenExel California Neuroscience Research, Sherman Oaks, United States

P032 Advancing Alzheimer's Research Through Community-Based Neurology Trials: A Profound Research Model

Presenter: Gregory Sahagian

Gregory SAHAGIAN^{1,2}, Lora PARAHOVNIK²

¹ The Neurology Center of Southern California, Carlsbad, United States, ² Profound Research, Nashville, United States

P033 Lessons from Real-world Clinical Implementation of Anti-amyloid ? Antibodies: Bridging the Gap to Clinical Trials

Presenter: Ryoko Ihara

Ryoko IHARA, Masanori KURIHARA, Keiko HATANO, Taro BANNAI, Ryosuke SHIMASAKI, Akira HATAKEYAMA, Ko FURUTA, Fumio SUZUKI, Aya TOKUMARU, Kenji ISHII, Atsushi IWATA
Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan

P034 Successful Strategies for Recruitment and Retention as a Foundation for ADRD-focused Clinical Trials in a Rural Cohort

Presenter: Lisa Wiese

Lisa WIESE¹, Christine WILLIAMS¹, Diane J COOK², Juyoung PARK³, Jan HOLT¹, Diana MITSOVA¹, Sheryl MAGZAMEN⁴, Lilah BESSER⁵, Madeline TOURELLE⁵,⁵
¹ Florida Atlantic University, Boca Raton, United States, ² Washington State University, Pullman, United States, ³ Washington State University, Phoenix, United States, ⁴ Colorado State University, Fort Collins, United States, ⁵ University of Miami, Miami, United States

P035 Effect of consenting clinician degree on screen fail rate in Alzheimer's Disease clinical trials

Presenter: Ralph Lee

Yu-Jay HUOH, Razyya ABDULMUMIN, James LUAYON, Dana NGUYEN, Tara PARNITVITHIKUL, Elizabeth SOSA, Edward ZAMRINI, Ralph LEE
Irvine Clinical Research, Irvine, United States

P036 Click or Clinic? Comparing Referral-to-Pre-Screen Attendance Rates Between Digital Advertisements and HCP Referrals in Alzheimer's Clinical Trials

Presenter: Thibaud Belleface

Thibaud BELLEFACE, Jeffrey APTER
Global Medical Institutes, Princeton, United States

P037 Minimal clinically important differences are often misapplied and misinterpreted and should be used with caution

Presenter: Kent Hendrix

Patrick O'KEEFE, Mitchell WASSOM, Kent HENDRIX, Craig MALLINCKRODT, Suzanne HENDRIX, Samuel DICKSON
Pentara, Millcreek, United States

P038 Rethinking Interim Analyses: When and Why to Avoid Them

Presenter: Samuel Johnson

Samuel JOHNSON, Katelyn MILLER, Kent HENDRIX, Craig MALLINCKRODT, Suzanne HENDRIX, Samuel DICKSON
Pentara Corporation, Millcreek, United States

P039 Improving Study Power Through Continuous Modeling of a Global Treatment Effect Versus Composite Responder Analysis

Presenter: Abe Durrant

Abe DURRANT¹, Andrew MILLANE², Craig MALLINCKRODT², Kent HENDRIX², Suzanne HENDRIX², Samuel DICKSON²
¹ Author, Salt Lake City, United States, ² Co-Author, Salt Lake City, United States

P040 Feasibility of Participants with Symptomatic Alzheimer's Disease to Self-Administer Remternetug Subcutaneously: Results from the TRAILRUNNER-ALZ 1 Phase 3 Trial

Presenter: Matthew Hufford

Matthew HUFFORD, Kevin BIGLAN, Chad STROUD, Anna Eames SEFFERNICK, Meilin JIANG, Mausumi LIDOGASTER, Matan DABORA
Eli Lilly and Company, Indianapolis, United States

P041 Breaking down the influences of placebo progression and percent slowing in the context of time saved in Alzheimer's Disease clinical trials for populations in different disease stages

Presenter: Caleb Dayley

Caleb DAYLEY, Suzanne HENDRIX, Samuel DICKSON, Kent HENDRIX, Jason COOK
Pentara Corporation, Millcreek, United States

P042 The effect of corticosteroid pre-treatment with modified titration of donanemab on amyloid reduction and safety: TRAILBLAZER-ALZ 6 addendum design

Presenter: Hong Wang

Emel Serap NERY¹, Hong WANG¹, Paul ARDAYFIO¹, Rashna KHANNA¹, Diana SVALDI¹, Sergey SHCHERBININ¹, Wen XU¹, Paula HAUCK¹, Jin-Tai YU², Jiong SHI³, Dawn BROOKS¹, Emily COLLINS¹, Mark MINTUN¹, John SIMS¹

¹ Eli Lilly and Company, Indianapolis, United States, ² Huashan Hospital, Shanghai, China, ³ The First Affiliated Hospital of University of Science and Technology of China, Hefei, China

P043 Study Insight Analytics (SIA) Algorithms Validation for SMART Independent Review of the ADAS-Cog Scale

Presenter: Selam Negash

Selam NEGASH, Matt WELCH, B ECHEVARRIA, Chris RANDOLPH

Clario, Philadelphia, United States

P044 REACHED – a pilot study exploring electronic health records and digital assessments to identify potential participants from understudied populations for clinical studies in Alzheimer’s disease

Presenter: Ruth Croney

Frank BOESS¹, Nicola MAIORANO¹, Janice SMITH², Alexandria WISE-BROWN³, Kelly COULTES⁴, Giuseppe FILOSA¹, Frank PERILLI⁵, Erin BECK⁵, Ira GOODMAN⁵, Ruth CRONEY²

¹ F. Hoffmann-La Roche, AG, Basel, Switzerland, ² Roche Products Ltd, Welwyn Garden City, United Kingdom, ³ Genentech, Inc., South San Francisco, United States,

⁴ F. Hoffmann-La Roche Ltd, Mississauga, Canada, ⁵ SiteRx, New York, United States

P045 Web-Based Prescreening Survey for Alzheimer’s Disease Clinical Trials: Enhancing Efficiency and Diversity

Presenter: Elisabeth Burnett

Elisabeth BURNETT, Anna SLADKY, Jenny ECHEVARRIA MEDINA, Ijeoma MBA, Patricia LOWE, Karen COLOMBO, Terrence LAFRANCE, Mariah ALEXIS, Juris JANAUS, Lauren MARCONI, Joette GIOVINCO, Ram BISHNOI, Amanda SMITH, Wendy BELDEN

USF Health Byrd Alzheimer’s Institute, Tampa, United States

P046 Trends on patients’ recruitment and retention in Alzheimer’s disease modification trials.

Presenter: Karla Kanis

Andreas LYSANDROPOULOS¹, Jessica GARINGER², Karla KANIS²

¹ Parexel, Wavre, Belgium, ² Parexel, Newton, United States

02 ● CLINICAL TRIALS: RESULTS

MONDAY, DECEMBER 1 (3:00 P.M.) – TUESDAY, DECEMBER 2 (5:30 P.M.)

P047 Transcranial Vibroacoustic Stimulation Enhances Cognitive Function and Neural Plasticity in Older Adults: A Double-Blind Randomized Trial

Presenter: Fred Kim

Chang-Ho SHIN ^{1, 2}, Jang-Han BAE ^{3, 4}, Jae-Young HA ¹, Jai Jun CHOUNG ¹, Min-Woo CHO ¹, Byung-In OH ⁵, Kun Ho LEE ^{6, 7}, Young Chul YOUN ⁸, Sangyun KIM ⁹, Dong-Keun SONG ¹, Vitella FOMENKO ¹⁰, Tianyang XI ¹⁰, Fred KIM ¹⁰

¹ AriBio Co., Ltd., Seongnam-Si, Republic of Korea, ² Department of AI Convergence Biomedical Engineering, Dongguk University, Goyang-Si, Republic of Korea, ³ Digital Health Research Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea, ⁴ Aging Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea, ⁵ Jangsoo Industry Co., Ltd., Seoul, Republic of Korea, ⁶ Gwangju Alzheimer's Disease and Related Dementias GARD Cohort Research Center, Chosun University, Gwangju, Republic of Korea, ⁷ Department of Biomedical Science, Chosun University, Gwangju, Republic of Korea, ⁸ Department of Neurology, Chung-Ang University College of Medicine, Seoul, Republic of Korea, ⁹ Department of Neurology, Seoul National University College of Medicine and Seoul National University Bundang Hospital, Seongnam-Si, Republic of Korea, ¹⁰ AriBio Co., Ltd., San Diego, United States

P049 Stability and Improvement in Early Alzheimer's Disease with Lecanemab: Sub-analysis from a United States Multicenter, Retrospective Real-World Study

Presenter: Curtis Schreiber

Curtis SCHREIBER ¹, David WEISMAN ², Marwan SABBAGH ³, Michael ROSENBLUM ^{4, 5, 6}, Jose SORIA-LOPEZ ^{7, 8}, Gregory COOPER ⁹, Samuel GILES ¹⁰, Cara LEAHY ¹¹, Paul SCHULZ ¹², Christian CAMARGO ¹³, Brooke ALLEN ¹⁴, Feride FRECH ¹⁵, Courtney ADAMS ¹⁵, Daryl JONES ¹⁵

¹ Missouri Memory Center, Citizens Memorial Hospital, Bolivar, United States, ² Department of Neurosciences and the Alzheimer's Disease Research Center, University of California, San Diego, United States, ³ Department of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, United States, ⁴ Memory and Brain Wellness Center, University of Washington, Seattle, United States, ⁵ Department of Neurology, University of Washington, Seattle, United States, ⁶ University of Washington Alzheimer's Disease Research Center, Seattle, United States, ⁷ The Neuron Clinic, Chula Vista, United States, ⁸ Department of Neurosciences, University of California San Diego, La Jolla, United States, ⁹ Norton Neuroscience Institute, Louisville, United States, ¹⁰ Memory Treatment Centers, Jacksonville Beach, United States, ¹¹ Memorial Healthcare Institute for Neuroscience, Owosso, United States, ¹² Neurocognitive Disorders Center, Department of Neurology, The McGovern Medical School of UTHealth-Houston, Houston, United States, ¹³ Department of Neurology and Evelyn F. McKnight Brain Institute, University of Miami Miller School of Medicine, Miami, United States, ¹⁴ Roaring Fork Neurology, Basalt, United States, ¹⁵ Eisai Inc., Nutley, United States

P050 A Phase 1b study of the safety and tolerability of ALX-001 (BMS-984923) in Alzheimer's disease with a pilot study of synaptic imaging

Presenter: Adam Mecca

Adam MECCA ¹, Ryan O'DELL ¹, Emma COOPER ¹, Jesse STANHOPE ¹, Natalie BAER ¹, Audra CURTIN ¹, Elaheh SALARDINI ¹, Mika NAGANAWA ¹, Juan YOUNG ¹, Susan DESTEFANO ¹, Patrick SIMMS ², Richard CARSON ¹, Timothy SIEGERT ², Stephen STRITTMATTER ¹, Christopher VAN DYCK ¹

¹ Yale School of Medicine, New Haven, United States, ² Allyl Therapeutics, New Haven, United States

P051 POLARIS-AD: Record-Breaking Global Enrollment in the Largest Phase 3 Trial of an Oral Multi-Mechanistic PDE5 Inhibitor for Early AD Using Biomarker-Agnostic Modalities for Amyloid Confirmation

Presenter: Sharon J Sha

Niels PRINS ¹, Alireza ATRI ², Fernando MELGAR-SOMOZA ³, Marzena ZBOCH ⁴, Do Hoon KIM ⁵, Yi TANG ⁶, Jennifer LYNCH ⁷, Howard CHERTKOW ⁸, Sangyun KIM ⁹, David GREELEY ¹⁰, James A ROCK ¹¹, Fred KIM ¹¹, Tianyang XI ¹¹, Jai Jun CHOUNG ¹¹, Sharon J SHA ¹²

¹ Brian Research Center, Amsterdam, Netherlands, ² Banner Sun Health Research and Banner Alzheimer's Institutes, Sun City, United States, ³ Melgar-Caro MedCenter and Community Research, Miami, United States, ⁴ Wroclawskie Centrum Alzheimerowski, Wroclaw, Pologne, ⁵ Department of Psychiatry, Chuncheon Sacred Heart Hospital, Chuncheon, Republic of Korea, ⁶ Xuanwu Hospital Capital Medical University, Beijing, China, ⁷ Glasgow NeuroClin, Excel House, Motherwell, United Kingdom, ⁸ Baycrest Centre for Geriatric Care, Ontario, Canada, ⁹ Seoul National University College of Medicine & Seoul National University, Seoul, Republic of Korea, ¹⁰ Northwest Neurological, Spokane, United States, ¹¹ AriBio Co., Ltd, San Diego, United States, ¹² Stanford, Palo Alto, United States

P052 Long-Term Benefit of Lecanemab in Patients with Low Baseline Amyloid: Estimation of Time Saved

Presenter: Sam Dickson

Sam DICKSON ¹, John WHETTEN ¹, Suzanne HENDRIX ¹, Katherine YOUMANS-KIDDER ², Daryl JONES ²

¹ Pentara Corporation, Millcreek, United States, ² Eisai Inc., Nutley, United States

P053 Patient, Care Partner, and Health Care Professional Acceptability of the Autoinjector for the Subcutaneous Delivery of Lecanemab in Patients With Early Alzheimer's Disease in the US

Presenter: Courtney Adams

Courtney ADAMS¹, Leah ZULLIG², Raymond TURNER³, Daryl JONES¹

¹ Eisai Inc., Nutley, United States, ² Department of Population Health Sciences, Duke University School of Medicine, Durham, United States, ³ Department of Neurology, Georgetown University, Washington, United States

P054 Effects of Oral Valiltramiprosate on Clinical Efficacy, Safety and Brain Volume Outcomes in APOE4/4 Homozygotes with Early AD: Topline Results of APOLLOE4 Randomized, Placebo-Controlled 78-Week Multi-Center Trial

Presenter: Susan Abushakra

Susan ABUSHAKRA¹, David WATSON², Aidan POWER¹, Anton PORSTEINSSON³, Marwan SABBAGH⁴, Sharon COHEN⁵, Emer MACSWEENEY⁶, Merce BOADA⁷, Pierre Jean OUSSET⁸, Earvin LIANG¹, Susan FLINT¹, Patrick KESSLAK¹, John HEY¹, Adem ALBAYRAK¹, Martin TOLAR¹

¹ Alzheon, Inc, Framingham, United States, ² Alzheimer's Research and Treatment Center, Wellington, United States, ³ University of Rochester School of Medicine and Dentistry, Rochester, United States, ⁴ Barrow Neurological Institute, Phoenix, United States, ⁵ Toronto Memory Program, Toronto, Canada, ⁶ Re:Cognition Health, London, United Kingdom, ⁷ Ace Alzheimer Center, Barcelona, International University of Catalunya, Barcelona, Spain, ⁸ University of Toulouse and Toulouse Gerontopole, Toulouse, France

P055 Baseline Characteristics and Preliminary Safety from a Multicenter, Safety Surveillance Study of Lecanemab Treatment for Alzheimer's Disease in Real-World Clinical Practice using Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) Registry

Presenter: Marwan Sabbagh

Marwan SABBAGH¹, Laura CORNELISSEN², Barry MICHEL², Ilona SURICK², Shobha DHADDA², Michio KANEKIYO², Steven HERSCH², Michael IRIZARRY²

¹ Barrow Neurological Institute, Phoenix, United States, ² Eisai Inc., Nutley, United States

P056 Clinical Stabilization in APOE4 Carriers with MCI over 3 Years Correlates with Reduced Hippocampal Atrophy in a Phase 2 Long Term Extension Study with Oral Valiltramiprosate

Presenter: John Hey

John HEY¹, Susan ABUSHAKRA¹, Jakub HORT², Katerina SHEARDOVA³, Jeremy YU¹, Pat KESSLAK¹, Jean SCHAEFER¹, Adem ALBAYRAK¹, Margaret BRAY¹, Luc BRACOUD⁴, Chris CONKLIN⁵, Joyce SUHY⁵, Aidan POWER¹, Martin TOLAR¹

¹ Alzheon, Inc., Framingham, United States, ² Charles University, Prague, Czech Republic, ³ International Clinical Research Center, Brno, Czech Republic, ⁴ Clario, Lyon, France, ⁵ Clario, San Mateo, United States

P057 XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer's Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial

Presenter: Kim A. Staats

Kim A. STAATS¹, Judith JAEGER², Sarah BARNUM², Sharon COHEN³, Malu GAMEZ TANSEY⁴, Christopher J. BARNUM¹

¹ INmune Bio, Inc., Boca Raton, United States, ² CognitionMetrics, LLC, Hixon, United States, ³ Toronto Memory Program, Toronto, Canada, ⁴ Department of Neurology, Indiana University School of Medicine, Stark Neuroscience Research Institute, Indianapolis, United States

P058 Correlations of Valiltramiprosate Effects on Hippocampal Volume and Cortical Thickness with Clinical Outcomes in APOE4/4 Subjects with MCI: Prespecified Analysis of MCI Group in the 78-Week APOLLOE4 Phase 3 Trial

Presenter: Aidan Power

Aidan POWER¹, Dugyu TOSUN², Earvin LIANG¹, Susan ABUSHAKRA¹, David WATSON³, Emer MACSWEENEY⁴, Merce BOADA⁵, Karim BENNYNS⁶, Jorge MATIAS-GUIU⁷, John A. HEY¹, Susan FLINT¹, J. Patrick KESSLAK¹, Luc BRACOUD⁸, Margaret BRAY¹, Martin TOLAR¹

¹ Alzheon Inc., Framingham, United States, ² University of California San Francisco, San Francisco, United States, ³ Alzheimer's Research and Treatment Center, Wellington, United States, ⁴ Re:Cognition Health, London, United Kingdom, ⁵ International University of Catalunya, Barcelona, Spain, ⁶ Hopital Gui de Chauiac - CHRU de Montpellier, Montpellier, France, ⁷ Hospital Clinico San Carlos, Madrid, Spain, ⁸ Clario Inc., Philadelphia, United States

P059 Baseline antihypertensive medication use is associated with lower frequency of amyloid-related imaging abnormalities-edema with donanemab treatment even after controlling for mean arterial blood pressure: Analysis from TRAILBLAZER-ALZ randomized clinical trials

Presenter: Paul Ardayfio

Paul ARDAYFIO, Chakib BATTIOUI, Rashna KHANNA, Steve LAUZON, Mariângela LUCHEZI, Alessio ERAMO, Jennifer Ann ZIMMER, Cynthia D. EVANS, Emel Serap Monkul NERY, Hong WANG, Dawn A. BROOKS, John R. SIMS
Eli Lilly & Company, Indianapolis, United States

P060 Effects of the Oral Anti-amyloid Agent Valiltramiprosate on Measures of Microstructural Integrity: Diffusion MRI Results of the Phase 3 APOLLOE4 Trial in APOE4/4 Homozygotes with Early AD

Presenter: Earvin Liang

Earvin LIANG¹, Dugyu TOSUN², Susan ABUSHAKRA¹, David WATSON³, Sharon COHEN⁴, Emer MACSWEENEY⁵, Chris CONKLIN⁶, Madhura INGALHALIKAR⁶, John A HEY⁶, J Patrick KESSLAK¹, Susan FLINT¹, Martin TOLAR¹

¹ Alzheon Inc., Framingham, United States, ² University of California San Francisco, San Francisco, United States, ³ Alzheimer's Research and Treatment Center, Wellington, United States, ⁴ Toronto Memory Program, Toronto, United States, ⁵ Re:Cognition Health, London, United States, ⁶ Clario Inc, Philadelphia, United States

P061 Effects of transcranial Photobiomodulation(tPBM) on Cognitive Function and Brain functional connectivity: A Preliminary Clinical Study

Presenter: Morihiro Tsujishita

Morihiro TSUJISHITA^{1,2}, Nam Heon KIM³, Jun-Yeop KIM³, Seung Wan KANG^{3,4}

¹ Faculty of Health and Medical Sciences, Department of Rehabilitation, Nara, Japan, ² Nara Gakuen University; Graduate School of Rehabilitation Studies, Nara Gakuen University, Nara, Japan, ³ iMediSync Inc, Seoul, Republic of Korea, ⁴ National Standard Reference Data Center for Korean EEG, Seoul National University College of Nursing, Seoul, Republic of Korea

P062 Safety Outcomes of Lecanemab in Korean Real-World Clinical Practice: A Multicenter Observational Study

Presenter: Heekyoung Kang

Heekyoung KANG¹, Hyemin JANG², Jehyun AHN³, Jae-Hong LEE⁴, Duk L NA⁵, Byeong Chae KIM⁶, Eun-Joo KIM⁷, Min Young CHUN⁸, Jihwan YUN⁹, Si Eun KIM¹⁰, Soo Hyun CHO⁶, Jun Pyo KIM¹¹, Sang Won SEO³, Jae-Sung LIM², Hee Jin KIM¹

¹ Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea - Seoul Korea, Republic of, Seoul, Republic of Korea, ² Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea - Seoul Korea, Republic of, Seoul, Republic of Korea, ³ Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, ⁴ Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, ⁵ HappyMind Clinic, Seoul, Republic of Korea, Seoul, Republic of Korea, ⁶ Department of Neurology, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Republic of Korea, Seoul, Republic of Korea, ⁷ Department of Neurology, Pusan National University Hospital, Busan, Republic of Korea, Seoul, Republic of Korea, ⁸ Department of Neurology, Yongin Severance Hospital, Yonsei University Health System, Yongin-si, Gyeonggi-do, Republic of Korea, Seoul, Republic of Korea, ⁹ Department of Neurology, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, ¹⁰ Department of Neurology, Inje University Haeundae Paik Hospital, Busan, Republic of Korea, Seoul, Republic of Korea, ¹¹ Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea - Seoul Korea, Republic of - Seoul Korea, Republic of, Seoul, Republic of Korea

P063 Cognitive and electrophysiological effects of postbiotic dietary supplementation in older adults: results from a randomised double-blind, placebo-controlled trial

Presenter: Hariom Yadav

Alina WARREN-WALKER¹, Courtney DAVIES¹, Charly MORGAN¹, Nigel HOLT¹, Douglas LYNCH², Denis KAY³, Kevin STEPHENS⁴, Hariom YADAV⁵, Alexander Nw TAYLOR¹, Amanda J LLOYD¹

¹ Aberystwyth University, Aberystwyth, United Kingdom, ² Postbiotics Inc, Winston Salem, United States, ³ Neurodyn Life Sciences Inc, Charlottetown, Canada, ⁴ Agroceutical Products Ltd, Glasbury, United Kingdom, ⁵ University of South Florida, Tampa, United States

P064 Valacyclovir treatment of mild cognitive impairment with herpes simplex seropositivity: the VALMCI trial

Presenter: Davangere Devanand

Davangere DEVANAND, Terry GOLDBERG, Min QIAN, Renjie WEI, Howard ANDREWS, Lola NEDIC, Deborah DELIYANNIDES, Lawrence MAAYAN, Francesca ZANDERIGO, Edward HUEY
Columbia University, New York, United States

P065 Results from a Phase 1b trial on anti-A β oligomer vaccine ALZ-101 in early Alzheimer's disease

Presenter: Anders Sandberg

Anders SANDBERG¹, Juha RINNE², Zsófia LOVRÓ³, Mika SCHEININ³, Stefan PIERROU¹, Henrik ZETTERBERG⁴

¹ Alzinova AB, Mölndal, Sweden, ² University of Turku and Turku University Hospital, Turku, Finland, ³ CRST / Link Medical, Turku, Finland, ⁴ University of Gothenburg, Göteborg, Sweden

P067 Effects of PoZibio® and Cerbella® supplementation on brain function and wellbeing in older adults

Presenter: Amanda J Lloyd

Courtney DAVIES¹, Alina WARREN-WALKER¹, Charly MORGAN¹, Nigel HOLT¹, Douglas LYNCH², Denis KAY³, Kevin STEPHENS⁴, Hariom YADAV⁵, Alexander Nw TAYLOR¹, Amanda J LLOYD¹

¹ Aberystwyth University, Aberystwyth, United Kingdom, ² Postbiotics Inc, Winston Salem, United States, ³ Neurodyn Life Sciences Inc, Charlottetown, Canada, ⁴ Agroceutical Products Ltd, Glasbury, United Kingdom, ⁵ University of South Florida, Tampa, United States

P069 Computerised cognitive training benefits cognition in older adults with cognitive impairment in Long Covid: Outcomes from the BEACON randomised controlled trial

Presenter: Anne Corbett

Anne CORBETT¹, Shanice TULLOCH², Abbie PALMER², Millie SANDER², Arit INOK², Dag AARSLAND³, Nerina FRAMPTON², Adam HAMPSHIRE³, Clive BALLARD¹

¹ Exeter, Exeter, United Kingdom, ² University of Exeter, Exeter, United Kingdom, ³ King's College London, London, United Kingdom

P070 Anti-Abeta treatment without ARIA-E using the oligomer disassembling compound PRI-002 in an ongoing Phase 2 trial

Presenter: Oliver Peters

Oliver PETERS^{1,2}, Dagmar JÜRGENS², Gerhard TISCHLER³, Alexander BRENER³, Tina BARTSCH³, Gunther KAUSELMANN², Knut ADERMANN², Kathrin ZEIGER³, Katja LINDNER³, Julie-Anne GABELICH³, Dieter WILLBOLD²

¹ Charité, Berlin, Germany, ² Priavoid, Düsseldorf, Germany, ³ Prinnovation, Leipzig, Germany

P071 Neflamapimod Significantly Lowers Plasma GFAP and Correlates with Clinical Benefit in Dementia with Lewy Bodies: Results from the RewinD-LB Trial

Presenter: John J Alam

John J ALAM¹, Hui-May CHU², Amanda GARDNER³, Blackburn KELLY³, Charlotte E TEUNISSEN⁴

¹ CeroMed, Inc, Boston, United States, ² Anoxis Corporation, Natick, United States, ³ CervoMed, Boston, United States, ⁴ Amsterdam Medical Center, Amsterdam, Netherlands

P072 Real-World Clinical, Safety and Patient-Reported Outcomes of Treatment with Lecanemab in a New England Alzheimer's Disease Center

Presenter: Salvatore Napoli

Salvatore NAPOLI, Rachel O' DONNELL, Lauren NASSR, Emily MAIZE

Alzheimer's Neurology and Infusion Centers of New England, Foxboro, United States

P073 Amyloid Co-Pathology and Cognitive Decline in Buntanetap Treated Parkinson's Disease Dementia Patients

Presenter: Cheng Fang

Cheng FANG¹, Hui LIU¹, David FENG², Melissa GAINES¹, Maria MACCECCHINI¹

¹ Annovis Bio, Malvern, United States, ² TCM, New Jersey, United States

P074 Comparing the Effects of a Multi-component Behavioral Intervention for People with Mild Cognitive Impairment by Care partner Type

Presenter: Zhigang Xie

Zhigang XIE¹, Gelan YING¹, Stephanie AGHAMOOSA², Dona LOCKE³, Glenn SMITH¹, Anne SHANDERA-OCHSNER⁴, Melanie CHANDLER⁵

¹ University of Florida, Gainesville, United States, ² The Medical University of South Carolina, Charleston, United States, ³ Mayo Clinic, Phoenix, United States, ⁴ Mayo Clinic, La Crosse, United States, ⁵ Mayo Clinic, Jacksonville, United States

P075 JOY-ALZ: First Nationwide Real-World Data Registry for Alzheimer's Disease in Korea

Presenter: Geon Ha Kim

Geon Ha KIM¹, Sung Hoon KANG², Seong-Ho KOH³, So Young MOON⁴, Young Ho PARK⁵, Yong Soo SHIM⁶, Dong Won YANG⁷, Young Chul YOUN⁸, Jae-Sung LIM⁹, Hanna CHO¹⁰, Hojin CHOI³, Jung-Min PYUN⁵, Kee Hyung PARK¹¹, Seong Hye CHOI¹²

¹ Ewha Womans University Mokdong Hospital, Seoul, Republic of Korea, ² Korea University Guro Hospital, College of Medicine Korea University, Seoul, Republic of Korea, ³ Hanyang University Guri Hospital, Guri, Republic of Korea, ⁴ Ajou University School of Medicine, Suwon, Republic of Korea, ⁵ Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ⁶ The Catholic University of Korea, St. Vincent's Hospital, Suwon, Republic of Korea, ⁷ Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, ⁸ Chung-Ang University Hospital, Seoul, Republic of Korea, ⁹ Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, ¹⁰ Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, ¹¹ Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea, ¹² Inha University School of Medicine, Incheon, Republic of Korea

P076 Oral Blarcamesine Comparison to Normal Cognitive Aging: Demonstrating Alignment with Prodromal Cognitive Aging Trajectories in Precision Medicine Patient Population Phase IIb/III Trial—for Early Alzheimer's Disease Patients

Presenter: Audrey Gabelle

Audrey GABELLE¹, Marwan SABBAGH², Timo GRIMMER³, Juan Carlos LOPEZ-TALavera⁴, David GOULD⁴, Wolfgang LIEDTKE⁴, William R CHEZEM⁴, Jin KUN⁴, Christopher U MISSLING⁴

¹ Montpellier University, Montpellier, France, ² Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Arizona, Phoenix, United States, ³ Technical University of Munich, School of Medicine and Health, Klinikum rechts der Isar, Munich, Germany, ⁴ Anavex Life Sciences, New York, ¹⁰¹¹¹, New York, United States

P077 A Phase 1 Clinical Trial of BDNF Gene Therapy for AD and MCI: Update

Presenter: Mark Tuszynski

Douglas SCHARRE¹, Gabriel LEGER², Russell.Lonser@Osumc.Edu LONER³, Krzysztof BANKIEWICZ³, Mark TUSZYNSKI²

¹ Ohio State University Medical Center, Columbus, United States, ² UC San Diego, La Jolla, United States, ³ Ohio State University, Columbus, United States

P078 Randomised controlled trial of extended-release guanfacine in Alzheimer's disease dementia (NorAD)

Presenter: Paresh Malhotra

Paresh MALHOTRA¹, Hilary WATT¹, Karen HOANG², Mara GOLEMME¹, Johanna BRANDT³, Chara TRIANTAFYLLOU¹, Richard PERRY¹, Praveen SINGH⁴, Craig RITCHIE⁵, Danielle WILSON¹, James PICKETT⁶, Chris FOX⁷, Rachel BURTON³, James CARPENTER³, Robert HOWARD³

¹ Imperial College London, London, United Kingdom, ² Queen Mary University of London, London, United Kingdom, ³ University College London, London, United Kingdom, ⁴ Central and North West London NHS Foundation Trust, London, United Kingdom, ⁵ Brain Sciences Scotland, London, United Kingdom, ⁶ Owkin, London, United Kingdom, ⁷ University of Exeter, London, United Kingdom

P079 Results of a «First-in-Human» Open Label, Phase 1 Clinical Study of Intracerebroventricular Injections of Ex Vivo Expanded, Autologous, Wnt Activated, Adipose-Derived Stem Cells in 6 Participants with Mild to Moderate Alzheimer's Disease (AD)

Presenter: Christopher Duma

Christopher DUMA¹, Hans KEIRSTEAD¹, Gabriel NISTOR¹, Robert LYNN¹, Gus ALVA², Karlyssa CHUNG¹, Ashley HARRIS¹, Sawyer FARMER¹, Jessica BUXTON¹, Zoe HARENG¹

¹ Regeneration Biomedical, Inc., Newport Beach, United States, ² Hoag Memorial Hospital Presbyterian, Newport Beach, United States

P080 Results of a Phase II Randomized, Double-Blind, Placebo-Controlled Trial of S-Adenosyl Methionine in Participants with Mild Cognitive Impairment or Dementia Due to Alzheimer's Disease

Presenter: Sarah Holper

Sarah HOLPER^{1,2,3}, Kevin J. BARNHAM³, Leonid CHURILLOV¹, Paul YATES^{4,5}, Amy BRODTMANN⁶, Sally JOHNS⁷, Colin L. MASTERS^{3,8}, Rosie WATSON^{1,2}, Nawaf YASSI^{1,2,3}

¹ Department of Medicine, Melbourne Brain Centre @ The Royal Melbourne Hospital, University of Melbourne, Parkville, Vic, Australia, ² Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Vic, Australia, ³ The Florey Institute of Neuroscience and Mental Health, Parkville, Vic, Australia, ⁴ Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Vic, Australia, ⁵ Medical and Cognitive Research Unit, Department of Geriatric Medicine, Austin Health, Heidelberg, Vic, Australia, ⁶ Department of Neurology, Eastern Health, Monash University, Box Hill, Vic, Australia, ⁷ Department of Geriatric Medicine, Modbury Hospital, Northern Adelaide Local Health Network, South Australia, Australia, ⁸ University of Melbourne, Parkville, Vic, Australia

P081 ABvac40 Vaccine Is Associated with Reduced Cortical Perfusion Decline in Early-Stage Alzheimer's Disease: Results from the AB1601 Phase 2 Study

Presenter: María Pascual-Lucas

María PASCUAL-LUCAS¹, Ana María LACOSTA¹, María MONTAÑÉS¹, Jesús CANUDAS¹, Jorge LOSCOS¹, Jose TERCICIO^{1,2}, Elena PRIETO³, Kathie HIRSCHMUELLER³, Javier ARBIZU³

¹ Araclon Biotech-Grifols, Zaragoza, Spain, ² Grifols, Barcelona, Spain, ³ Clínica Universidad de Navarra, Pamplona, Spain

P082 The ORCHID Study: Optimizing Rural Community Health through Interdisciplinary Detection and Care

Presenter: Lisa Wiese

Lisa WIESE¹, Candy WILSON¹, Beth KING¹, Bianca TOLEA², Magdalena TOLEA²

¹ Florida Atlantic University, Boca Raton, United States, ² University of Miami, Miami, United States

P083 VNA-318, a first-in-class small molecule with a unique dual mode of action, exhibits properties in the first-in-human trial ideal for becoming a novel combination partner in the treatment of patients with Alzheimer's Disease

Presenter: Klaus Dugi

Klaus DUGI¹, Marina KLEIN², Silke KERN¹, Tanes IMAMURA DE LIMA¹, Leila MIRMOHAMADSADEGHI¹, Penelope ANDREUX¹

¹ Vandria Ltd, Epalinges, Switzerland, ² Biotrial, Rennes, France

P084 Advancing Alzheimer's Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine

Presenter: Marwan Sabbagh

Marwan SABBAGH¹, Timo GRIMMER², Juan Carlos LOPEZ-TALAVERA³, William CHEZEM³, Kun JIN³, Christopher MISSLING³

¹ Barrow Neurological Institute, Phoenix, United States, ² Technical University of Munich, Munich, Germany, ³ Anavex, New York, United States

P085 Biomarker Positive APOE4 Carriers with MCI Show Stability on MMSE Over 208-weeks of Treatment with Oral Valiltramiprosate in a Phase 2 Multi-Center Single-Arm Trial

Presenter: Patrick Kesslak

Patrick KESSLAK¹, Susan ABUSHAKRA¹, John HEY¹, Katrina SHEARDOVA², Jakub HORT³, Niels PRINS⁴, Margaret BRAY¹, Adem ALBAYRAK¹, Aidan POWER¹, Martin TOLAR¹,¹

¹ Alzheon, Inc, Framingham, United States, ² International Clinical Research Centre at St. Anne's University Hospital, Brno, Czech Republic, ³ Memory Clinic, Department of Neurology, Charles University, Prague, Czech Republic, ⁴ Alzheimer Center Amsterdam, Vrije University Medical Center, Amsterdam, Netherlands

P086 The Safety, Tolerability and ARIA Effects of the Oral Anti-Amyloid Agent Valiltramiprosate from the Phase 3 APOLLOE4 Trial in APOE4/4 Homozygotes with Early AD

Presenter: David Watson

David WATSON¹, Susan ABUSHAKRA², Jerome BARAKOS³, J. Patrick KESSLAK², Earvin LIANG², Anton PORSTEINSSON⁴, Marwan SABBAGH⁵, Emer MACSWEENEY⁶, Sharon COHEN⁷, Merce BOADA⁸, Rosalind MCLAINE², Susan FLINT², Aidan POWER², John A. HEY², Martin TOLAR²

¹ Alzheimer's Research and Treatment Center, Wellington, FL, United States, ² Alzheon Inc., Framingham, MA, United States, ³ Pacific Medical Center and Clario Inc, San Mateo, CA, United States, ⁴ University of Rochester School of Medicine and Dentistry, Rochester, NY, United States, ⁵ Barrow Neurological Institute, Phoenix, AZ, United States, ⁶ Re:Cognition Health, London, United Kingdom, ⁷ Toronto Memory Program, Toronto, Canada, ⁸ Ace Alzheimer Center, Barcelona, Spain



P087 Cognitive Effects of Postbiotics in Aging and Cognition: Stroop Performance Benefits in a Double-Blind Study

Presenter: Yadav Hariom

Alina WARREN-WALKER^{1,2}, Courtney DAVIES¹, Amanda LLOYD¹, Nigel HOLT¹, Denis KAY³, Kevin STEPHENS⁴, Ram BISHNOI⁵, Shalini JAIN⁶, Yadav HARIOM⁵

¹ Aberystwyth University, Wales, United Kingdom, ² Postbiotics Inc, Winston Salem, United States, ³ Neurodyn Life Sciences Inc, Charlottetown, Prince Edward Island, Canada, ⁴ Agroceutical Products Ltd, Glasbury, United Kingdom, ⁵ University of South Florida, Tampa, United States, ⁶ MusB Research LLC, New Port Richey, United States

P088 VIVA-MIND: Pharmacokinetic, pharmacodynamic, and MRI effects in a Phase 2 study evaluating varoglutamstat (PQ912) in early Alzheimer's disease

Presenter: Howard H. Feldman

Andrew J. MACKELFRESH^{1,2}, Karen MESSER^{3,4}, January DURANT^{1,2}, Jing ZHANG³, Carolyn REVTA^{1,2}, James BREWER^{1,2}, Nicola LAMA⁵, Tanja WASSMANN⁶, Torsten HOFFMANN⁶, Antje MEYER⁶, Sylvia SCHELL-MADER⁶, Christine WENZKOWSKI⁶, Michael SCHAEFFER⁶, Frank WEBER⁶, Howard H. FELDMAN^{1,2}

¹ Department of Neurosciences, University of California San Diego, La Jolla, United States, ² Alzheimer's Disease Cooperative Study, University of California San Diego, La Jolla, United States, ³ Moores Cancer Center, University of California San Diego, La Jolla, United States, ⁴ Division of Biostatistics and Bioinformatics, Herbert Wertheim School of Public Health, University of California San Diego, La Jolla, United States, ⁵ Certara, Basel, Switzerland, ⁶ Vivoryon Therapeutics N.V., Halle, Germany

P089 Real-World Effectiveness and Safety of Lecanemab in Japanese Patients with Alzheimer's Disease: A Single-Center Study

Presenter: Ryosuke Shimaskai

Ryosuke SHIMASKAI¹, Masanori KURIHARA^{1,2}, Taro BANNAI¹, Keiko HATANO¹, Fumio SUZUKI³, Aya TOKUMARU³, Kenji ISHII⁴, Ko FURUTA⁵, Ryoko IHARA^{1,2}, Atsushi IWATA^{1,2}

¹ Department of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, ² Integrated Research Initiative for Living Well with Dementia, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, ³ Department of Diagnostic Radiology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, ⁴ Research Team for Neuroimaging, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, ⁵ Department of Psychiatry, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan

P090 Real-world experience with Lecanemab therapy for Alzheimer's disease in the Intermountain West

Presenter: Nicholas Frost

Nicholas FROST¹, Bethany CURD¹, Camilla ZUBRICK¹, Christine CLIATT BROWN¹, Michelle SORWEID², Sarah DEHONEY¹, Yoshimi ANZAI³, Satoshi MINOSHIMA³, Anna PARKS⁴

¹ Department of Neurology, University of Utah, Salt Lake City, United States, ² Division of Geriatrics, University of Utah, Salt Lake City, United States, ³ Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, United States, ⁴ Department of Internal Medicine, University of Utah, Salt Lake City, United States

P091 Semaglutide Concentration in Cerebrospinal Fluid from Patients with Early Alzheimer's Disease After 12 Weeks of Subcutaneous Treatment

Presenter: Peter Johannsen

Peter JOHANNSEN¹, Marie Aare BENTSEN¹, Dylan Mathew BELMONT-RAUSCH¹, Lisbeth CARSTENSEN¹, Rose JEPPESEN¹, Gabriel MARTINO¹, Martí Jiménez MAUSBACH¹, Anne BÖRJESSON-HANSON^{2,3}, Lotte Bjerre KNUDSEN¹

¹ Novo Nordisk, Copenhagen, Denmark, ² Department of Aging, Karolinska University Hospital, Stockholm, Sweden, ³ Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden

P092 Analytical and clinical validation of the APOE genotyping PCR test in patients from the Phase III Clarity AD trial.

Presenter: Kozue Matsuda

Kozue MATSUDA

Sysmex Corporation, Kobe, Japan

P093 Brexpiprazole Treatment for Agitation Associated with Dementia due to Alzheimer's Disease : Post Hoc Subgroup Analysis Based on Care Setting (Inpatient/Outpatient) in Brexpiprazole for Alzheimer's Disease Patients with Agitated Symptoms (BRIDGE) Study

Presenter: Shimizu Koichi

Shimizu KOICHI¹, Seiyama YUTA², Shibasaki YOSHIYUKI¹, Toda RIKIYA¹, Nakamichi NORIHIRO¹, Adachi JUN³, Hirota NAOKI⁴, Nakai MASAMI⁴, Takahashi KANEYOSHI¹, Nakamura YU⁵

¹ Department of Medical Affairs, Otsuka Pharmaceutical Co., Ltd, Tokyo, Japan, ² Department of Medical Affairs, Otsuka Pharmaceutical Co., Ltd, Osaka, Japan, ³ Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd, Tokyo, Japan, ⁴ Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd, Osaka, Japan, ⁵ Faculty of Medicine/Graduate School of Medicine, Kagawa University, Kagawa, Japan

P094 Assessment of Orthostatic tolerance and Efficacy of Fimasartan in elderly Alzheimer's disease patients with Hypertension: A 16-Week Observational study

Presenter: Mee Y Park

Mee Y PARK¹, Hyeun J HAN², Jean S AN³

¹ Yeungnam Medical University Center, Daegu, Republic of Korea, ² Ilsan Brain Neurology Clinic, Ilsan, Republic of Korea, ³ University of Illinois Chicago, Chicago, United States

03 ● NEW THERAPIES AND CLINICAL TRIALS

MONDAY, DECEMBER 1 (3:00 P.M.) – TUESDAY, DECEMBER 2 (5:30 P.M.)

P095 PrP-siRNA: Rationale and Design for a First-in-Human Evaluation of the Safety and Pharmacology of Intrathecally Administered Divalent Small Interfering RNA (di-siRNA) to Reduce Prion Protein (PrP) in Patients with Prion Diseases

Presenter: Steven Arnold

Steven ARNOLD¹, Aleksander VIDENOVIC¹, Merit CUDKOWICZ¹, Marianne CHASE¹, David KLEMENTS¹, Christopher COFFEY², Dixie ECKLUND², Lumy SAWAKI-ADAMS³, Gabriel LEGER⁴, Sonia VALLABH⁵, Eric MINIKEL⁵

¹ MassGeneral Brigham, Boston, United States, ² University of Iowa, Iowa City, United States, ³ NINDS, NIH, Bethesda, United States, ⁴ University of California San Diego, San Diego, United States, ⁵ Broad Institute, Cambridge, United States

P096 Comparison of Amyloid-related Imaging Abnormalities Risk for Lecanemab versus Donanemab and the Potential Implications

Presenter: Anna Burke

Marwan SABBAGH¹, Sharon COHEN², Ariel CHAO³, Keith BETTS³, Ashley HOLUB³, Anna BURKE¹, Christopher VAN DYCK⁴

¹ Barrow Neurological Institute, Phoenix, AZ, USA, Phoenix, United States, ² Toronto Memory Program, Toronto, ON, Canada, Toronto, Canada, ³ Analysis Group Inc., Boston, MA, USA, Boston, United States, ⁴ Yale Alzheimer's Disease Research Center, New Haven, CT, USA, New Haven, United States

P097 Outcomes from a Real-World Academic Anti-Amyloid Therapy Adjudication Board

Presenter: Michael Rosenbloom

Varun MEHTA, Andrea SCHNEE, Thomas GRABOWSKI, Michael ROSENBLOOM
University of Washington, Seattle, United States

P099 Multicenter Case Registry Study of Lecanemab in Early Alzheimer's Disease in Northwest China

Presenter: Peijie Liu

Peijie LIU, Simeng CUI, Jie LIU, Liangjun DANG, Qiumin QU, Jin WANG

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

P100 Repeated Theta Burst Stimulation to Brain Area 8AV Transiently Improves Memory Retention in Early-Stage Alzheimer's Disease

Presenter: Michael Rosenbloom

Michael ROSENBLOOM, John YI, Andrea STOCCO
University of Washington, Seattle, United States

P101 Real-world treatment with lecanemab: medically significant and insignificant ARIA, and pseudo-ARIA.

Presenter: Lawrence Honig

Lawrence HONIG
Columbia University, New York, United States

P102 Reduced brain neuroinflammation after laromestrocel treatment in mild AD: results from the CLEAR MIND study

Presenter: Brian Rash

Brian RASH¹, John REEVES¹, Chris CONKLIN², Madhura INGALHALIKAR³, Nataliya AGAFONOVA¹, Joshua HARE¹

¹ Longeveron INC, Miami, United States, ² Clario, Philadelphia, United States, ³ Clario, Miami, United States

P103 A Delphi panel exploring the burden of ARIA management from the provider's perspective

Presenter: Marwan Sabbagh

Marwan SABBAGH¹, Feride FRECH², Chenyue ZHAO², Hideki TOYOSAKI², Richard PERRY³, Medi STONE³, Sophie POPE³, Jerome BARAKOS⁴, Raymond TURNER⁵

¹ Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona, United States, ² Eisai, Inc., Nutley, New Jersey, United States, ³ Adelphi Values PROVE, Bollington, Cheshire, United Kingdom, ⁴ Sutter Health California Pacific Medical Center, San Francisco, California, United States, ⁵ Department of Neurology, University of Georgetown, Washington, District Of Columbia, United States

P104 Clinical trials (phases 1 & 2) of transdermal ALC919 peptide to activate brain mitochondrial complex I

Presenter: Sam Gandy

Sam GANDY¹, Toshiharu SUZUKI², Yasuomi OUCHI³, Hirotochi ADACHI⁴, Eugenii RABINER⁵, Manfred WINDISCH⁶, Mary SANO¹

¹ Icahn School of Medicine at Mount Sinai, New York, United States, ² Hokkaido University & Tokyo Metropolitan University, Sapporo & Tokyo, Japan, ³ Hamamatsu University School of Medicine, Hamamatsu, Japan, ⁴ PassPort Technologies, San Diego, United States, ⁵ Perceptive Discovery, London, United Kingdom, ⁶ NeuroScios, Graz, Autriche

P105 A Review of Patient Demographics, Clinical Characteristics, Eligibility, and Treatment Planning for lecanemab in an Academic Medical Center

Presenter: Nour Abi Chakra

Nour ABI CHAKRA, John DICKSON, Liliana RAMIREZ GOMEZ, Daniel SAUKKONEN, Michael ERKKINEN

Mass General Brigham, Boston, United States

P106 MTX46943, a Novel TREM2 Small Molecule Agonist For The Treatment of Early-Stage Alzheimer's Disease ?

Presenter: Niels Plath

Manuela POLYDORO¹, Ivana GERIC², Jin ZHENG¹, Tina SOMMER BISGAARD¹, Ashley COMER¹, Laura SANS¹, Joachim VILSTRUP¹, Leen WOLFS², Arya NAIR², Morten S ANDERSEN¹, Ninna FREDERIKSEN¹, Peter FLAGSTAD¹, Maria DALBY¹, Rita BALICE-GORDON¹, Niels PLATH¹

¹ Muna Therapeutics, Copenhagen, Denmark, ² Muna Therapeutics, Leuven, Belgium

P107 International Registry for Alzheimer's Disease and Other Dementias (InRAD): design, data model, and interoperability

Presenter: Robert Perneczky

Casper DE BOER¹, Jean VONSY², Johan VAN BEEK², Robert HYDE², Chen WANG³, Giovanni FRISONI³, Wiesje VAN DER FLIER⁴, Jung-Lung HSU⁵, Frank JESSEN⁶, Robert PERNECZKY^{7,8,9}

¹ Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, Netherlands, ² TW² Healthcare Consulting Ltd, London, United Kingdom, ³ Memory Centre, Department of Rehabilitation and Geriatrics, Geneva University Hospitals; Laboratory of Neuroimaging of Aging LANVIE, University of Geneva, Geneva, Switzerland, ⁴ Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, Netherlands, ⁵ New Taipei Municipal TuCheng Hospital; President of the Taiwan Dementia Society, New Taipei City, Taiwan, République de China, ⁶ Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany; German Centre for Neurodegenerative Diseases DZNE Cologne; Chair, European Alzheimer's Disease Consortium EADC, Cologne, Germany, ⁷ Department of Psychiatry and Psychotherapy, LMU Hospital, Ludwig-Maximilians-Universität München, Munich, Germany; German Centre for Neurodegenerative Diseases DZNE Munich, Munich, Germany; Munich Cluster for Systems Neurology SyNergy, Munich, Germany, ⁸ Ageing Epidemiology Research Unit AGE, School of Public Health, Imperial College London, London, United Kingdom, ⁹ Division of Neuroscience, University of Sheffield, Sheffield, United Kingdom

P108 Safety, Pharmacokinetics and Cardiodynamics of CMS121, a Novel Small Molecule Fisetin Derivative with Neuroprotective Properties, in Phase 1 Healthy Adult Volunteers

Presenter: Pamela Maher

Pamela MAHER¹, Ronald CHRISTOPHER², Rebecca EVANS², William RASCHKE²

¹ Salk Institute, La Jolla, United States, ² Virogenics, San Diego, United States

P109 Study Design in a Phase 2a Registration Trial for OAB-14 in the Treatment of Mild Cognitive Impairment (MCI) or Mild and Moderate Dementia due to Alzheimer's Disease

Presenter: Tang Yi

Tang YI¹, Zheng ZHONGHUI², Wang YIYUN²

¹ Xuanwu Hospital Capital Medical University, Beijing, China, ² Shandong Xinhua Pharmaceutical Company Limited, Zibo, China

P110 THN391 – A Novel, First-In-Class Anti-fibrin Antibody for Treatment of Inflammation in Alzheimer's Disease: An Ongoing Phase 1b Study for the Treatment of Early Alzheimer's Disease

Presenter: Brad Navia

Brad NAVIA¹, Aaron KANTOR¹, Tanja HOFFMAN¹, June KAPLOW¹, Henk MUTSAERTS², Frederik BARKHOF², Khalid ABD-ELAZIZ³, E. Jort VIJVERBEG², Catherine MUMMERY⁴, Craig RITCHIE⁵

¹ Therini Bio, Sacramento, Ca, United States, ² Amsterdam UMC, Amsterdam, Netherlands, ³ UniverUniversity Medical Center Groningen, Groningen, Netherlands, ⁴ University College London Hospitals, London, United Kingdom, ⁵ Scottish Brain Science, Edinburgh, United Kingdom

P111 PNA5 For Treatment of Vascular Dementia: Composite Serum Biomarkers for VCID Patients Enrollment Stratification.

Presenter: Meredith Hay

Meredith HAY^{1,2,3}, Lee RYAN^{1,4}, Nancy SWEITZER⁵, Christina HOYER-KIMURA¹

¹ University of Arizona, Tucson, United States, ² ProNeurogen, Inc, Tucson, United States, ³ Evelyn F. McKnight Brain Institute, Tucson, United States, ⁴ Evelyn F. McKnight Brain Institute, Tucson, United States, ⁵ Washington University School of Medicine, St. Louis, United States

P112 Phase 1 studies of MK-2214, a novel antibody targeting pS413 tau, for the treatment of Alzheimer's disease

Presenter: Seth Robey

Seth ROBEY¹, Jonathan KURZ¹, Kristine CERCHIO¹, Zhiqing XU¹, Jan DE HOON², An BAUTMANS³, Kristien VAN DYCK³, Kazuki MATSUDA⁴, Katsukuni FUJIMOTO⁴, Arie STRUYK¹

¹ Merck & Co., Inc., Rahway, United States, ² University Hospital Leuven, Leuven, Belgium, ³ MSD Europe Belgium, Brussels, Belgium, ⁴ MSD K.K., Tokyo, Japan



P113 Incidence, Risk Factors with Cut-off Values, and Management of Lecanemab-Related Infusion-Related Reactions in Chinese Patients with Early Alzheimer's Disease: A Multicenter Retrospective Study

Presenter: Yuchen Qiao

Yuchen QIAO¹, Hong CHEN¹, Kaiting FAN¹, Zhen WANG², Zhengluan LIAO³, Mengli YANG⁴, Ying GU⁵, Jiehao ZHAO⁶, Jin WANG⁷, Lijun CHI⁸, Xian LIU⁹, Pingqiao YUAN¹⁰, Hairong QIAN¹¹, Ai SUN¹², Kunmu ZHENG¹³

¹ Xuanwu Hospital Capital Medical University, Beijing, China, ² The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, ³ Zhejiang Provincial People's Hospital, Hangzhou, China, ⁴ Henan Provincial People's Hospital, Zhengzhou, China, ⁵ The First Hospital of China Medical University, Shenyang, China, ⁶ Guangdong Provincial People's Hospital, Guangzhou, China, ⁷ The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, ⁸ The First Affiliated Hospital of Harbin Medical University, Harbin, China, ⁹ Tianjin Medical University General Hospital, Tianjin, China, ¹⁰ The Affiliated Hospital of Guizhou Medical University, Guiyang, China, ¹¹ The Third Medical Center, PLA General Hospital, Beijing, China, ¹² The First Hospital of Hebei Medical University, Shijiazhuang, China, ¹³ The First Affiliated Hospital of Xiamen University, Xiamen, China



P114 Clinical Trials with Laughter Interventions for Alzheimer's Disease and Related Disorders (ADRD) and At-Risk Populations

Presenter: Tara Rose

Tara ROSE

Department of Neurology, Keck School of Medicine of USC, University of Southern California, Los Angeles, United States

P116 Transcranial Direct Current Stimulation–Augmented Cognitive Training in Mild Cognitive Impairment and Alzheimer's Disease: Protocol Design and Preliminary Findings

Presenter: Choe Young Min

Lee MIN JI¹, Choi HYE JI¹, Kim JEE WOOK^{1,2}, Choe YOUNG MIN^{1,2}

¹ Department of Neuropsychiatry, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Republic of Korea, ² Department of Psychiatry, Hallym University College of Medicine, Chuncheon, Republic of Korea

P117 Region-Specific Effects of 40Hz Transcranial Current Stimulation (tACS) on EEG Activity in Patients with Mild Cognitive Impairment

Presenter: Do Hoon Kim

Do Hoon KIM

Department of Psychiatry, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Gangwon, Republic of Korea

P118 Barriers to Current Anti-Amyloid ? Infusion Therapies for Alzheimer's Disease and Preferences for Future Treatment: A Quantitative Survey

Presenter: Chad Swanson

Abigail SILBER¹, Amod ATHAVALA¹, Matthew O'HARA¹, Preeti S. BAJAJ², Chad SWANSON²

¹ Trinity Life Sciences, Waltham, Ma, United States, ² Prothena Biosciences, Inc, Brisbane, Ca, United States

P119 Design and Rationale for a Study to Evaluate Blood and Imaging Biomarkers of Personalized Neuromodulation Therapy of the Default Mode Network in patients with Alzheimer's Disease

Presenter: Lisa Fosdick

Lisa FOSDICK¹, Giacomo KOCH^{2,3}

¹ Synaptica Therapeutics, Cambridge, United States, ² Santa Lucia Foundation IRCCS, Rome, Italie, ³ University of Ferrara, Ferrara, Italie

P120 Evaluation of an ultra-high-frequency visual stimulation intervention on mild cognitive impairment and

Alzheimer's Disease

Presenter: Julian Keil

Julian KEIL ^{1,2,3}, Maria BUTHUT ¹, Ravit HADAR ³, Jana FASS ⁴, Liam DOHERTY ³, Jakob LITSCH ³, Nikolett GAJDA ³, Victor HERNANDEZ-URBINA ³, Fabian QUEISNER ³, Markus MÜSCHENICH ³, Surjo SOEKADAR ¹

¹ Clinical Neurotechnology Lab, Department of Psychiatry and Neurosciences, Charité Campus Mitte CCM, Charité – Universitätsmedizin Berlin, Berlin, Germany, ² Potsdam Embodied Cognition Group, Department of Cognitive Science, University of Potsdam, Potsdam, Germany, ³ Nuuron GmbH, Berlin, Germany, ⁴ Medical School Berlin, Berlin, Germany

P121 Phase 1, Multiple Ascending Dose Study of a Novel Orally Administered Mitochondria-Directed Drug Candidate (SUL-238) in Healthy Volunteers

Presenter: Nadir Ulu

Nadir ULU ¹, Daniël H SWART ^{2,3}, Zafer SEZER ^{4,5}, Ahmet INAL ^{4,5}, Mustafa M MAZICIOGLU ⁶, Sedat ALTUG ⁷, Serhat KOZLU ¹, Adrianus C VAN DER GRAAF ³, Robert H HENNING ², Guido KRENNING ^{2,3}, Murat EMRE ⁸

¹ Gen ?laç ve Sa?lk Ürünleri A.?, Ankara, Türkiye, ² Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³ Sulfateq B.V., Groningen, Netherlands, ⁴ Department of Pharmacology, Faculty of Medicine, Erciyes University, Kayseri, Türkiye, ⁵ Hakan Cetinsaya Good Clinical Practice and Research Centre IKUM, Kayseri, Türkiye, ⁶ Department of Family Medicine, Faculty of Medicine, Erciyes University, Kayseri, Türkiye, ⁷ Department of Pharmacology, Faculty of Medicine, Demiroglu Bilim University, Istanbul, Türkiye, ⁸ Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye



P122 A First-in-Human, Single Dose-Escalation Study of CM383, a Novel Anti- Amyloid Beta antibody, in healthy volunteers

Presenter: Qing Wen

Kun HE ¹, Cuigang LI ¹, Yaoqi HAN ¹, Yanshuang LI ¹, Ning LI ¹, Libo ZHANG ², Zhichuan LI ², Jingyue MA ², Bo CHEN ², Qing WEN ¹

¹ Jinan Central Hospital, Jinan, China, ² Keymed Biosciences Chengdu Co., Ltd - Chengdu China, Chengdu, China

P123 Masupirdine (A Pure 5-HT6 Receptor Antagonist): Update on the Phase-3 Clinical Study Targeting Agitation in Patients with Dementia of Alzheimer's Type

Presenter: Pradeep Jayarajan

Pradeep JAYARAJAN, Satish JETTA, Vinod Kumar GOYAL, Vijay BENADE, Anil SHINDE, Santosh Kumar PANDEY, Ramkumar SUBRAMANIAN, Abdul Rasheed MOHAMMED, Ramakrishna NIROGI, Jasti VENKAT
Suven Life Sciences Ltd, Hyderabad, Inde

04 ● BEYOND AMYLOID AND TAU

MONDAY, DECEMBER 1 (3:00 P.M.) – TUESDAY, DECEMBER 2 (5:30 P.M.)

P124 Modeling Brain Homeostasis Failure in Alzheimer's: A Digital Twin Platform for Target Discovery, Biomarkers, and Trial Design

Presenter: Cory Funk

Cory FUNK ¹, Tom PATERSON ¹, Allan LEVEY ², Laura Beth MCINTIRE ³, Rima KADDURAH-DAOUK ⁴, Hohman TIMOTHY ⁵, Mapstone MARK ⁶, Meikle PETER ⁷, Hood LEE ⁸

¹ Fulcrum Neuroscience, Palo Alto, United States, ² Emory University, Emory, United States, ³ Cornell University, Ithaca, United States, ⁴ Duke University, Durham, United States, ⁵ Vanderbilt University, Nashville, United States, ⁶ UC Irvine, Irvine, United States, ⁷ Baker Institute, Melbourne, Australia, ⁸ Phenome Health, Seattle, United States

P125 Alzheimer's and Lewy Body Co-Pathology: Interactive Effects on Clinical Trajectories in Preclinical

Disease

Presenter: Niklas Mattsson-Carlgrén

Niklas MATTSSON-CARLGREN¹, Philip INSEL²

¹ Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden, ² Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, United States

P126 The DNA Damage Repair Pathway as a Potential Route for Alzheimer's Disease Treatment

Presenter: David Lynch

David LYNCH^{1,2}, Madison SAMPLES^{1,2}, Abbigael ADAY^{1,2}, Rakez KAYED^{1,2}, Mauro MONTALBANO^{1,2}

¹ Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, United States, ² Department of Neurology and Neurobiology, University of Texas Medical Branch

P127 Bone and senescence biomarkers assessed in the plasma of MCI and AD patients from the ROSMAP cohort

Presenter: Vidyani Suryadevara

Valerie HUANG¹, Siddharth KAIPA¹, Mounica BANDELA², Sai Rama Krishna MEKA³, Patricia Moran LOSADA¹, Shinya TASAKI³, Yan LI³, Tony Wyss CORAY¹, David BENNETT³, Vidyani SURYADEVARA¹

¹ Stanford University, Los Altos, United States, ² University of Illinois at Chicago, Chicago, United States, ³ Rush University Medical Center, Chicago, United States

P128 Development of Potent, Selective cPLA2 Inhibitors for Targeting Neuroinflammation in Alzheimer's Disease

Presenter: Amy Wang

Amy WANG¹, Anastasiia SADYBEKOV², Marlon DURO², Xiaohui YU², Stan LOUIE², Shaowei WANG², Vsevolod KATRITCH², Hussein YASSINE²

¹ PebRx, Los Angeles, United States, ² USC, Los Angeles, United States

P129 Misfolding of alpha-synuclein as a blood based fluid biomarker for Parkinson's disease

Presenter: Klaus Gerwert

Klaus GERWERT

Centre for Protein Diagnostics/Ruhr University Bochum, Bochum, Germany



P130 Microbiome–Brain Volume Associations in Cognitively Unimpaired Adults in a Cohort Enriched for Alzheimer's Disease Risk

Presenter: Muhaison Ibrahim

Muhaison IBRAHIM¹, Jea Woo KANG², Margo HESTON^{3,4}, Gilda ENNIS¹, Sandra HARDING¹, Sterling JOHNSON^{1,4,5}, Sanjay ASTHANA^{1,4,5}, Federico REY⁶, Barbara BENDLIN^{1,4,5}

¹ University of Wisconsin School of Medicine and Public Health, Madison, United States, ² Wisconsin Alzheimer's Disease Research Center, Madison, United States, ³ Wisconsin Alzheimer's Disease Center, Madison, United States, ⁴ Division of Geriatrics, University of Wisconsin, Madison, United States, ⁵ Wisconsin Alzheimer's Institute, Madison, United States, ⁶ Department of Bacteriology, University of Wisconsin, Madison, United States

P131 Comparing the Effects of Disclosure of Multiple Risk Factors for Alzheimer's Disease on Mood and Distress Levels in Cognitively Healthy Individuals

Presenter: Marycia Malloy

Marycia MALLOY¹, Athene LEE, PHD², Hannah JOYCE, SCB³, Philip CAFFERY, PHD¹, Louisa THOMPSON, PHD⁴, Alyssa DE VITO, PHD⁵, Melanie FAUST, MS, FNP-C¹, Lyndsay DEMATTEO, MSG, MSN, AGPCNP-C¹, Andrea DOLAHAR, MSN, AGPCNP-C¹, Brittany DAWSON, MS, FNP-BC¹, Meghan RIDDLE, MD⁶, Edward HUEY, MD⁶, Preeti SUNDERARAMAN^{7,7}

¹ Memory and Aging Program, Butler Hospital, Providence, United States, ² Memory and Aging Program, Providence, United States, ³ University of Georgia, Athens, United States, ⁴ Alpert Medical School at Brown University, Providence, United States, ⁵ Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, United States, ⁶ Memory and Aging Program at Butler Hospital, Department of Psychiatry Warren Alpert School of Medicine, Providence, United States, ⁷ Butler Hospital and Alpert Medical School of Brown University, Providence, United States



P132 Efficacy and Safety of Levetiracetam to Prevent Seizures in Down Syndrome Alzheimer's Disease: The Phase III LESS-AD Trial

Presenter: Isabel Barroeta

Isabel BARROETA¹, Diego REAL DE ASÚA², Lucía MAURE-BLESA^{1,1}, Beatriz SÁNCHEZ MORENO², Gina PAOLA MEJÍA³, Miren ALTUNA⁴, Joaquín ESCOBAR⁵, Eloy RODRÍGUEZ⁶, Juan FORTEA¹, María CARMONA-IRAGUI¹

^{1,1}. Sant Pau Memory Unit, IR SANT PAU, Hospital de la Santa Creu i Sant Pau, Barcelona, ⁰⁸⁰²⁵ Spain, Barcelona, Spain, ^{2,2}. Internal Medicine Department, Adult Down Syndrome Unit, Hospital Universitario de La Princesa, Madrid, Spain, Madrid, Spain, ^{3,3}. Clinical Pharmacology Department, Hospital Universitario de La Princesa, Madrid,



P134 Early microglial activation and astrogliosis in preclinical Alzheimer's disease

Presenter: Marta Fernández-Matarrubia

Marta FERNÁNDEZ-MATARRUBIA ¹, Andrea VALERA-BARRERO ², Mónica RENUNCIO-GARCÍA ³, Marcos AGUILELLA ⁴, Carmen LAGE ¹, Gonzalo OCEJO-VIÑALS ³, Sara LÓPEZ-GARCÍA ¹, Francisco MARTÍNEZ-DUBARBIE ¹, Ana POZUETA-CANTUDO ⁴, María GARCÍA-MARTÍNEZ ⁴, María BRAVO ⁴, Andrea CORRALES-PARDO ⁴, Juan IRURE-VENTURA ³, Pascual SÁNCHEZ-JUAN ⁵, Eloy RODRÍGUEZ-RODRÍGUEZ ⁶

¹ Neurology Service, Marqués de Valdecilla University Hospital, Santander, Spain. Institute for Research Marqués de Valdecilla IDIVAL, Santander, Spain. CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, Institute of Health Carlos III, Madrid, Spain., Santander, Spain, ² Neurology Service, Marqués de Valdecilla University Hospital, Santander, Spain., Santander, Spain, ³ Institute for Research Marqués de Valdecilla IDIVAL, Santander, Cantabria, Spain. Immunology Department, Marqués de Valdecilla University Hospital, Santander, Spain., Santander, Spain, ⁴ Neurology Service, Marqués de Valdecilla University Hospital, Santander, Spain. Institute for Research Marqués de Valdecilla IDIVAL, Santander, Spain., Santander, Spain, ⁵ Institute for Research Marqués de Valdecilla IDIVAL, Santander, Cantabria, Spain. Alzheimer's Centre Reina Sofía-CIEN Foundation-ISCIII, Madrid, Spain., Madrid, Spain, ⁶ Neurology Service, Marqués de Valdecilla University Hospital, Santander, Spain. Institute for Research Marqués de Valdecilla IDIVAL, Santander, Cantabria, Spain. Medicine and Psychiatry Department, University of Cantabria, Santander, Spain, Santander, Spain

P135 Relationships between near end-of-life plasma biomarkers and postmortem cerebral and vascular amyloid, tau, TDP-43, and alpha-synuclein measurements

Presenter: Alpana Singh

Alpana SINGH ¹, Marisa DENKINGER ¹, Kewei CHEN ², Kari DIECKHOFF ¹, James LIU ¹, Taina MARQUES ¹, Geidy E. SERRANO ¹, Thomas G. BEACH ¹, Antoine LEUZY ¹, Alireza ATRI ¹, Eric M. REIMAN ², Nicholas J. ASHTON ^{2,1}

¹ Banner Health, Sun City, United States, ² Banner Alzheimer's Institute, Phoenix, United States

P136 Fanning the flames: Did COVID-19 accelerate progression of Alzheimer's disease in the ADNI cohort?

Presenter: Patricia Andrews

Patricia ANDREWS, Ke XU, Kiara BAKER, Kathleen MATHER, Brian BOYD, Hakmook KANG, Warren TAYLOR, Paul NEWBOUSE
Vanderbilt University Medical Center, Nashville, United States

P137 Degenerative Pathologies on Cortical Biopsy, Dopaminergic Depletion, and Shunt Efficacy in iNPH

Presenter: Byoung Seok Ye

Minsun CHOI ^{1,2}, Su-Hee JEON ¹, Sohyeon LEE ¹, Yeojun KIM ¹, Byoung Seok YE ^{1,2}

¹ Yonsei University College of Medicine, Seoul, Republic of Korea, ² Metabolism-Dementia Research Institute, Seoul, Republic of Korea



P138 Perceptions of and Engagement in Brain Health Activities Among Middle-Aged and Older Adults: Associations with Level of Concern, Family History of Dementia, Subjective Memory Loss, and Demographics

Presenter: Raymond L Ownby

Raymond L OWNBY ¹, Gesulla CAVANAUGH ¹, Shannon WEATHERLEY ¹, Shazia AKHTARULLAH ¹, Joshua CABALLERO ²

¹ Nova Southeastern University, Fort Lauderdale, United States, ² University of Georgia, Athens, United States

05 ● ARTIFICIAL INTELLIGENCE IN AD CLINICAL TRIALS

MONDAY, DECEMBER 1 (3:00 P.M.) – TUESDAY, DECEMBER 2 (5:30 P.M.)

P140 Facilitating Patient Eligibility Matching for Recruitment with a RAG-LLM Framework

Presenter: Nansu Zong

Xiaodi LI¹, Yang XIAO², Munhwan LEE¹, Maria VASSILAKI¹, Nansu ZONG¹

¹ Mayo Clinic, Rochester, United States, ² University of Tulsa, Tulsa, United States

P142 Efficient Clinical Development and Research via an AI-Ready Multimodal Data Platform

Presenter: Janis Reinelt

Manuel KIENAST¹, Aroma DABAS¹, Eoin MOLLOY¹, Elisa PIEHLER¹, Matteo UGOLINI¹, Sarah KEPPNER-WITTER², Mia TICHY², Emanuela VILLIGER², Fabian BULLER², Christoph HOCK², Roger M. NITSCH², Augusta MODESTINO¹, Janis REINELT¹, Konstantin THIERBACH¹

¹ AICURA medical GmbH, Berlin, Germany, ² Neurimmune AG, Schlieren, Switzerland

P143 Expanding Patient Coverage in Alzheimer's Disease Studies through Robust Multimodal Data Integration

Presenter: Sungjoon Park

Juhyun LEE^{1,2}, Sungjoon PARK¹, Kyungwook LEE¹, Soorin YIM¹, Doyeong HWANG¹, Kiwoong YOO¹, Soonyoung LEE¹, Kiyoung KIM¹

¹ LG AI Research, Seoul, Republic of Korea, ² University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

P144 Bridging the Biomarker–AI Divide: Redesigning Trials and Incentives for Disease-Modifying Success in Alzheimer's Disease

Presenter: Ara Khachaturian

Ara KHACHATURIAN¹, Ornit CHIBA-FALEK², Paulo PINHO³, Larry ALPHS⁴

¹ PAD^{20/20}, Potomac, United States, ² Duke University, Durham, United States, ³ PAD^{20/20}, Newark, United States, ⁴ Alphs Solutions, Princeton, United States

P145 Practical Implementation of a MaChina Learning Model in Alzheimer's Disease trials following the recent FDA's Guidance on the use of AI to support regulatory decision making

Presenter: Ole Graff

Ole GRAFF¹, Deli WANG¹, Hana FLORIAN¹, Yujie ZHAO¹, Shau Yu LYNCH¹, Weining Z ROBIESON¹, Coco KUSIAK², Alyssa VANDERBEEK², Jonathan R WALSH², Run ZHUANG²

¹ AbbVie, North Chicago, United States, ² Unlearn, San Francisco, United States

P146 Brain health data pilot: a national dataset of routine brain imaging for artificial intelligence and epidemiology

Presenter: William Whiteley

Brenda BAUER¹, Maria VALDES HERNANDEZ¹, Jackie CALDWELL², Robert WALLACE², Andrew BROOKS¹, Ruairidh MACLEOD¹, Kara MORAW¹, Michael CAMILLERI¹, Dorian GOUZOU¹, Eoghan FORDE³, Matthew CLEMENT⁴, Neil POSTLETHWAITE³, William WHITELEY¹

¹ The University of Edinburgh, Edinburgh, United Kingdom, ² Public Health Scotland, Edinburgh, United Kingdom, ³ Health Data Research UK, London, United Kingdom, ⁴ Alzheimer's Disease Data Initiative, Seattle, United States

P147 The SANDBOX Study: An NHS-Embedded Multimodal Platform for AI-Enabled Dementia Diagnostics

Presenter: Hayley Holt

Hayley HOLT¹, Javkhlan-Ochir GANBAT¹, Gubbins SAMUEL¹, O'Connor SORCHA¹, Madan HANNAH¹, Wan JONATHAN¹, Solanki RAVI², Koychev IVAN³

¹ Prima Mente, London, United Kingdom, ² Prima Mente, San Francisco, United States, ³ Imperial College London, London, United Kingdom

P148 Comparison between auditory, textual, and late-fusion Transformer models for the discrimination of prodromal Alzheimer's disease based on spontaneous speech

Presenter: Rik Vandenberghe

Bastiaan TAMM¹, Helena BALABIN¹, Laure SPRUYT¹, Kevin STATZ¹, Hugo VAN HAMME², Rik VANDENBERGHE³

¹ Laboratory for Cognitive Neurology KU Leuven, Leuven, Belgium, ² Department of Electrical Engineering, Leuven, Belgium, ³ Neurology Service UZ Leuven, Leuven, Belgium

P149 AI+MRI imaging biomarker for clinical characterization of Alzheimer's disease biological heterogeneity

Presenter: Tae Youn Kwon

Tae Youn KWON, Yeong-Hun JEON, Yeong-Hun SONG, Wha Jin LEE, Joon-Kyung SEONG, Jeong-Yeon SONG
Neuroxt, Seoul, Republic of Korea

P150 Simulating cognitive decline using generative AI model

Presenter: Youn Kwon Tae

Yeong-Hun SONG^{1,2}, Youn Kwon TAE^{1,2}, Wha Jin LEE², Joon-Kyung SEONG^{1,3,2}

¹ Department of Artificial Intelligence, College of Informatics, Korea University, Seoul, Republic of Korea, ² NeuroXT, Seoul, Republic of Korea, ³ School of Biomedical Engineering, College of Health Science, Korea University, Seoul, Republic of Korea

P151 Post hoc data-driven subgroup analysis of the A4 Study: spatiotemporal atrophy predicts differential treatment response to solanezumab

Presenter: Neil Oxtoby

Cameron SHAND^{1,2,3}, An ZHAO^{1,2}, Pawel MARKIEWICZ^{1,4}, Gonzalo CASTRO LEAL^{1,2}, David CASH^{1,5}, Daniel ALEXANDER^{1,2}, Michael DONOHUE⁶, Frederik BARKHOF^{1,7,8}, Neil OXTOBY^{1,2}

¹ UCL Hawkes Institute, University College London, London, United Kingdom, ² Department of Computer Science, University College London, London, United Kingdom, ³ Crick Institute, London, United Kingdom, ⁴ Department of Medical Physics and Biomedical Engineering, University College London, London, United Kingdom, ⁵ Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom, ⁶ Alzheimer Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, United States, ⁷ UCL Queen Square Institute Of Neurology, University College London, London, United Kingdom, ⁸ Amsterdam University Medical Center, Amsterdam, Netherlands

P152 Speech Biomarker for Cognition and Correlation with Clinical Outcome Measures Over Time in Preclinical Alzheimer's Disease

Presenter: Alexandra König

Alexandra KÖNIG¹, Elisa MALLICK¹, Johannes TRÖGER¹, Oriol GRAU-RIVERA², Andreea RADOI², Claudia PORTA-MAS²

¹ ki:elements, Saarbrücken, Germany, ² Barcelona?eta Brain Research Center BBRC, Pasqual Maragall Foundation, Barcelona, Spain

P153 Development of a Community-Based Predictive Model for Mild Cognitive Impairment Using Digital Clock Drawing and Complex Figure Tests

Presenter: Ruochen Li

Xiaonan ZHANG¹, Ruochen LI², Yang LI¹, ¹

¹ First Hospital of Shanxi Medical University, Taiyuan, China, ² University of California, Davis, United States

P154 Toward In Silico Clinical Trial Emulation for Alzheimer's Disease: The Therapeutic Simulation Agent (TSA)

Presenter: Binita Rajbanshi

Binita RAJBANSHI¹, Khalid IQBAL², Anuj GURUACHARYA¹

¹ Nanil Therapeutics Inc., Calgary, Canada, ² New York State Institute for Basic Research, Staten Island, United States,

P155 Brain-Age Prediction in One Minute from Structural MRI Using Artificial Intelligence: Toward a Scalable Biomarker

Presenter: Hyun Woo Kim

Hyun Woo KIM, Kyu Bin JEON, Sun Young HWANG, Hyun Woong ROH, Chang Hyung HONG, Sunhwa HONG, Sang Joon SON
Ajou Medical Center, Suwon-Si, Republic of Korea

P156 Regulatory Considerations on Utilizing Prognostic Models for Sample Size Reduction in Alzheimer's Disease Clinical Trials

Presenter: Elena Ryapolova-Webb

Elena RYAPOLOVA-WEBB, Cary MURRAY, Run ZHUANG, Aaron SMITH, Jonathan WALSH
Unlearn.AI, San Francisco, United States

P157 Machine Learning-Based Differentiation of Amnestic and Non-Amnestic Mild Cognitive Impairment Using Multimodal Physiological and Neuroimaging Biomarkers

Presenter: Yeo Jin Kim

Ingyu PARK¹, Sang-Kyu LEE², Hui-Chul CHOI², Moo-Eob AHN², Ohk-Hyun RYU², Yong Soon PARK², Dong-Kyu KIM³, Unjoo LEE¹, Yeo Jin KIM⁴

¹ Hallym University, Chuncheon, Republic of Korea, ² Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon, Republic of Korea, ³ OneSleep Clinic, Seoul, Republic

P158 Assessing variability in brain segmentation across multiple recent automated methods

Presenter: Luc Bracoud

Cheng C.J. CHU ¹, Chen C.J. CHU ², Thomas CAJGFINGER ¹, Joël SCHAËRER ³, Po-Han CHEN ⁴, Janos SZALMA ⁵, Chris CONKLIN ⁶, Madhura INGALHALIKAR ⁶, David SCOTT ⁶, Alessandro DELMONTE ¹, Luc BRACAUD ¹

¹ Clario, Lyon, France, ² Wistron ITS, Taipei, Taiwan, République de China, ³ Clario, Geneva, Switzerland, ⁴ Clario, Estenfeld, Germany, ⁵ Clario, Budapest, Hongrie, ⁶ Clario, Philadelphia, United States

P159 Improving FreeSurfer robustness by integrating automated failure detection using Artificial Intelligence for consistent quantitative biomarker extraction

Presenter: Luc Bracoud

Thomas CAJGFINGER ¹, Alessandro DELMONTE ¹, Joël SCHAËRER ², Po-Han CHEN ³, Joonmi OH ⁴, Qui CAO ⁴, Madhura INGALHALIKAR ⁴, Chris CONKLIN ⁴, David SCOTT ⁴, Luc BRACAUD ¹

¹ Clario, Lyon, France, ² Clario, Geneva, Switzerland, ³ Clario, Estenfeld, Germany, ⁴ Clario, Philadelphia, United States

P160 Large Language Models for Clinical Dementia Rating Severity Assessment: Domain-Specific Performance Analysis

Presenter: Hahyun Lee

Hahyun LEE ^{1,2}, Da Young OH ^{1,3}, Jun-Young LEE ^{1,2,3}

¹ Department of Psychiatry, Seoul Metropolitan Government-Seoul National University College Boramae Medical Center,, Seoul, Republic of Korea, ² Interdisciplinary Program in Cognitive Science, Seoul National University, , Seoul, Republic of Korea, ³ Department of Biomedical Sciences, Seoul National University, Seoul, Republic of Korea

P161 Tracking Cognitive Change over Time Using a Remote Telephone-Based AI-Driven Digital Cognitive Assessment

Presenter: Alexandra König

Elisa MALLICK ¹, Johannes TRÖGER ¹, Stefanie KÖHLER ², Alexandra KÖNIG ³, Anika WUESTEFELD ⁴, Erik STOMRUD ⁴, Pontus TIDEMAN ⁴, Oskar HANSSON ⁴, Sebastian PALMQVIST ⁴, Stefan TEIPEL ², Nicklas LINZ ¹

¹ ki elements GmbH - Saarbrücken Germany, Saarbrücken, Germany, ² German Center for Neurodegenerative Diseases DZNE, Rostock, Germany, Rostock, Germany, ³ ki elements GmbH, Saarbrücken, Germany, ⁴ Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Lund, Sweden, Lund, Sweden

06 ● CLINICAL TRIALS: IMAGING

WEDNESDAY, DECEMBER 3 (7:15 A.M. – 5:30 P.M.)

P162 Cerebral blood flow ratio of the default mode network to the central executive network as a predictor of executive function following N-acetylcysteine supplementation in vascular mild cognitive impairment participants from the MOVE-IT trial

Presenter: Melissa Wong

Melissa WONG^{1,2}, Guocheng JIANG^{1,3}, Bradley J. MACINTOSH^{1,3}, Sandra E. BLACK^{1,4,5,6}, Damien GALLAGHER^{1,7}, Fuqiang GAO^{1,5,6}, Joel RAMIREZ^{1,3,4,5}, Nathan HERRMANN^{1,7}, Yejin KANG^{1,2}, Ethan MAH^{1,2}, Jennifer S. RABIN¹, Krista L. LANCTÔT^{1,2,7}, Move-It INVESTIGATORS⁸

¹Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Canada, ²Department of Pharmacology & Toxicology, University of Toronto, Toronto, Canada, ³Department of Medical Biophysics, University of Toronto, Toronto, Canada, ⁴Graduate Department of Psychological Clinical Science, University of Toronto Scarborough, Scarborough, Canada, ⁵Dr. Sandra Black Centre for Brain Resilience and Recovery, LC Campbell Cognitive Neurology, Sunnybrook Hospital, Toronto, Canada, ⁶Neurology Division, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada, ⁷Department of Psychiatry, University of Toronto, Toronto, Canada, ⁸MOVE-IT Investigators, Toronto, Canada

P163 Automated Neurodegeneration Index to Enhance Alzheimer's Disease Trials

Presenter: David Vaillancourt

David VAILLANCOURT, Jesse DESIMONE, Angelos BARMPOUTIS, Robin CHEN, Freydel ESPINOZA URBINA, Wei-En WANG
University of Florida, Gainesville, United States

P166 Biodistribution of radiolabeled MAPT antisense oligonucleotide BIIB080 following intrathecal administration in healthy adults

Presenter: Jessica Collins

Jessica COLLINS¹, Brendon COOK¹, Jonathan DUBIOS¹, Lori JONES¹, Osama RASLAN², Phu HUYNH², Amanda EDWARDS¹, Melanie SHULMAN¹, Danielle GRAHAM¹, R. Matthew HUTCHISON¹, Simon CHERRY², Sen FATMA²

¹Biogen, Cambridge, United States, ²Department of Radiology, University of California Davis, Davis, United States

P167 Monitoring and predicting amyloid therapy response using arterial spin labelling perfusion MRI

Presenter: Thomas Kirk

Thomas KIRK¹, Gloria CHIANG², Logan ZHANG¹, Anna NORDVIG², Michael CHAPPELL^{1,3}

¹Quantified Imaging, London, United Kingdom, ²Weill Cornell Medicine, New York, United States, ³University of Nottingham, Nottingham, United States

P171 Discordance Between Visual and Quantitative Amyloid PET in Nearly 500 Real-World Clinical Cases

Presenter: Maria Ponisio

Maria PONISIO, Anna HOFMANN, Suzanne SCHINDLE, Ines OH, Joy SNIDER, Tammie BENZINGER
Washington University, St. Louis, United States

P173 Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET

Presenter: Robin Wolz

Colm MCGINNITY, Anthony S GABAY, Katherine R GRAY, R MANBER, R JOULES, Robin WOLZ
IXICO, London, United Kingdom

P174 Extending the CenTauR Standardization Framework to the Voxel Level: Preliminary Validation Using [¹⁸F]flortaucipir and [¹⁸F]MK-6240

Presenter: Alexis Moscoso

Alexis MOSCOSO¹, Antoine LEUZY², Victor L. VILLEMAGNE³, Alex DEL BENE⁴, Brian LOPRESTI⁴, Alexandra GOGOLA⁴, Gregory KLEIN⁵, Hartmuth C KOLB⁶, Nadine TATTON⁷, Yashmin KARTEN⁷, Matteo TONIETTO⁵, Emily OLAFSON⁸, Ruben SMITH⁹, Oskar HANSSON⁹, Vincent DORÉ¹⁰

¹Critical Path for Alzheimer's Disease CPAD Consortium, Critical Path Institute, Tucson, USA; Nuclear medicine department and Molecular Imaging Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Travesía da Choupana s/n, Santiago de Compostela, Spain, Santiago De Compostela, Spain, ²Critical Path for Alzheimer's Disease CPAD Consortium, Critical Path Institute, Tucson, USA; Enigma Biomedical Group, Knoxville, USA, Knoxville, United States, ³Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, USA; Department of Molecular Imaging & Therapy, Austin Health, Victoria, Australia, Pittsburgh, United States, ⁴Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, USA, Pittsburgh, United States, ⁵F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland, ⁶Enigma Biomedical Group, Knoxville, USA, Knoxville, United States, ⁷Critical Path for Alzheimer's Disease CPAD Consortium, Critical Path Institute, Tucson, USA, Tucson, United States, ⁸Clinical Imaging Group, Genentech, Inc., South San Francisco, USA, San Francisco, United States, ⁹Clinical Memory Research Unit,

P175 Evaluating the Effects of Non-Linear SUVR Transformations for Harmonization on Statistical Power in Longitudinal Tau-PET Studies

Presenter: Alexs Moscoco

Alexs MOSCOSO ^{1,2}, Antoine LEUZY ^{1,3}, Hartmuth KOLB ³, Victor VILLEMAGNE ^{4,5}, Gregory KLEIN ⁶, Brian LOPRESTI ⁷, Alexandra GOGOLA ⁷, Diane STEPHENSON ¹, Nadine TATTON ¹, Yashmin KARTEN ¹, Fang XIE ⁸, Christopher C ROWE ^{9, 10}, Vincent DORÉ ^{9, 11}

¹ Critical Path for Alzheimer's Disease CPAD Consortium, Critical Path Institute, Tucson, United States, ² Nuclear Medicine department and Molecular Imaging Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Travesía da Choupana s/n., Santiago De Compostela., Spain, ³ Enigma Biomedical Group, Knoxville, United States, ⁴ Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, United States, ⁵ Department of Molecular Imaging & Therapy, Austin Health, Victoria, Australia, ⁶ F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁷ Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, United States, ⁸ Department of Nuclear Medicine & PET Center, Huashan Hospital, University, Shanghai, China, ⁹ Florey Department of Neuroscience, University of Melbourne, Victoria, Australia, ¹⁰ The Australian Dementia Network ADNeT, The University of Melbourne, Victoria, Australia, ¹¹ Health and Biosecurity Flagship, The Australian eHealth Research Centre, CSIRO, Victoria, Australia

P177 Functional Network Segregation as a Neural Correlate of Cognitive Reserve in Alzheimer's Disease Spectrum

Presenter: Na Young Yeo

Na Young YEO ¹, Christian G. HABECK ², Yaakov STERN ², Jae-Won JANG ³, Yeshin KIM ³

¹ Kangwon National University, Chuncheon, Republic of Korea, ² Columbia University, New York, United States, ³ Kangwon National University Hospital, Chuncheon, Republic of Korea

P178 Lower Antemortem [18F]flortaucipir PET retention in Males and Older Individuals is Explained by Lower Postmortem Tau Tangle Density

Presenter: Emma Coomans

Emma COOMANS ^{1,2}, Ruben SMITH ^{3,4}, Sebastian PALMQVIST ^{3,4}, Michael PONTECORVO ⁵, Sergey SHCHERBININ ⁵, Vikas KOTARI ⁵, Thomas BEACH ⁶, Geidy SERRANO ⁶, Erik STOMRUD ^{3,4}, Niklas MATTSSON-CARLGREN ^{3,7}, Wiesje VAN DER FLIER ^{1,2}, Yolande PIJNENBURG ^{1,2}, Elsmarieke VAN DE GIESSEN ^{8,9}, Oskar HANSSON ³, Rik OSSENKOPPELE ^{1,3}

¹ Department of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands, Amsterdam, Netherlands, ² Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands, Amsterdam, Netherlands, ³ Clinical Memory Research Unit, Department of Clinical Sciences in Malmö, Lund University, Lund, Sweden, Lund, Sweden, ⁴ Memory Clinic, Skåne University Hospital, Malmö, Sweden, Lund, Sweden, ⁵ Eli Lilly and Company, Indianapolis, USA, Indianapolis, United States, ⁶ Banner Sun Health Research Institute, Sun City, Arizona, USA, Sun City, United States, ⁷ Department of Neurology, Skåne University Hospital, Lund University, Lund, Sweden, Lund, Sweden, ⁸ Department of Radiology & Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands, Amsterdam, Netherlands, ⁹ Amsterdam Neuroscience, Brain Imaging, Amsterdam, The Netherlands, Amsterdam, Netherlands

P179 Towards correcting for pseudo atrophy in monoclonal antibody clinical trials on Alzheimer's disease: a model of amyloid-removal related atrophy predicts treatment benefit

Presenter: Neil Oxtoby

Neil OXTOBY ¹, Bojidar RANGELOV ¹, Michael DONOHUE ²

¹ UCL Hawkes Institute and Department of Computer Science, University College London, London, United Kingdom, ² Alzheimer Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, United States

P180 Recommendations for DTI harmonization in multicenter clinical trials.

Presenter: Madhura Ingalhalikar

Madhura INGALHALIKAR ¹, Stefan RADONJIC ¹, Luc BRACOUD ², Chris CONKLIN ¹, Meredith BURKE ¹, David SCOTT ¹, Adni ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE ³

¹ Clario., Philadelphia, United States, ² Clario., Lyon, France, ³ ADNI, Adni.loni.usc.edu, United States

P181 Associations of amyloid-beta with entorhinal cortical thickness and episodic memory among a diverse oldest-old cohort: The Life After 90 Study

Presenter: Batool Rizvi

Batool RIZVI ¹, Christina YOUNG ¹, Molly LAPOINT ², Adam BRICKMAN ³, Pauline MAILLARD ¹, Charles DECARLI ¹, Paola GILSANZ ², Maria CORRADA ⁴, Rachel WHITMER ¹

¹ UC Davis, Davis, United States, ² Kaiser Permanente Northern California Division of Research, Pleasanton, United States, ³ Columbia University, New York, United States, ⁴ UC Irvine, Irvine, United States

P183 Association between the incidence of amyloid-related imaging abnormalities and amyloid plaque clearance on positron emission tomography of amyloid-targeting therapies

Presenter: Thorsten Bartsch

Jonathan Merkel¹, Robert Perneczky², Frank Jessen³, Lutz Froelich⁴, Joerg Schulz⁵, Thorsten Bartsch¹

¹Dept. of Neurology, Univ. of Kiel - Kiel (Germany), ²Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich - Munich (Germany), ³Department of Psychiatry and Psychotherapy, University of Cologne, Cologne - Cologne (Germany), ⁴Department of Geriatric Psychiatry, Central Institute of Mental Health, Mannheim - Mannheim (Germany), ⁵Department of Neurology, University Hospital RWTH Aachen, Aachen - Aachen (Germany)

P184 Florbetaben binding to amyloid plaques is unaffected by amyloid-targeting antibodies lecanemab and donanemab

Presenter: Marianne Chapleau

Marianne CHAPLEAU¹, Andre MUELLER², Aleksandar JOVALEKIC², Julius SEIDEL², Maria RITTER², Eva BICKEL², Nadine KIESSLING², Emer MACSWEENEY³, Andrew STEPHENS², Norman KOGLIN²

¹Life Molecular Imaging, San Francisco, United States, ²Life Molecular Imaging, Berlin, Germany, ³Re:Cognition Health, London, United Kingdom

P186 Metabolic syndrome risk factors associated with lower cerebral blood flow and MoCA scores in healthy older adults

Presenter: Mason B Pirner

Mason B PIRNER¹, Swati RANE LEVENDOVSKY², Kristen M FARRIS¹, Jessica E REHMANN¹, Angela J HANSON¹

¹University of Washington Medical Center, Seattle, Wa, United States, ²University of Kansas Medical Center, Kansas City, Ks, United States

P187 Integrating visual assessments and quantification methods for tau PET staging

Presenter: Cho Soo Hyun

Cho SOO HYUN¹, Gu YUNA², Moscoso ALEXIS³, Schöll MICHAEL³, Yun JIHWAN², Shin DAEUN², Lee EUN HYE², Kang HEEKYONG², Kim JUN PYO², Kim HEE JIN², Na DUK L.⁴, Kang SUNG HOON⁵, Jang HYEMIN⁶, Cho HANNA⁷, Seo SANG WON²

¹Chonnam National University Medical School and Chonnam National University Hospital, Gwangju, Republic of Korea, ²Samsung Medical Center, Seoul, Republic of Korea, ³University of Gothenburg, Gothenburg, Republic of Korea, ⁴Happymind Clinic, Seoul, Republic of Korea, ⁵Korea University Guro Hospital, Seoul, Republic of Korea, ⁶Seoul National University Hospital, Seoul, Republic of Korea, ⁷Gangnam Severance Hospital, Seoul, Republic of Korea

P188 Allopregnanolone Increases Hippocampal Volume in Early Alzheimer's Disease: Importance of Segmentation Method and Baseline Atrophy

Presenter: Roberta D. Brinton

Adam C, RAIKES¹, Dawn MATTHEWS², Gerson HERNANDEZ¹, Ana S. LUKIC², Randolph D. ANDREWS², Claudia LOPEZ¹, Lon SCHNEIDER³, Roberta D. BRINTON¹

¹Center for Innovation in Brain Science, University of Arizona, Tucson, United States, ²ADM Diagnostics, Chicago, United States, ³Keck School of Medicine, University of Southern California, Los Angeles, United States

P189 Longitudinal Impact of Sarcopenia on Amyloid Deposition, Brain Atrophy, and Cognitive Decline: A Multi-modal Linear Mixed Model Analysis

Presenter: Sunghwan Kim

Sunghwan KIM¹, Sheng-Min WANG¹, Dong Woo KANG², Yoo Hyun UM³, Su-Hyeong KIM³, Yoon HAN MIN¹, Hyun Kook LIM¹

¹The Catholic University of Korea, Yeouido ST. Mary's Hospital, Seoul, Republic of Korea, ²The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul, Republic of Korea, ³The Catholic University of Korea, St. Vincent's Hospital, Suwon, Republic of Korea

P190 Exploring Individual Variation in Tau PET and CDR-SB: A Meta-Analysis of Placebo Arm Data

Presenter: Yashmin Karten

Yashmin KARTEN¹, Dries DE WITTE², Gregory KLEIN³, Antoine LEUZY^{4,1}, Alexis MOSCOSO RIAL^{5,1}, Philip INSEL⁶, Ariel Alonso ABAD^{2,7}, Geert MOLENBERGHS^{2,7}, Nadine TATTON¹, Cpad ON BEHALF OF THE CRITICAL PATH FOR ALZHEIMER'S DISEASE CONSORTIUM¹

¹Critical Path Institute, Tucson, United States, ²L-BioStat, KU Leuven, Leuven, Belgium, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁴Enigma Biomedical Group, Knoxville, United States, ⁵Instituto de Investigación Sanitaria de Santiago de Compostela, Travesía da Choupana s/n., Santiago De Compostela, Spain, ⁶University of California, San Francisco, San Francisco, United States, ⁷I-BioStat, Hasselt, Belgium

P191 Advancing Clinical Research with PET Imaging: Emerging Radiotracers and Evolving Roles in Alzheimer's Dementia Diagnosis

Presenter: Abby Fuller

Ioan Laurentiu GUTIU¹, Abby FULLER², Tetyana KORCHAK²

¹Fortrea GmbH, Munich, Germany, ²Fortrea, Durham, United States

07 ● CLINICAL TRIALS: BIOMARKERS INCLUDING PLASMA

WEDNESDAY, DECEMBER 3 (7:15 A.M. – 5:30 P.M.)

P192 The BEYONDD Study: Preliminary Plasma Biomarker Findings within a Community-Based Sample

Presenter: Eden V. Barragan

Eden V. BARRAGAN¹, Hilary W. HEUER¹, Rachel L. NOSHENY^{2,3}, Monica CAMACHO^{2,4}, Krista NAVARRA^{2,4}, Paul AISEN⁵, Omobolanle AYO⁶, Julia CULHANE⁷, Vanessa GUZMAN⁶, Michelle HIGUERA⁶, Melissa SOTELO¹, Desiree BYRD⁸, Monica RIVERA-MINDT^{6,7,9}, Gil D. RABINOVICI¹, Adam L. BOXER¹

¹ Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, United States, ² VA Advanced Imaging Research Center, San Francisco Veteran's Administration Medical Center, San Francisco, United States, ³ Department of Psychiatry, University of California, San Francisco, San Francisco, United States, ⁴ Northern California Institute for Research and Education NCIRE, San Francisco, United States, ⁵ Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United States, ⁶ Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, United States, ⁷ Department of Psychology, Fordham University, New York, United States, ⁸ Department of Psychology, Queens College, Department of Neurology, Icahn School of Medicine at Mount Sinai, Flushing, United States, ⁹ Departments of Latin American Latino Studies, and African and African American Studies, Fordham University, New York, United States

P193 Impact of plasma collection time of day on plasma p-tau217 measures in Autism and Reproductive trials

Presenter: Stephanie Slania

Stephanie SLANIA¹, Gallen TRIANA-BALTZER², David HENLEY³, Tricia THORNTON-WELLS⁴, Janice WONG⁴, Lennert STEUKERS⁵, Maggie FEDGCHIN³, Ziad SAAD²

¹ Precision Measures, Neuroscience, Johnson & Johnson, Spring House, United States, ² Precision Measures, Neuroscience, Johnson & Johnson, San Diego, United States, ³ Clinical Development, Neuroscience, Johnson & Johnson, Titusville, United States, ⁴ Clinical Development, Neuroscience, Johnson & Johnson, Cambridge, United States, ⁵ Clinical Development, Neuroscience, Johnson & Johnson, Beerse, Belgium

P194 Automated Plasma Immunoassay for APOE ε4 Zygosity Identification in Alzheimer's Disease Biomarker Research

Presenter: Corey Carlson

Brian ENGEL¹, Scott LEVIN^{2,3}, Katharine HOFFMAN¹, Ye Eun BAE¹, Miklos SZABO¹, Corey CARLSON¹, Mark HOLLAND¹, Kinal BHATT¹, Jeremiah HINSON^{2,3}, Dan FIGDORE⁴, Hyun Kook LIM⁵, Laurent TIERS⁶, Sylvain LEHMANN⁶, Yoo Hyun UM⁵, Alicia ALGECIRAS-SCHIMNICH⁴

¹ Beckman Coulter, Inc., Chaska, Mn, United States, ² Danaher Diagnostics, Washington, Dc, United States, ³ Johns Hopkins School of Medicine, Baltimore, Md, United States, ⁴ Mayo Clinic, Rochester, Mn, United States, ⁵ The Catholic University of Korea, Seoul, Republic of Korea, ⁶ Montpellier University Hospital of Montpellier, Montpellier, France

P195 Association of Plasma Alzheimer's Disease and Neurodegeneration Biomarkers with Perceived Stress, Neighborhood Disadvantage, and Socioeconomic Status

Presenter: Miriam Ashford

Miriam ASHFORD¹, Vanessa GUZMAN², Adam DIAZ^{3,4}, Alyssa ARENTOFT⁵, Melanie MILLER^{3,4}, Stephen CUBBELLOTTI², Duygu TOSUN⁴, Laurel BECKETT⁶, Jacqueline PONTES MONTEIRO⁷, Rachel NOSHENY¹, Susan LANDAU⁸, Michael WEINER³, Monica RIVERA MINDT^{9,2}, Okonkwo OZIOMA⁹, For The ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE ADNI³

¹ University of California San Francisco, Department of Psychiatry and Behavioral Sciences, San Francisco, United States, ² Icahn School of Medicine at Mount Sinai Department of Neurology, New York, United States, ³ Northern California Institute for Research and Education NCIRE, San Francisco, United States, ⁴ University of California San Francisco, Radiology and Biomedical Imaging, San Francisco, United States, ⁵ California State University Northridge Department of Psychology, Northridge, United States, ⁶ University of California Davis, Department of Public Health Sciences, Davis, United States, ⁷ Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, United States, ⁸ University of California Berkeley, Neuroscience Department, Berkeley, United States, ⁹ Fordham University Department of Psychology, New York, United States

P196 Diagnostic Accuracy of Novel Plasma pTau-217 and p-Tau181 Assays for Alzheimer's Disease

Presenter: Jessica Colon-Franco

Jessica COLON-FRANCO, Lynn BEKRIS, Christopher BOYER, Ardesir HASHIMI, Hiba KHAN, James LEVERENZ, Drew PAYTO, Jagan PILLAI, Jordan STENGEL, Sarah ZILKA, Saket SAXENA
Cleveland Clinic, Cleveland, United States

P197 High diagnostic performance of the random-access HISCL-5000 pTau217, A β 42 and A β 40 plasma assays for detecting amyloid pathology across the Alzheimer's disease clinical continuum.

Presenter: Charlotte Teunissen

Inge VERBERK¹, Daniel ANTWI-BERKO¹, Thomas CLAESSEN², Hans HEIJST¹, Azzam ALADDIN¹, Yuko SASAKI MORI³, Roman BOEER⁴, Argonde VAN HARTEN², Charlotte TEUNISSEN¹

¹ Neurochemistry Laboratory, Laboratory Medicine, Amsterdam UMC, Amsterdam, Netherlands, ² Alzheimer Center Amsterdam, Neurology, Amsterdam UMC, Amsterdam, Netherlands, ³ Sysmex R&D Center Europe GmbH, Hamburg, Germany, ⁴ Neurochemistry Laboratory, Laboratory Medicine, Amsterdam UMC, Hamburg, Germany

P198 Multiomics Blood Biomarkers Combined with Amyloid Status Improve Prediction of Alzheimer's Dementia in Cognitively Unimpaired Individuals

Presenter: Jérôme Braudeau

Benoit SOUCHET¹, Sami SAKLY¹, Maud HEUILLET², Aude DUPUY-GAYRAL², Eloi HAUDEBOURG², Catherine PECH², Antoine BERTHEMY², François AUTELITANO², Baptiste BILLOIR¹, Kimiko DOMOTO-REILLY³, Christopher FOWLER⁴, Thomas GRABOWSKI³, Suman JAYADEV³, Colin L. MASTERS⁴, Jérôme BRAUDEAU¹

¹ AgenT, Evry, France, ² Evotec, Toulouse, France, ³ University of Washington, Seattle, United States, ⁴ Florey Institute of Neuroscience and Mental Health, Parkville, Australia

P199 VeraBIND Tau: A Novel Plasma Assay Reflecting Tau Aggregation in Alzheimer's Disease Increases Over Time in Individuals with Positive Tau-PET Signal.

Presenter: Josh Soldo

Josh SOLDO¹, Lisa QUENON^{2,3}, Kavya SHAMSUNDAR¹, Winnie PAK¹, Khalid IQBAL^{4,5}, Bernard HANSEEUW^{2,3,6}

¹ Veravas, Inc, Austin, United States, ² Institute of Neuroscience, UCLouvain, Brussels, Belgium, ³ Department of Neurology, Saint-Luc University Hospital, Brussels, Belgium, ⁴ SUNY Downstate/NYSIBR Center for Developmental Neuroscience, Brooklyn, United States, ⁵ New York State Institute for Basic Research in Developmental Disabilities, Brooklyn, United States, ⁶ Massachusetts General Hospital, Gordon Center for Medical Imaging and the Athinoula A. Martinos Center for Biomedical Imaging, Boston, United States

P200 Changes of Blood Biomarker in Alzheimer's Disease During Lecanemab Treatment: A Real-World Clinical Study

Presenter: Yanjiang Wang

Shan HUANG¹, Yanjiang WANG¹, Dian HE², Rongchang ZHAO¹, Yuhui LIU¹

¹ Daping Hospital, Third Military Medical University, Chongqing, China, ² Affiliated Hospital of Guiyang Medical College, Guiyang, China

P202 SpectrisTM Treatment may mitigate the natural progression of resting state EEG in Alzheimer's disease

Presenter: Chandran Seshagiri

Chandran SESHAGIRI¹, Offir LAUFER², Brennan JACKSON¹, Julia RIDDLE¹, Evan HEMPEL¹, Zachary MALCHANO¹, Ralph KERN¹, Gil ISSACHAR², Mihaly HAJOS^{1,3}

¹ Cognito Therapeutics, Cambridge, United States, ² Firefly Neuroscience, Buffalo, United States, ³ Yale University, New Haven, United States

P203 Naturally Occurring IgG Targeting Neurotoxic A β 42 Oligomers in Healthy Elderly

Presenter: Stefan Pierrou

Anders SANDBERG, Stefan PIERROU

Alzinova AB, Mölndal, Sweden

P204 Plasma GFAP identifies a transitional pathophysiological stage from misfolded protein accumulation to neurodegeneration in Alzheimer's disease

Presenter: Jun Pyo Kim

Jun Pyo KIM¹, Minyoung CHO², Hyunwoo LEE², Bo-Hyun KIM¹, Daeun SHIN¹, Sohyun YIM¹, Heekyung KANG¹, Hong-Hee WON², Sang Won SEO¹

¹ Samsung Medical Center, Seoul, Republic of Korea, ² Samsung Advanced Institute for Health Sciences & Technology, Seoul, Republic of Korea

P205 Association of Neighborhood-Level Disadvantage with Alzheimer's Disease Blood Based Biomarkers

Presenter: Alison Myoraku

Alison MYORAKU¹, Isabella HAUSLE¹, Marta MILA-ALOMA¹, Pamela THROPP¹, Laura WANG², Murali DORAISWAMY², Duygu TOSUN³

¹ NCIRE, San Francisco, United States, ² Duke University, Durham, United States, ³ UCSF, San Francisco, United States

P206 Diagnostic Performance of Multi-Analyte Algorithms and %p-tau217 using High Resolution LC-MS/MS in a Mixed Memory Clinic Cohort

Presenter: Kristian Steen Frederiksen

Sara RIAZI¹, Steen Gregers HASSELBALCH¹, Daniel CONNELL², Tim WEST², Philip VERGHESE², Joel BRAUNSTEIN², Kristopher KIRMESS², Justine COPPINGER², Anja Hviid SIMONSEN¹, Kristian Steen FREDERIKSEN¹

¹ Danish Dementia Research Centre, Copenhagen, Denmark, ² C2N Diagnostics, St. Louis, Missouri, United States

P207 Clinical evaluation of blood-based assays for rapid detection of Amyloid- β pathology in Alzheimer's disease (CLEAR-AD) —a prospective double-blinded head-to-head comparison study of blood-based biomarker

Presenter: Jiong Shi

Xinyi LV, Kaiyuan SHEN, Jiong SHI

Department of Neurology, College of Life Science and Medicine, University of Science and Technology of China, Hefei, China

P209 CSF Proteomics Reveals SPECTRIS-Induced Neuritin-1 Upregulation and Modulation of Brain Resilience Pathways

Presenter: Ralph Kern

Ralph KERN¹, Allan LEVEY², James LAH², Saima RATHORE³, Annabelle SINGER⁴, Nicholas SEYFRIED⁵, Duc DUONG⁵, Eric DAMMER⁵, Mihaly HAJOS¹, Robbert ZUSTERZEEL¹, Lily LEE¹, Monika SHPOKAYTE¹, Zach MALCHANO¹, Julia RIDDLE¹, Chandran SESHAGIRI¹

¹ Cognito Therapeutics, Cambridge, United States, ² Emory University School of Medicine, Atlanta, United States, ³ Emtherapro Inc, Atlanta, United States, ⁴ Georgia Institute of Technology, Atlanta, United States, ⁵ Emory University Department of Biochemistry, Atlanta, United States

P210 Validation of an Alzheimer's Disease conformation-specific p53 antibody in patient samples

Presenter: Shmuel Agus

Shmuel AGUS¹, David LYNCH², Simona PICCIRELLA³, Madisson SAMPLES², Michael RASCHE⁴, Rakez KAYED²

¹ Diadem Inc, Roslindale, United States, ² UTMB, Galveston, United States, ³ Diadem SpA, Milan, Italy, ⁴ Diadem SpA, Munich, Germany

P211 Concordance of ApoE proteotype vs genotype assays: a low friction method for obtaining E4 carrier status

Presenter: Gallen Triana-Baltzer

Gallen TRIANA-BALTZER¹, Thierry VERBINNEN², Silke MILLER¹, Ziad SAAD¹, Janice WONG³, David HENLEY³, Yanina FLOSSBACH², Gahan PADINA³, Stanley BELKOWSKI³

¹ Johnson & Johnson, San Diego, United States, ² Johnson & Johnson, Beerse, Belgium, ³ Johnson & Johnson, Springhouse, United States

P212 Targeted Plasma Proteomic Biomarker Profiling in the FINGER Multimodal Lifestyle Intervention Trial

Presenter: Anna Matton

Anna MATTON^{1,2,3}, Alina SOLOMON^{3,4}, Andrea LESSA BENEDET⁵, Jenni LEHTISALO⁶, Esko LEVÄLAHTI⁶, Anna ROSENBERG⁷, Makrina DANILIDOU^{8,2}, Francesca MANGIALASCHE^{8,2,9}, Henrik ZETTERBERG⁵, Tiia NGANDU⁶, Miia KIVIPELTO⁸

¹ Department of Neurobiology, Care Sciences and Society, Karolinska Institutet - Stockholm Sweden, Stockholm, Sweden, ² FINGERS Brain Health Institute, Stockholm, Sweden, ³ The Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, United Kingdom, ⁴ Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland, ⁵ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden, ⁶ Department of Public Health, Lifestyles and Living Environments, Finnish Institute for Health and Welfare, Helsinki, Finland, ⁷ Department, Helsinki, Finland, ⁸ Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden, ⁹ Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden

P213 Does Amyloid Plaque Reduction Mediate the Clinical Effect of Amyloid-targeting Antibodies?

Presenter: Lon Schneider

Lon SCHNEIDER¹, James LUO¹, Richard KENNEDY²

¹ Keck School of Medicine of USC, Los Angeles, United States, ² University of Alabama Birmingham, Birmingham, United States

P214 Age-related changes in plasma p-tau217 and reference levels in cognitively unimpaired A β -negative individuals

Presenter: Anna Mammel

Anna MAMMEL¹, Ali MOUSAVI^{2,3}, Kelsey HALLETT¹, Mary ENCARNACION², Donald BIEHL¹, Pradip GILL¹, Fernando GONZALEZ^{1,4}, Hans FRYKMAN^{1,2,3}

¹ Neurocode, Bellingham, United States, ² BC Neuroimmunology, Vancouver, Canada, ³ University of British Columbia, Vancouver, Canada, ⁴ University of Gothenburg, Gothenburg, Sweden

P215 A Comparative Analysis of Creatinine- and Cystatin C-based eGFR equations for the Assessment of Chronic Kidney Disease Influence on Plasma p-tau217 Concentrations

Presenter: Joshua Bornhorst

Joshua BORNHORST¹, Stephen WEIGAND², Daniel FIGDORE¹, Michael GRISWOLD³, Carly LUNDGREEN², Heather WISTE², Prashanthi VEMURI⁴, Jonathan GRAFF-RADFORD⁵, David KNOPMAN⁵, Petrice COGSWELL⁴, Clifford JACK JR.⁴, Ronald PETERSEN⁵, Alicia ALGECIRAS-SCHIMNICH¹

¹ Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, United States, ² Department of Quantitative Health Sciences, Mayo Clinic, Rochester, United States, ³ Center of Biostatistics and Bioinformatics University of Mississippi Medical Center, Jackson, United States, ⁴ Department of Radiology, Mayo Clinic, Rochester, United States, ⁵ Department of Neurology, Mayo Clinic, Rochester, United States

P216 Research on Biomarkers of Early Alzheimer's Disease in China in the past decade? a scoping review

Presenter: Guoping Peng

Guoping PENG¹, Yan YANG², Ying WANG², Sagar Anil CHANDEKAR³, Jintai YU⁴

¹ Department of Neurology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, ² Novo Nordisk China Pharmaceuticals Co., Ltd., Beijing, China, ³ Novo Nordisk A/S, Søborg, Denmark, ⁴ Department of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China

P217 Clinical Trial Patient Cohort Enrichment Using Cost-Effective Blood-Based Biomarker Screening

Presenter: Noah Elder

Robert LIN¹, Jason WAN², Noah ELDER², Hien NGUYEN², Paul HUNG²

¹ Taudia, San Carlos, ² Taudia, San Carlos, United States

P218 P-tau217 testing impact on patient management in a racially/ethnically diverse population: six-month follow up in a randomized clinical utility study.

Presenter: Rose C Beck

Samantha C BURNHAM¹, Haoyan HU¹, Yifeng TANG¹, Anthony SIRECI¹, Michael J PONTECORVO¹, Paul E SCHULZ², Curtis P SCHREIBER³, Rose C BECK¹

¹ Eli Lilly & Company, Indianapolis, United States, ² Neurocognitive Disorders Center, McGovern Medical School of UTHealth, Houston, Texas, United States, ³ Missouri Memory Center, Citizen's Memorial Hospital, Bolivar, Missouri, United States

P219 Novel biomarkers drive a distinct pattern of clinical characterization of two cohorts: a Chinese Aging and Neurodegenerative Disorder Initiative (CANDI) and a Hefei Aging Study Urban Community (HAS)

Presenter: Yong Shen

Yong SHEN

University of Science and Technology of China, Hefei, China

P220 Migrating the use of plasma p-tau217 from research setting to clinical practice: a real-world study in Subjective Cognitive Decline and Mild Cognitive Impairment

Presenter: Giulia Giacomucci

Giulia GIACOMUCCI¹, Chiara CRUCITTI¹, Assunta INGANNATO¹, Silvia BAGNOLI¹, Elisa MARCANTELLI¹, Sonia PADIGLIONI², Valentina MOSCHINI², Carmen MORINELLI², Salvatore MAZZEO³, Sandro SORBI⁴, Benedetta NACMIAS¹, Valentina BESSI¹

¹ Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italie, ² Research and Innovation Centre for Dementia-CRIDEM, AOU Careggi, Florence, Italie, ³ Vita-Salute San Raffaele University, Milan, Italie, ⁴ IRCCS Fondazione Don Carlo Gnocchi, Florence, Italie

P221 Impact of recruitment modality on plasma pTau217 eligibility in clinical trials of Alzheimer's Disease

Presenter: Ralph Lee

Yu-Jay HUOH¹, Ralph LEE¹, Dung TRINH²

¹ Irvine Clinical Research, Irvine, United States, ² Healthy Brain Clinic, Long Beach, United States

P222 Baseline Gut Microbiome Composition Informs About Cognitive Changes in Lifestyle and Diet Interventions in Older Adults: Results from the U.S. POINTER-Microbiome Study

Presenter: Lucas Patel

Lucas PATEL^{1,2,3}, Lora KHATIB^{1,4}, Siamak MAHMOUDIANDHEKORDI⁵, Christopher R. BRYDGES⁵, Leyla SCHIMMEL⁵, Colette BLACH⁶, Edgar A. DIAZ⁵, Alzheimer Gut Microbiome Project -⁵, Madison AMBRE¹, Gilian M. WRIGHT¹, Mark A. ESPELAND⁷, Laura D. BAKER⁷, Rima KADDURAH-DAOUK^{5,8,9}, Rob KNIGHT^{1,10,11,12}

¹ Department of Pediatrics, University of California San Diego, La Jolla, United States, ² Bioinformatics and Systems Biology Program, University of California San Diego, La Jolla, United States, ³ Medical Scientist Training Program, University of California San Diego, La Jolla, United States, ⁴ Neurosciences Graduate Program, University of California San Diego, La Jolla, United States, ⁵ Department of Psychiatry and Behavioral Sciences, Duke University, Durham, United States, ⁶ Duke Molecular Physiology Institute, Duke University, Durham, United States, ⁷ Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, United States, ⁸ Duke Institute of Brain Sciences, Duke University, Durham, United States, ⁹ Department of Medicine, Duke University, Durham, United States, ¹⁰ Department of Bioengineering, University of California San Diego, La Jolla, United States, ¹¹ Department of Computer Science and Engineering, University of California San Diego, La Jolla, United States, ¹² Halicio?lu Data Science Institute, University of California San Diego, La Jolla, United States

P223 Multiple Plasma Biomarker Diagnostic Cascade: Performance of the Beckman Coulter p-Tau217, A β 42, and NFL assays in a cohort of individuals with cognitive impairment

Presenter: Andrew Becker

Andrew BECKER¹, Mark HOLLAND¹, Paul WYNVEEN¹, Justin LENGFELD¹, Dusten UNRUH¹, Jeff TODTLEBEN¹, Hyun Kook LIM², Yoo Hyun UM³, Kinal BHATT³, Narayan VAIBHAV⁴, Irene MEIER⁴

¹ Beckman Coulter, Inc., Chaska, Mn, United States, ² Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, ³ Department of Psychiatry, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, ⁴ Davos Alzheimer's Collaborative, Wayne, Pa, United States

P224 Comprehensive biomarker assessment of the gamma-secretase modulator nivegaceter in presymptomatic carrier participants of the PSEN1 E280A mutation

Presenter: Rosanna Tortelli

Agnès POIRIER¹, Enrique GASPAR¹, Gwendlyn KOLLMORGEN², Dominik LOTT¹, Stella YILMAZ¹, Tianxu YANG³, Agnès PORTRON¹, Kalbinder MAHIL⁴, Tayo BODEDE⁴, David AGUILLÓN⁵, David GORDON⁶, Robert ALEXANDER⁶, Thomas MUEGGLER¹, Rosanna TORTELLI¹, Irene GERLACH¹

¹ F. Hoffmann-La Roche Ltd, Basel, Switzerland, ² Roche Diagnostics GmbH, Penzberg, Germany, ³ F. Hoffmann-La Roche Ltd, Roche China Holding, Shanghai, China, ⁴ Roche Products Ltd, Welwyn Garden City, Welwyn, United Kingdom, ⁵ Grupo de Neurociencias de Antioquia, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia, ⁶ Banner Alzheimer's Institute, Phoenix, United States

P225 Developing microRNA classifiers enriched in brain and associated with inflammation in plasma samples to classify Cognitively Unimpaired, MCI, and AD study participants.

Presenter: Alidad Mireskandari

Kenny ABLORDEPPEY¹, Jacob GOLDMAN¹, Kira SHEINERMAN¹, Samuil UMANSKY¹, Alidad MIRESKANDARI¹, Jon LINKS², Alok VEDVYAS², Chodosh JOSHUA², Karyn MARSH², Arjun MASURKAR², Thomas WISNIEWSKI², Gyanendra KUMAR¹

¹ Diamir BioSciences, New Haven, United States, ² NYU Alzheimer's Disease Research Center, NYU Grossman School of Medicine, New York, United States

P226 Performance of plasma pTau217/A β 42 ratio and pTau217 to predict A β pathology status defined by CSF testing in SPIN cohort

Presenter: Yuko Mori Sasaki

Yuko MORI SASAKI¹, Roman BOEER², Javier ARRANZ³, Daniel ALCOLEA³

¹ Sysmex R&D Center Europe, Hamburg, Germany, ² Sysmex Europe SE, Hamburg, Germany, ³ Department of Neurology, Sant Pau Memory Unit, IR SANT PAU, Hospital de la Santa Creu i Sant Pau – IIB Sant Pau, Barcelona, Spain

P227 Development of MTBR-tau Fragment Assay Using a Fully Automated Immunoassay System

Presenter: Shun Murakami

Shun MURAKAMI¹, Yuki HOSHINA¹, Shunsuke WATANABE², Kengo ISHIKI¹, Kazuto YAMASHITA¹, Masahiro MIURA¹, Toshiyuki SATO¹

¹ Central Research Laboratories, Sysmex Corporation, Kobe, Japan, ² Technology Innovation Division, Sysmex Corporation, Kobe, Japan

P228 Combination of Plasma A β 42/40 and p-tau217 Measured Using Fully Automated Immunoassay System Accurately Predicts Amyloid Pathology Determined by Amyloid PET

Presenter: Masanori Kurihara

Masanori KURIHARA^{1,2}, Kazuto YAMASHITA³, Shun MURAKAMI³, Kengo ISHIKI³, Tomomi MASUDA⁴, Yoshikazu OKAMURA⁴, Masahiro MIURA³, Kenji ISHII^{2,5}, Toshiyuki SATO³, Atsushi IWATA^{1,2}

¹ Department of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, ² Department of Biomarkers, Integrated Research Initiative for Living Well with Dementia, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, ³ Central Research Laboratories, Sysmex Corporation, Kobe, Japan, ⁴ Medical & Scientific Affairs, Sysmex Corporation, Kobe, Japan, ⁵ Research Team for Neuroimaging, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan

P229 Differential Age Effects on Plasma p-tau217 by Amyloid Status, Cognitive Stage, and Sex in Alzheimer's Disease

Presenter: Seonghyeon Kim

Seonghyeon KIM¹, Daeun SHIN¹, Sohyun YIM¹, Heekyoung KANG¹, Hee Kyung PARK¹, Junah LEE², Junpyo KIM¹, Heejin KIM¹, Sangwon SEO¹

¹ Department of neurology, Samsung Medical center, Seoul, Republic of Korea, ² Alzheimer's Disease Convergence Research Center, Samsung Medical Center, Seoul, Republic of Korea

P230 The SPRING Trial: Treatment of P. gingivalis-positive mild-to-moderate Alzheimer's disease with the second-generation gingipain inhibitor LHP588

Presenter: Michael Detke

Michael DETKE¹, Marwan SABBAGH², Joanna BOLGER³, Mark RYDER¹, Craig MALLINCKRODT⁴, Casey LYNCH³, Stephen DOMINY³
¹ Lighthouse Pharma - San Francisco United States, San Francisco, United States, ² Barrow Neurological Institute, Phoenix, United States, ³ Lighthouse Pharma, San Francisco, United States, ⁴ Pentara, Millcreek, United States

P231 Prognostic Models for Development of Elevated Plasma P-tau217 in Preclinical Alzheimer's Disease: Insights from A4/LEARN

Presenter: Roy Yaari

Roy YAARI¹, Nalin PAYAKACHAT¹, Nicolae DONE², Urvi DESAI², Yun-Fei CHEN¹, Chia-Lun LIU², Pete ZUCKERMAN², Zachary SHEFF¹, Jolanda MUENZEL¹, Karen Chilcott HOLDRIDGE¹, Dulanji KURUPPU¹, Michael S. RAFII³, Noam KIRSON², Reisa SPERLING⁴
¹ Eli Lilly and Company, Indianapolis, United States, ² Analysis Group, Boston, United States, ³ University of Southern California, Los Angeles, United States, ⁴ Harvard Medical School, Boston, United States

P232 Evaluation of the Clinical Impact of Blood-Based Biomarker Assays on dementia specialists' decision-making (CIMBBBA): Preliminary report from a real-world dementia subspecialty clinic study

Presenter: Mark Eldaief

Mark ELDAIEF¹, Erin KRAHN¹, Sam MURDOCK¹, Neguine REZAI¹, Diane CHAN¹, Steven ARNOLD², Marina AVETISYAN², John DICKSON², Liliana RAMIREZ GOMEZ², Seth GALE³, Scott MCGINNIS³, Bradford DICKERSON¹
¹ Frontotemporal Disorders Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, United States, ² Memory Disorders Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, United States, ³ Center for Brain Mind Medicine, Department of Neurology, Brigham & Women's Hospital and Harvard Medical School, Boston, United States

P233 Combining Cognivue Clarity and Lucent AD Complete for a Time and Cost Efficient Two Stage Screening for Alzheimer's Disease Clinical Trial Recruitment Enrichment and Treatment Protocols

Presenter: James Galvin

James GALVIN¹, Lindsey METTE², David WILSON², Heather HARRIS³, Paul ESTES³
¹ University of Miami, Boca Raton, United States, ² Lucent Diagnostics, Billerica, United States, ³ Cognivue, Inc, Victor, United States

P234 Performance testing of the novel DDC Xplorer Lumipulse G1200 Immunoassay for measuring DOPA Decarboxylase in Cerebrospinal Fluid (CSF)

Presenter: Erik Stoops

Erik STOOPS¹, Megan DE PAUW¹, Nathan BLANCHE¹, Julie GOOSSENS¹, Eugene VANMECHELEN¹, Giovanni BELLOMO², Federico PAOLINI PAOLETTI³, Lorenzo GAETANI³, Davide CHIASSERINI³, Yihua MA⁴, Carly FARRIS⁴, Luis CONCHA-MARAMBIO⁴, Lucilla PARNETTI⁴
¹ ADx NeuroSciences, Gent, Belgium, ² University of Perugia, Perugia, Italie, ³ Centro Disturbi della Memoria, Perugia, Italie, ⁴ Amprion, San Diego, United States

P235 Blood Biomarker Testing in Real-World Care Settings: Early Learnings from the Accurate Diagnosis Implementation Project

Presenter: Amy Deckert

Amy DECKERT, Monica ZIGMAN SUCHSLAND, Karen WEYRAUCH, Tim MACLEOD, Alissa KURZMAN, Katherine J. SELZLER
Davos Alzheimer's Collaborative, Wayne, United States

P236 ADxPLOTORER: filling the gap for early-stage fluid biomarker research on the fully automated LUMIPULSE® G1200 platform ???

Presenter: Nathan Blanche

Nathan BLANCHE, Elisa SCHAERLAECKEN, Cindy FRANCOIS, Charlotte LAMBRECHTS, Shreyasee DAS, Charlotte DE ROCKER, Leentje DEMEYER, Megan DE PAUW, Jeroen VANBRABANT, Erik STOOPS
ADx NeuroSciences, Gent, Belgium

P237 Novel high-throughput, fully automated immunoassay for cerebrospinal fluid tau microtubule binding region (MTBR-tau)

Presenter: Dusten Unruh

Dusten UNRUH, Miklos SZABO, Brian ENGEL, Katharine HOFFMANN, Kara JOHNSON, Mikaela NICHKOVA-DOSEVA
Beckman Coulter, Chaska, United States

P238 High Fat Feeding Effects on Peripheral and Cerebrospinal Measures of Glucose, Insulin and Appetite Hormones

Presenter: Jessica E Rehmann

Jessica E REHMANN, Mason B PIRNER, Kristen M FARRIS, Sarah SPECKMAIER, Pavan K BHATRAJU, Angela J HANSON
University of Washington Medical Center, Seattle, Wa, United States

P240 Characterization of stages of neurodegeneration using circulating brain-enriched and inflammation-associated microRNAs

Presenter: Alidad Mireskandari

Kenny ABLORDEPPEY¹, Jacob GOLDMAN¹, David WOLK², Kira SHEINERMAN¹, Samuil UMANSKY¹, Alidad MIRESKANDARI¹, Kumar GYANENDRA¹

¹ Diamir BioSciences, New Haven, United States, ² University of Pennsylvania, Philadelphia, United States

P241 Performing multiple biomarker tests delays initiation of lecanemab treatment

Presenter: Anna Hofmann

Anna HOFMANN¹, Madeline PACZYNSKI¹, Maria PONISIO², Jessica ROBERTS³, William POWELL⁴, Aditi GUPTA⁴, Inez OH⁴, Mackenzie HOFFORD⁴, Zachary POSEY³, Melissa ALDINGER³, Tammie BENZINGER², John MORRIS¹, Joy SNIDER¹, Suzanne SCHINDLER¹

¹ Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA, Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA, St. Louis, United States, ² Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA, St. Louis, United States, ³ Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA, St. Louis, United States, ⁴ Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St. Louis, MO, USA, St. Louis, United States

P242 A novel approach for recruiting patients for early phase trials in Alzheimer's Disease: Faster, simpler, and with reduced patient burden

Presenter: Lydia Morris

Lydia MORRIS¹, Lev GERTSIK², Svetlana SEMENOVA³

¹ California Clinical Trials Medical Group in affiliation with Parexel International, Glendale, Îles mineures éloignées des United States, ² California Clinical Trials Medical Group in affiliation with Parexel International, Glendale, United States, ³ Parexel International, Glendale, United States

P243 Amplified Tau Aggregates in Cerebrospinal Fluid Track Tau PET and Cognitive Decline in Alzheimer's Disease

Presenter: Md Tohidul Islam

Md Tohidul ISLAM¹, Thomas K KARIKARI², Kaj BLENNOW¹

¹ University of Gothenburg, Gothenburg, Sweden, ² University of Pittsburg, Pittsburg, United States

P244 A Comparison of Levels and Longitudinal Trends of p-Tau 217 with MMSE, ADAS-Cog, and CDR in a Cohort of 113 Cognitively Normal and Cognitively Impaired Individuals Over 6 Years Using ADNI Data Set

Presenter: Aishwarya Prasad

Aishwarya PRASAD, Anshu ARORA, Diya NARAYAN, Dhea PUSHRAJ, Arun ARORA, Jeena VAID, Wisam ALJUMAILI, Arif KHAN
Northwest Clinical Research Center, Bellevue, Washington, United States

P245 Regional Amyloid Positivity Predicts Alzheimer's Disease Progression Despite Low Centiloid Values in Mild Cognitive Impairment

Presenter: Oh Minyoung

Oh MINYOUNG¹, Ryu JEONGRYUL¹, Lim JAE-SUNG², Kim JAE SEUNG¹, Lee JAE-HONG²

¹ Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, ² Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

P246 Head-to-head comparison of 4 capillary blood sampling devices for measuring p217 tau

Presenter: Setareh Moughadam

Setareh MOUGHADAM¹, Hanna HUBER², Laia MONTOLIU-GAYA², Nicholas ASHTON^{2,3}, Henrik ZETTERBERG², Annemie CHIAU⁴, Katrin HAEVERANS⁵, Gallen TRIANA BALTZER¹

¹ Johnson and Johnson, San Diego, United States, ² University of Gothenburg, Gothenburg, Sweden, ³ Banner Alzheimer's Institute, Phoenix, United States, ⁴ ICON, Beerse, Belgium, ⁵ Johnson and Johnson, Beerse, Belgium

P247 Leveraging recent advances in biomarkers to optimize early phase drug development in Alzheimer's Disease

Presenter: Garrett Duncan

Garrett DUNCAN

Pentara Corporation, Salt Lake City, United States

P248 Identifying Neuropsychological and Sociodemographic Predictors of a Blood-Based Biomarker of Alzheimer's Disease

Presenter: Isaiah Gamble

Isaiah GAMBLE, Stephanie RUTRICK, Sarah STARLING, Hailie HALE, Jake PETITT, Sean WOMACK

Adams Clinical, Watertown, United States

P249 MK-1167, a positive allosteric modulator of $\alpha 7$ nicotinic cholinergic receptors: proof-of-biology, dose selection, and clinical trial design

Presenter: Sarah Janicki Hsieh

Sarah Janicki HSIEH¹, Corin MILLER¹, Graeme MASON², Douglas ROTHMAN², Gerard SANACORA², Evita C WIEGERS³, Dennis W J KLOMP³, Narjes AHMADIAN³, Sarah JACOBS³, An BAUTMANS⁴, Kristien VAN DYCK⁴, Yi MO¹, Michael F EGAN¹, S Aubrey STOCH¹, MK-1167_003 MK-1167_003 CLINICAL STUDY TEAM^{1,3}

¹ Merck & Co., Inc., Rahway, United States, ² Yale School of Medicine, New Haven, United States, ³ University Medical Center, Utrecht, Netherlands, ⁴ MSD Europe Belgium, Brussels, Belgium

P250 Optimizing Plasma p-Tau217 Cutoffs for Amyloid Pathology According to Kidney Function, Body Weight, and Anemia

Presenter: Jihwan Yun

Jihwan YUN¹, Daeun SHIN², Eun Hye LEE², Jun Pyo KIM², Hongki HAM², Yuna GU², Min Young CHUN³, Sung Hoon KANG⁴, Hee Jin KIM², Duk L. NA⁵, Henrik ZETTERBERG⁶, Kaj BLENNOW⁶, Fernando GONZALEZ-ORTIZ⁶, Sang Won SEO², Hyemin JANG⁷

¹ Department of Neurology, Kyung Hee University College of Medicine, Kyung Hee University Hospital, Seoul, Republic of Korea, ² Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ³ Department of Neurology, Yongin Severance Hospital, Yonsei University Health System, Yongin, Republic of Korea, ⁴ Department of Neurology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea, ⁵ Hapymid Clinic, Neurology, Seoul, Republic of Korea, ⁶ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden, ⁷ Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea

P251 Predicting Alzheimer's Disease Progression Using Neuroimaging and Genetics Markers

Presenter: Seok Woo Moon

Seok Woo MOON¹, Bumjun KIM¹, Ivo DINOVI²

¹ Konkuk University Chungju Hospital, Chungju, Republic of Korea, ² UMICH, Ann Arbor, United States

P252 Semaglutide impacts proteomic signatures related to dementia risk in the SELECT cardiovascular outcomes trial

Presenter: Martí Jiménez-Mausbach

Martí JIMÉNEZ-MAUSBACH¹, Jan Christian REFSGAARD¹, Gabriel MARTINO¹, Teresa Leon COLOMBO¹, Betty TIJMS², Clare PATERSON³

¹ Novo Nordisk A/S, Søborg, Denmark, ² Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, Netherlands,

³ Clinical Research and Development, Standard BioTools, Boulder, Colorado, United States



P253 Robustness of Plasma A β 42/A β 40 as a Predictive Biomarker for Brain Amyloid Deposition: Independence from Renal Function and Body Mass Index in a Real-World Tertiary Care Cohort with Mild Cognitive Impairment.

Presenter: José Antonio Allué

José Antonio ALLUÉ¹, Leticia SARASA¹, Noelia FANDOS¹, Jorge LOSCOS¹, Judith ROMERO¹, Adrián SÁNCHEZ¹, Jose TERCENIO^{1,2}, Gerard PIÑOL-RIPOLL^{3,4}, María PASCUAL-LUCAS¹

¹ Araclon Biotech-Grifols, Zaragoza, Spain, ² Grifols S.A., Barcelona, Spain, ³ Hospital Universitari Santa Maria, Lleida, Spain, ⁴ Hospital Clínic, Barcelona, Spain

P254 Modeling Age-Related Amyloid-? Trajectories in Cognitively Unimpaired Individuals using GAMLSS: A Ethnic Comparison between Korean and Non-Hispanic White Cohorts

Presenter: Chun Min Young

Chun MIN YOUNG ¹, Sungjoo LEE ², Kim KYUNGA ³, Kim HEE JIN ⁴, Na DUK L. ⁴, Weiner MICHAEL ⁵, Schindler SUZANNE E. ⁶, Kim JUN PYO ⁴, Seo SANG WON ⁴

¹ Department of Neurology, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Republic of Korea, ² Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine - Seoul Korea, Republic of, Seoul, Republic of Korea, ³ Biomedical Statistics Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul, Republic of Korea, ⁴ Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ⁵ University of California, San Francisco, San Francisco, United States, ⁶ Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, United States

P255 Age-related blood CD8 T cells binding a non-self peptide/HLA epitope track with Alzheimer's and related MCI status in HLA-A2+ and HLA-A2- cohorts: expanding the reach of a T cell biomarker assay to all patients.

Presenter: Christopher Wheeler

Christopher WHEELER ^{1,2}, Debby VAN DAM ^{3,4}, Yannick VERMEIREN ^{3,4}, Hans DE REU ³, Peter Paul DE DEYN ^{3,4}

¹ T-Neuro Pharma, Aptos, United States, ² Soc. for Brain Mapping & Therapeutics, Pacific Palisades, United States, ³ University of Antwerp, Antwerp, Belgium, ⁴ University of Groningen, Groningen, Netherlands

P256 C2N Eligibility, APOE genotype Identification, Amyloid Confirmation. Results from the AHEAD 3-45 programme at Neuroclin Glasgow

Presenter: Jennifer Linch

Kanwal AADIL, Cowan LEWIS, Jennifer LYNCH, Inglis FRASER

NeuroClin Ltd, Motherwell, United Kingdom



P257 The role of lipids on changes of plasma pTau181, pTau217 and the 217/181 ratio in Alzheimer's disease over time: a pilot study in a memory clinic population.

Presenter: Michaela Defrancesco

Michaela DEFRANCESCO, Alex HOFER, Christian HUMPEL

Medical University, Innsbruck, Autriche

P258 Development and Evaluation of an MTBR Tau Fragment Immunoassay for the Assessment of Alzheimer's Disease Tau Pathology

Presenter: Shannon Leslie

Shannon LESLIE ¹, Setareh MOUGHADAM ¹, Kristof VAN KOLEN ², Gallen TRIANA-BALTZER ¹

¹ Johnson and Johnson Innovative Medicine, San Diego, United States, ² Johnson and Johnson Innovative Medicine, Beerse, Belgium

P259 Tau-Dependent Divergent Associations of Soluble and Plaque Amyloid with Glucose Dysregulation

Presenter: Dong Woo Kang

Dong Woo KANG ¹, Hyun Kook LIM ²

¹ Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, ² Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

P260 A Correlation Between Plasma P-Tau181 Levels and Clinical Diagnosis of Alzheimer's Disease

Presenter: Anshu Arora

Aishwarya PRASAD ¹, Anshu ARORA ^{1,2}, Arun ARORA ¹, Mahima PATIL ¹, Arif KHAN ^{1,3}

¹ Northwest Clinical Research Center, Bellevue, United States, ² Washington State University Elson S. Floyd College of Medicine, Spokane, United States, ³ Pacific Northwest University of Health Sciences College of Osteopathic Medicine, Yakima, United States

08 ● PROOF OF CONCEPT FOR ALZHEIMER DRUG DEVELOPMENT INTERVENTIONS

WEDNESDAY, DECEMBER 3 (7:15 A.M. – 5:30 P.M.)

P261 Clinical and PET outcomes following A β -targeting therapies in sporadic Early Onset Alzheimer's disease: Trial Emulation using the LEADS cohort

Presenter: Renaud La Joie

Konstantinos CHIOTIS ¹, Ani ELOYAN ², Kala KIRBY ³, Ganna BLAZHENETS ⁴, Piyush MAITI ⁴, Zoe LIN ⁴, Maryanne THANGARAJAH ², Alexandra TOUROUTOGLOU ⁵, Dustin HAMMERS ³, Maria CARRILLO ⁶, Bradford DICKERSON ⁵, Liana APOSTOLOVA ³, Gil RABINOVICI ⁴, Renaud LA JOIE ⁴

¹ Karolinska Institutet, Solna, Sweden, ² Brown University, Providence, United States, ³ Indiana University School of Medicine, Indianapolis, United States, ⁴ University of California, San Francisco, San Francisco, United States, ⁵ Massachusetts General Hospital, Boston, United States, ⁶ Alzheimer's Association, Chicago, United States

P262 Advancing AKV9 (NU9) Towards Phase I Clinical Evaluation: A Small-Molecule Autophagy-Enhancing Therapeutic for Proteinopathies in Alzheimer's Disease and ALS

Presenter: Raghad Nowar

Raghad NOWAR, Elizabeth JOHNSON, Pedro SOARES, Elizabeth SMITH, William KLEIN, Richard SILVERMAN
Northwestern University, Evanston, United States

P263 Thiethylperazine Reduces Phosphorylated Tau in Alzheimer's Disease: Confirming iN-based Results with Clinical Trial Data

Presenter: Markus Krohn

Markus KROHN ^{1,2}, Camilla ORBJÖRN ^{3,4}, Janelidze SHORENA ³, Stomrud ERIK ³, Mattsson NIKLAS ³, Hansson OSKAR ³, Toresson HÅKAN ^{3,4}

¹ Immunogenetics AG, Hamburg, Germany, ² Caladrix Inc., Dover, United States, ³ Lund University, Lund, Sweden, ⁴ Cell Invent Sweden AB, Lund, Sweden

P264 Intradermal BCG Immunotherapy Induces Durable Trained Immunity Signatures in CNS Monocytes and Reprograms Neuroimmune Pathways in Aging and Alzheimer's Disease

Presenter: Steven Arnold

Steven ARNOLD ¹, Mahesh KODALI ¹, Zhaozhi LI ¹, Kelli DEVITTE-MCKEE ¹, Pia KIVISAKK ¹, Allison MCMANUS ¹, Jessica GERBER ¹, Rudolph TANZI ¹, Sudeshna DAS ¹, Denise FAUSTMAN ¹, Marc WEINBERG ²

¹ Massachusetts General Hospital, Boston, United States, ² AbbVie, North Chicago, United States

P265 Perivascular Macrophages: A Potential Novel Pathway for Lecanemab to Ameliorate Blood-Brain Barrier Integrity and Cognitive Function in the APP/PS1 mouse model of Alzheimer's Disease

Presenter: Wen Chen

Wen CHEN, Wang JUNYI, Niu QIONGQIONG, Liu SHUAI, Wu HAO, Wang PAN, Ji YONG
Tianjin Huanhu Hospital, Tianjin, China

P268 Optimized Delivery of Anti-Amyloid Therapeutics using Brain Shuttles against Novel Blood-Brain-Barrier Receptors

Presenter: Naveen Mehta

Naveen MEHTA, Alvaro GARCIA, Isabel ALBUJA, John AVERA, Alex REIS, Kimberly SCEARCE-LEVIE, Gleb KUZNETSOV, Pierce OGDEN
Manifold Bio, Boston, United States

P269 Targeting of A β toxic oligomers via a designed peptide reduces plaque formation in an AD mouse model

Presenter: Carolyn Tallon

Carolyn TALLON, Sebastien PRADEL, Koya YAKABI, Emma BREYAK, Catalina PASCUALY, Chandresh GAJERA, Jeff POSAKONY, Gil BLOCK, Valerie DAGGETT

AltPep Corporation, Seattle, United States

P270 A treatment management platform to enable safe, scalable deployment of disease-modifying therapies in Alzheimer's disease

Presenter: Adrián Noriega De La Colina

Adrián NORIEGA DE LA COLINA ^{1, 2, 3}, Jorge J. LLIBRE-GUERRA ⁴, Mario MASELLIS ^{5, 6}, Eric E. SMITH ^{7, 8}, Zahinoor ISMAIL ^{7, 8}, Nikolaos SCARMEAS ^{9, 10}, Sinjan GHOSH ¹¹, Nilton CUSTODIO ¹², Gerard PIÑOL-RIPOLL ¹³, Paolo VITALI ^{1, 14}, Pedro ROSA-NETO ^{1, 15, 2, 16}, Mercè BOADA ^{17, 18}, Serge GAUTHIER ^{1, 19, 20}, Christian DANSEREAU ³, Andrew FRANK ^{21, 22}

¹ Department of Neurology and Neurosurgery, McGill University, Montreal, Canada, ² Montreal Neurological Institute-Hospital, Montreal, Canada, ³ Perceiv Research Inc., Montreal, Canada, ⁴ Department of Neurology, Washington University in Saint Louis School of Medicine, Saint Louis, United States, ⁵ Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Canada, ⁶ Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada, ⁷ Hotchkiss Brain Institute Cumming School of Medicine University of Calgary, Calgary, Canada, ⁸ Department of Clinical Neurosciences Cumming School of Medicine, University of Calgary, Calgary, Canada, ⁹ 1st Department of Neurology, Aiginition Hospital, National and Kapodistrian University, Athens, Grèce, ¹⁰ Department of Neurology, The Gertrude H. Sergievsky Center, Taub Institute for Research in Alzheimer's Disease and the Aging Brain, New York, United States, ¹¹ Narayana Health, Rabindranath Tagore International Institute of Cardiac Sciences, Kolkata, Inde, ¹² Instituto Peruano de Neurociencias, Lima, Pérou, ¹³ Unitat Trastorns Cognitius, Hospital Universitari Santa Maria, IRBLleida, Lleida, Spain, ¹⁴ McGill University Research Centre for Studies in Aging, Douglas Research Institute - Montreal Canada, Montreal, Canada, ¹⁵ McGill University Research Centre for Studies in Aging, Douglas Research Institute, Montreal, Canada, ¹⁶ The Peter O'Donnell Jr. Brain Institute OBI, University of Texas Southwestern Medical Centre UTSW., Dallas, United States, ¹⁷ Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain, ¹⁸ Networking Research Center On Neurodegenerative Diseases CIBERNED, Instituto de Salud Carlos III, Madrid, Spain, ¹⁹ Department of Psychiatry, McGill University, Montreal, Canada, ²⁰ McGill Dementia Education Program, Montreal, Canada, ²¹ Bruyère Health Research Institute, Ottawa, Canada, ²² University of Ottawa, Ottawa, Canada

P271 The brain permeable immunoproteasome-selective inhibitor AR-01 is a promising drug candidate for Alzheimer's disease

Presenter: Ji Eun Park

Ji Eun PARK ¹, Til Bahadur THAPA MAGAR ¹, Kyung Bo KIM ^{1, 2}

¹ Center for Translational Science, Florida International University, Port St Lucie, United States, ² Cellular and Molecular Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, United States

P272 Valiltramiprosate/ALZ-801 Inhibits Amyloid Oligomer Formation: Quantitative Systems Pharmacology Analysis of A β Aggregation Dynamics and Impact on AD Progression

Presenter: John Hey

John HEY ¹, Hugo GEERTS ², Shaina SHORT ², Jeremy YU ¹, Jean SCHAEFER ¹, Susan ABUSHAKRA ¹, Aidan POWER ¹, Martin TOLAR ¹

¹ Alzheon, Inc., Framingham, United States, ² Certara, Radnor, United States

P273 Proof-of-concept phase 2a clinical trial of a novel septin modulator reveals early EEG pharmacodynamic effects in Alzheimer's disease.

Presenter: Velislava Zoteva

Velislava ZOTEVA ¹, Julie CLAROT ¹, Mieke NUYTTEN ², Emiel VEREYCKEN ¹, Gert VANHOLLEBEKE ¹, Nigel COLENBIER ¹, Pieter VAN MIERLO ¹, Gerard GRIFFIOEN ²

¹ Clouds of Care NV, Ghent, Belgium, ² Remynd NV, Leuven, Belgium



P274 Efferocytosis-Driven Reduction of Neuroinflammation by Novel GAS6 Fusion Protein (GAIA) in Anti-A β Immunotherapies

Presenter: Jinkyung Lee

Soomin JI, Jinkyung LEE, Juho LEE, Sanghoon PARK

Illimis Therapeutics, Inc., Seoul, Republic of Korea

P275 Clinical Utility of Plasma Biomarkers in Anti-Amyloid Treatment Clinic to Evaluate Treatment Response and Predict of Side Effects

Presenter: Nicholas Schwartz

Nicholas SCHWARTZ, Tara ELLINGSON, Hong NGUYEN, Connor DIETZ, Gautam TAMMEWAR, Nhat Minh BUI, Rowan SALONER, Adam STAFFARONI, Melanie STEPHENS, Peter LJUBENKOV, Julio ROJAS, Gil RABINOVICI, Bruce MILLER, Adam BOXER, Lawren VANDEVREDE
University of California, San Francisco, San Francisco, United States

P276 Cross-Platform CSF Proteomics Reveals Reproducible Biomarkers and Novel Mechanisms Beyond Amyloid and Tau in Alzheimer's Disease

Presenter: Pallavi Sachdev

Pallavi SACHDEV¹, Yuanqing YE¹, Satya SAXENA¹, Takeo KAMAKURA², Kazunari SASAKI², Kazuhiro TAHARA², Hongmei NIU¹, Kristin WILDSMITH¹, Larisa REYDERMAN¹, Michael IRIZARRY¹, Viswanath DEVANARAYAN¹, Kanta HORIE^{1,2,3}
¹ Eisai Inc., Nutley, United States, ² Eisai Co., Ltd, Tsukuba, Japan, ³ Washington University School of Medicine, St. Louis, United States

P277 Valiltramiprosate Prevents Hippocampal Atrophy and Clinical Decline in An Early Symptomatic APOE4/4 AD Subpopulation in Phase 3 Study via Potential Neurogenesis/Neuroplasticity Action

Presenter: John Hey

Jeremy YU¹, Hugo GEERTS², Shaina SHORT², Jean SCHAEFER¹, Susan ABUSHAKRA¹, Aidan POWER¹, Pat KESSLAK¹, Martin TOLAR¹, John HEY¹
¹ Alzheon, Framingham, United States, ² Certara, Radnor, United States

P278 A Simulation of Long-Term Lecanemab Treatment Effect on the Alzheimer's Disease Progression in ApoE4 Non-Carriers and Heterozygous Carriers

Presenter: Se Ryeong Jang

Troy WILLIAMS¹, Se Ryeong JANG², Krista LANCOT³, Ashley KANG¹, Lisa BLOUDEK¹, Guoqiao WANG⁴
¹ Curta Inc., Seattle, United States, ² Eisai Inc., Nutley, United States, ³ Sunnybrook Health Sciences Centre, Toronto, Canada, ⁴ Washington University in Saint Louis, St. Louis, United States

P279 Neuro-Dynamic Quantitative Systems Pharmacology (QSP) Model Predicts Increasing Benefits of Continued Lecanemab Treatment with Clarity AD 48-Month Data

Presenter: Youfang Cao

Youfang CAO, Pallavi SACHDEV, Natasha PENNER, Kristin WILDSMITH, Kanta HORIE, Arnaud CHARIL, Akihiko KOYAMA, Michael IRIZARRY, Larisa REYDERMAN
Eisai Inc., Nutley, United States

P280 ACE-2223, a novel oral small molecule for TDP-43 proteinopathies, treats both gain- and loss-of-function TDP-43 pathology, extends survival and decreases NfL in vivo and has a favorable preclinical safety profile

Presenter: Katie Planey

Katie PLANEY¹, Vidhu MATHUR¹, Marcela KOKES¹, Arya SHRUTI¹, Devi KORUMILLI¹, Vanessa SEAWRIGHT¹, Haque MD ANZARUL², Naomi MORENO², Rakez KAYED²
¹ Acetel, South San Francisco, United States, ² UTMB, Galveston, United States

P281 Neonatal CSF and plasma p-tau exceed Alzheimer's disease levels: insights into antagonistic pleiotropy and potential tau therapies

Presenter: Fernando Gonzalez-Ortiz

Fernando GONZALEZ-ORTIZ¹, Henrik ZETTERBERG¹, Tormod FLADBY², Bjørn-Eivind KIRSEBOM², Peter HARRISON³, Michael TURTON³, Kaj BLENNOW¹
¹ Gothenburg University, Göteborg, Sweden, ² Oslo University, Oslo, Norway, ³ Bioventix, United Kingdom, United Kingdom

P282 Higher P-tau217 Levels in Type 2 Diabetes Mellitus: Sex Differences in Neuropathological Resilience

Presenter: Bernadette Fausto

Bernadette FAUSTO¹, Darian NAPOLEON², Salma ABEDULLAH², Mc Derby CENEUS², Victoria PARUZEL¹, Ashley POWELL¹, Maureen GICHURA¹, Robert PERNA¹, Stanley ROMAIN¹, Bisma IQBAL¹, Andrea DICKANTONE¹, Miray BUDAK¹, Mark GLUCK¹

¹ Rutgers University–Newark, Newark, United States, ² Rutgers New Jersey Medical School, Newark, United States

P283 An Optimized Polygenic Risk Score Predicts Amyloid-? Positivity, Longitudinal Cognitive Decline, and Brain Organoid Pathology

Presenter: Min Young Chun

Min Young CHUN¹, Jung SANG-HYUK², Choe JURAN³, Lee SEUNG-YEON⁴, Seo SANG WON⁵, Won HONG-HEE⁶, Seo JINSOO⁷, Kim HEE JIN⁵

¹ Department of Neurology, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Republic of Korea, ² Department of Medical Informatics, Kangwon National University College of Medicine, Chuncheon, Republic of Korea, ³ Department of Brain Sciences, Daegu Gyeongbuk Institute of Science & Technology, Daegu, Republic of Korea, ⁴ Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea, ⁵ Departments of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ⁶ Department of Digital Health, SAIHST, Sungkyunkwan University, Samsung Medical Center, Seoul, Republic of Korea, ⁷ Department of Systems Biology, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea

P284 The Global Neurodegeneration Proteomics Consortium (GNPC) V2: Expanding Real-World Proteomics to include lifestyle and drug interventions, additional geographies, and multiple proteomic platforms

Presenter: Farhad Imam

Farhad IMAM¹, Simon LOVESTONE², Krish VARSHA¹, Martin BRINGMANN²

¹ Gates Ventures, Seattle, United States, ² Johnson & Johnson, London, United Kingdom

P285 Translational Progress of NA-831, NA-911, and NA-931: Clinical Evidence Supporting a Unified Theory for Alzheimer's Disease, Stroke, and Obesity

Presenter: Lloyd Tran

Lloyd TRAN, Fern VU, Zung TRAN

Biomed Industries, Inc., San Jose, United States

P286 Biallelic Human Genetic Background: Foundation for Divergent Pathomechanisms

Presenter: Kinga Szigeti

Kinga SZIGETI, Ivanna IHNATOVYCH, Nicolas ROSAS, Michael DWYER, Niels BERGSLAND, Ralph BENEDICT, Robert ZIVADINOV

University at Buffalo, Buffalo, United States

P288 Exploration of Longitudinal Changes in Gut Microbiome Composition Stratified by Amyloid Status

Presenter: Jea Woo Kang

Jea Woo KANG¹, Rob KNIGHT², Rima KADDURAH-DAOUK³, Sterling C. JOHNSON¹, Sanjay ASTHANA¹, Cynthia M. CARLSSON¹, Nathaniel A. CHIN¹, Sandra HARDING¹, Kaj BLENNOW⁴, Henrik ZETTERBERG⁴, Tobey BETTHAUSER¹, Bradley CHRISTIAN¹, Tyler K. ULLAND⁵, Federico E. REY⁶, Barbara B. BENDLIN¹

¹ Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, United States, ² Department of Pediatrics, University of California, San Diego, La Jolla, United States, ³ Department of Psychiatry and Behavioral Sciences, Duke University, Durham, United States, ⁴ Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden, ⁵ Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, United States, ⁶ Department of Bacteriology, University of Wisconsin-Madison, Madison, United States

P289 Associations Between Alzheimer's Disease and Stroke: Clinical Studies of NA-831 for AD and NA-911 for Stroke

Presenter: Lloyd Tran

Lloyd TRAN, Fern VU, Zung TRAN

BioMed Industries, Inc., San Jose, United States

P290 Associations Between Alzheimer's Disease and Obesity: Clinical Trials of NA-831 for AD and NA-931 for the Treatment of Obesity

Presenter: Lloyd Tran

Lloyd TRAN, Fern VU, Zung TRAN

Biomed Industries, Inc., San Jose, United States

P291 Tfr1-binding peptides to transport antibodies across blood brain barrier in cynomolgus monkeys

Presenter: Hao Wu

Hao WU, Xuefeng ZHANG, Yibo QIU, Fei SHENG, Yue WU
ChainGen Bio, Shanghai, China

P292 Binding profiles of lecanemab and other amyloid-beta antibodies to amyloid-beta species isolated from Alzheimer's disease brain

Presenter: Linda Söderberg

Lars LANNFELT¹, Linda SÖDERBERG², Malin JOHANNESSON², Eleni GKANATSIU², Nicolas FRITZ², Charlotte SAHLIN², Patrik NYGREN², Olof ZACHRISSON², Christer MÖLLER²
¹ Uppsala University, Uppsala, Sweden, ² BioArctic AB, Stockholm, Sweden

P293 A diagnostic and prognostic plasma omics-biomarkers panel for Alzheimer's Disease based on microglial single-cell transcriptomics

Presenter: Ornit Chiba-Falek

Michael LUTZ, Ornit CHIBA-FALEK
Duke University, Durham, United States

P294 RNA Transcripts in Salivary Extracellular Vesicle Cargo isolated from Aged Populations

Presenter: Chuang-Kuo Wu

Chuang-Kuo WU¹, Sicheng WEN², Chang YU³, Maxfield KELSEY⁴, Mandy PEREIRA², Hannah ALAIMO¹, Em TEIXEIRA¹, Jenna PRACHT¹, Lori DAIELLO¹, Jonathan DRAKE¹, John SEDIVY⁴, Zhijin WU³, Peter QUESENBERRY², Jill KREILING⁴
¹ Department of Neurology, Warren Alpert Medical School of Brown University, Providence, United States, ² Department of Medicine, Division of Hematology/Oncology, Brown University, Providence, United States, ³ Department of Biostatistics, Brown University School of Public Health, Providence, United States, ⁴ Brown Center on the Biology of Aging, Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, United States

P295 AI-Driven Proteomics Analysis Reveals Distinct Molecular Subtypes in Neurodegeneration

Presenter: Jermaine Ross

Yoonjeong CHA, Aleksandra LESZCZYNSKA, Jermaine ROSS, Mohamedi KAGALWALA
Alleo Labs, San Francisco, United States

P296 Quantitative System Pharmacology Analysis of Oral Valiltramiprosate Natural Trajectory of Alzheimer's Disease Progression by APOE4 Genotype: Contribution of Anti-Amyloid Oligomer and APOE4 Corrector Modes of Action

Presenter: Jean Schaefer

Jean SCHAEFER¹, Hugo GEERTS², Shaina SHORT², Jeremy YU¹, Susan ABUSHAKRA¹, Aidan POWER¹, Martin TOLAR¹, John HEY¹
¹ Alzheon, Framingham, United States, ² Certara, Radnor, United States

P297 Analytical characterization of a highly sensitive and automated immunoassay for Brain-Derived pTau-217 in human biofluids

Presenter: Xiao-Jun Ma

Xiao-Jun MA, Li WANG, Adheesha DANTHANARAYANA, Sean KIM, Hayeun JI, Niyati JHAVERI, Bingqing ZHANG, Xiaolei QIU, Sasi MUDUMBA, Yuling LUO
Alamar Biosciences, Fremont, United States

P298 GLP-1 Agonists and Cognitive Decline in Alzheimer's Disease: Real-World Evidence from the SiteRx Alzheimer's Real World Data Network

Presenter: Daniel Gautieri

Daniel GAUTIERI, Ashish GAGNEJA, Jackson DOOLEY
SiteRx, New York, United States

P299 Utilization of Alzheimer's Disease Diagnostics by Patient Type: Real-World Evidence from the SiteRx Alzheimer's Real World Data Network

Presenter: Daniel Gautieri

Daniel GAUTIERI, Alex LI
SiteRx, New York, United States



P301 Assessing The Roles of Estrogen, Inflammation and Nutrition on Brain and Cognitive Decline in Aging Women: Factors Reducing Alzheimer's Disease

Presenter: Lephart Edwin

Klayton JOESEL ¹, Hedges DAWSON ², Lephart EDWIN ²

¹ University of Texas at Austin, Austin, United States, ² Brigham Young University, Provo, United States

P302 Plasm p-tau217 predictive ability of Cognitive and Functional Decline in Non-demented Amyloid PET positive Older Individual: Three-year follow up data from Japanese Trial Ready cohort for preclinical and prodromal AD.

Presenter: Yoshiki Niimi

Yoshiki NIIMI ¹, Saki NAKASHIMA ¹, Kenichiro SATO ¹, Kensaku KASUGA ², Takeshi IKEUCHI ³, Takeshi IWATSUBO ⁴

¹ The University of Tokyo Hospital, Tokyo, Japan, ² National Center for Geriatrics and Gerontology, Aichi, Japan, ³ Niigata University, Niigata, Japan, ⁴ National Center of Neurology and Psychiatry, Tokyo, Japan



P303 Amyloid aggregation inhibition by physiological levels of dopamine: towards levodopa drug reformulation for correcting mild dopamine deficits and delaying Alzheimer's disease progression

Presenter: Joana Saavedra

Joana SAAVEDRA, Zsuzsa SÁRKÁNY, Isabel CARDOSO, Sandra MACEDO-RIBEIRO, Pedro M MARTINS

i³S, Porto, Portugal

P304 Functional decline associated with all-cause mortality in patients with mild cognitive impairment and Alzheimer's dementia in real-world clinical practice

Presenter: Ying Wang

Peter MORIN ¹, Ying WANG ², Joel REISMAN ³, Dan BERLOWITZ ³, Donald MILLER ³, Wen HU ³, Shou-En LU ⁴, Raymond ZHANG ⁵, Amir Abbas TAHAMI MONFARED ⁵, Quanwu ZHANG ⁵, Weiming XIA ¹, ¹

¹ Boston University, Boston, United States, ² Wentworth Institute of Technology, Boston, United States, ³ University of Massachusetts, Lowell, United States, ⁴ Rutgers University, Piscataway, United States, ⁵ Eisai, Inc, Nutley, United States

P305 Integrating Cognitive and Biological Signals in Early Alzheimer's: Predicting p217tau and MCI using the multi-modal Altoida NeuroMarker Platform

Presenter: Nicholas Griffin

Nicholas GRIFFIN ¹, Srinivasan VAIRAVAN ², Gallen TRIANA-BALTZER ³, Anahita KYANI ², Ziad SAAD ³, Meenakshi KHARE ⁴, Kara BARTONE ³, Silvia FALLONE ¹, Victoria BRUGADA-RAMENTOL ¹, M. Florencia IULITA ¹, Marc JONES ¹, Gayle WITTENBERG ², Emmanuel STREEL ¹

¹ Altoida, Washington, Dc, United States, ² JNJ Innovative Medicine, Titusville, New Jersey, United States, ³ JNJ Innovative Medicine, San Diego, California, United States, ⁴ Quanterix, Billerica, Massachusetts, United States

10 ● CLINICAL TRIALS: COGNITIVE AND FUNCTIONAL ENDPOINTS

THURSDAY, DECEMBER 4 (7:15 A.M. – 5:00 P.M.)

P306 Worse cognitive performance and poorer quality of life are associated with lower self-reported confidence in accomplishing personal priorities: the utility of the electronic Person Specific Outcome Measure (ePSOM) tool

Presenter: Ali Jannati

Stina SAUNDERS ^{1,2}, Claudio TORO-SEREY ¹, Ali JANNATI ^{1,3}, Sean TOBYNE ¹, Craig RITCHIE ⁴, Sarah GREGORY ⁴, Miles WELSTEAD ⁴, Álvaro PASCUAL-LEONE ^{1,3,5}

¹ Linus Health, Boston, United States, ² University of Edinburgh, Edinburgh, United Kingdom, ³ Department of Neurology, Harvard Medical School, Boston, United States, ⁴ Scottish Brain Sciences, Edinburgh, United Kingdom, ⁵ Marcus Institute for Aging Research and Wolk Center for Memory Health, Hebrew SeniorLife, Boston, United States

P307 Four-Year Follow-Up of a Multimodal Intervention for Dementia Prevention: Extended Results from the J-MINT PRIME Tamba Randomized Controlled Trial

Presenter: Hisatomo Kowa

Hisatomo KOWA ¹, Tohmi OSAKI ², Ryoko KUMAGAI ¹, Yutaro OKI ¹

¹ Kobe University Graduate School of Health Sciences, Kobe, Japan, ² Kobe Gaukuin University, Faculty of Rehabilitation, Kobe, Japan

P308 Comparing longitudinal trajectories of Storyteller and CDR-SB: Initial data from ADNI4

Presenter: Emil Fristed

Emil FRISTED ¹, Jack WESTON ¹, Adni FOR THE ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE ²

¹ Novoic Ltd, London, United Kingdom, ² ADNI, San Francisco, United Kingdom

P309 Speed-Based Cognitive Training Improves Cholinergic Network Health: Implications for Cognitive Aging and Dementia Prevention from the INHANCE Randomized Clinical Trial

Presenter: Thomas Van Vleet

Thomas VAN VLEET ¹, Mouna ATTARHA ¹, Ana De Figueiredo PELEGRINO ², Paule-Joanne TOUSSAINT ², Sarah-Jane GRANT ¹, Lydia OUELLET ², Etienne DE VILLERS-SIDANI ²

¹ Posit Science, San Francisco, United States, ² McGill University, Montreal, Canada

P310 Evidence Supporting the Use of the Clinical Dementia Rating® as an Outcome Measure in Dementia with Lewy Bodies Clinical Trials

Presenter: James Galvin

James GALVIN, Andreas SALCEDO

University of Miami Miller School of Medicine, Boca Raton, United States



P311 Synergistic effects of Pozibio and Cerebella supplementation on brain function and wellbeing in older adults

Presenter: Hariom Yadav

Courtney DAVIES ¹, Alina WARREN-WALKER ¹, Nigel HOLT ¹, Denis KAY ², Kevin STEPHENS ³, Hariom YADAV ^{4,5}, Alexander TAYLOR ¹, Amanda LLOYD ¹

¹ Aberystwyth University, Wales, United Kingdom, ² Neurodyn Life Sciences Inc, Prince Edward Island, Canada, ³ Agroceutical Products Ltd, England, United Kingdom, ⁴ University of South Florida, Tampa, United States, ⁵ Postbiotics Inc, Winston-Salem, United States

P312 Toward clinical trial readiness for the posterior cortical atrophy phenotype: Baseline characteristics in a longitudinal, prospective cohort

Presenter: Victoria Pelak

Victoria PELAK ¹, Asher MAHMOOD ¹, Lily NOTEBOOM ¹, Bernard CROISILE ², Allison MCKENDRICK ³, Brianne BETTCHER ¹, Sebastian CRUTCH ⁴, Keir YONG ⁴

¹ University of Colorado School of Medicine, Aurora, United States, ² Neurological Hospital of Lyon, France Hôpital Neurologique Pierre Wertheimer, Lyon, France, ³ The University of Western Australia, Perth, Australia, ⁴ University of College London, London, United Kingdom

P313 Meaningful benefits in global AD trials: feasibility, applicability, and user acceptability of the ePSOM tool in Japanese memory clinics

Presenter: Atsushi Iwata

Atsushi IWATA¹, Hisatomo KOWA², Yuki TAKEDA², Stina SAUNDERS^{3,4}, Himanshi MALIK³, Claudio TORO-SEREY³, Ali JANNATI^{3,5}, Sean TOBYNE³, Álvaro PASCUAL-LEONE^{3,5}

¹ Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, ² Kobe University, Kobe, Japan, ³ Linus Health, Boston, United States, ⁴ University of Edinburgh, Edinburgh, United Kingdom, ⁵ Harvard Medical School, Boston, United States

P314 Baseline Study-Partner Reported ECog-12 score is associated with subsequent progression on CDR-SB over 78 weeks of follow-up

Presenter: Cai Gillis

Cai GILLIS, Jin WANG, Jing XIE, Melanie SHULMAN, Shuang WU, Sharda SHOWELL, Jennifer MURPHY
Biogen, Cambridge, United States

P315 Identifying individually-defined treatment priorities sensitive to change in cognition

Presenter: Ali Jannati

Stina SAUNDERS^{1,2}, Claudio TORO-SEREY¹, Ali JANNATI^{1,3}, Sean TOBYNE¹, Craig RITCHIE^{4,5}, Sarah GREGORY⁴, Miles WELSTEAD⁴, Álvaro PASCUAL-LEONE^{1,3,6}

¹ Linus Health, Boston, United States, ² University of Edinburgh, Edinburgh, United Kingdom, ³ Department of Neurology, Harvard Medical School, Boston, United States, ⁴ Scottish Brain Sciences, Edinburgh, United Kingdom, ⁵ School of Medicine, University of St Andrews, St Andrews, United Kingdom, ⁶ Marcus Institute for Aging Research and Wolk Center for Memory Health, Hebrew SeniorLife, Boston, United States

P316 Validation of the Early Mild Alzheimer's Cognitive Composite (EMACC) Through Associations with Blood-Based Biomarkers of Alzheimer's Disease

Presenter: Sarah Barnum

Sarah BARNUM¹, Kim STAATS², Judith JAEGER¹

¹ CognitionMetrics, LLC, Hixson, United States, ² CognitionMetrics, LLC, Boca Raton, United States

P317 Best-Fit Clinical Outcomes Assessment Measures to Evaluate What Matters Most in Alzheimer's Disease: Identifying a Core Outcomes Set from Existing Measures

Presenter: Russ Paulsen

Carla ROMANO¹, Jacqueline MOGLE¹, Audra GOLD¹, Ann HARTRY², Jim TAYLOR³, Leigh F. CALLAHAN⁴, Doreen MONKS⁵, Ian KREMER⁶, Debra LAPPIN⁷, Terry FRANGIOSA⁸, Jae LEE⁹, Elaheh SHIRNESHAN⁹, Diana SLOWIEJKO¹⁰, Russ PAULSEN¹¹

¹ RTI Health Solutions, Durham, United States, ² Eli Lilly & Co, Indianapolis, United States, ³ Memory Advocate Peers MAP, New York, United States, ⁴ University of North Carolina at Chapel Hill, Chapel Hill, United States, ⁵ Advocate and person living with Alzheimer's disease, Livingston, United States, ⁶ LEAD Coalition Leaders Engaged on Alzheimer's Disease, Washington, Dc, United States, ⁷ Lappin Kramer LLC, Denver, United States, ⁸ Faegre Drinker Consulting, Washington, Dc, United States, ⁹ AbbVie Inc., Chicago, United States, ¹⁰ Genentech, San Francisco, United States, ¹¹ UsAgainstAlzheimer's, Washington, Dc, United States

P318 Early Infusion-Related Reactions with CSF Inflammatory Changes in two Lecanemab-Treated Autosomal Dominant Alzheimer's Disease Cases

Presenter: Patricio Chrem Mendez

Patricio CHREM MENDEZ¹, Emiliana SEMINARA¹, Sofia ELGANI¹, Juan Pablo TARAVONE¹, Hernan CHAVES¹, Florencia YORIO¹, Yanina BERGAMO¹, Pablo BAGNATI¹, Ricardo ALLEGRI¹, David CLIFFORD², Lon SCHNEIDER², Eric MCDADE², Randall BATEMAN², Jorge LLIBRE²

¹ Dr., Buenos Aires, Argentina, ² Dr., Saint Louis, United States

P320 Validation of a novel cognitive-functional outcome measure optimized for early AD: Evidence from the VIVA-MIND trial

Presenter: Steven Edland

Jasmin DUEHRING¹, Diane JACOBS¹, Carolyn REVTA¹, Jody-Lynn LUPO¹, Andrew MACKELFRESH¹, Antje MEYER², Torsten HOFFMANN², Michael SCHAEFFER², Sylvia SCHELL-MADER², Tanja WASSMANN², Frank WEBER², Christine WENXKOWSKI², Howard FELDMAN¹, Steven EDLAND¹

¹ UCSD, La Jolla, United States, ² Vivoryon Therapeutics N.V., Halle, Germany

P321 Evaluating a Personalized Endpoint in Down Syndrome–Associated Alzheimer’s Disease: Feasibility and Stakeholder Perspectives

Presenter: Chere Chapman

Gunes SEVINC¹, Michelle GEORGE², Katherina CRESPO², Lois KELLY³, Hampus HILLERSTORM³, James A. HENDRIX^{4,3}, Chere CHAPMAN², Kenneth ROCKWOOD^{5,6,2}

¹ Ardea Outcomes, Vancouver, Bc, Canada, ² Ardea Outcomes, Halifax, Ns, Canada, ³ LuMind IDSC Foundation, Woburn, Ma, United States, ⁴ Eli Lilly and Company, Indianapolis, In, United States, ⁵ Dalhousie University, Halifax, Ns, Canada, ⁶ Nova Scotia Health Authority, Halifax, Ns, Canada

P322 Development of Prognostic Models for Five-Year Risk of Clinical Progression from Preclinical Alzheimer’s Disease (Stage 1 and 2) to Cognitive Impairment: Findings from the A4 Study

Presenter: Nalin Payakachat

Nalin PAYAKACHAT¹, Nicolae DONE², Urvi DESAI², Yun-Fei CHEN¹, Pete ZUCKERMAN², Chia-Lun LIU², E. Jolanda MUENZEL¹, Katie Ann VANDERGRIFF¹, Karen Chilcott HOLDRIDGE¹, Dulanji KURUPPU¹, Michael S. RAFII³, Roy YAARI¹, Noam KIRSON², Reisa SPERLING⁴

¹ Eli Lilly and Company, Indianapolis, United States, ² Analysis Group, Boston, United States, ³ University of Southern California, Los Angeles, United States, ⁴ Harvard Medical School, Boston, United States



P323 Regional Differences in the Presence of Data Quality Concerns in Dementia Clinical Trials

Presenter: David Miller

David MILLER¹, Xingmei WANG², Alan KOTT³

¹ Signant Health, Philadelphia, United States, ² Signant Health, Blue Bell, United States, ³ Signant Health, Prague, Czech Republic

P324 Comparative Sensitivity of MMSE, Resting-State EEG, and Event-Related Potentials in Longitudinal Cognitive Decline Detection

Presenter: Caroline Ma

Caroline MA¹, Amir MEGHDADI¹, Grant FOSTER¹, Corinne FISCHER², David SALAT³, Chris BERKA¹

¹ Advanced Brain Monitoring, Inc., Carlsbad, United States, ² St. Michael’s Hospital - Toronto Canada, Toronto, Canada, ³ Massachusetts General Hospital, Boston, United States

P325 Memory support training and lifestyle modifications to promote healthy aging in persons at risk for Alzheimer’s disease: Brain Boosters randomized controlled trial initial results

Presenter: Sarah Tomaszewski Farias

Sarah TOMASZEWSKI FARIAS¹, Jaclyn FOX¹, Hilary ARALIS¹, Danielle HARVEY¹, Michelle CHAN¹, Michael RYAN¹, Alyssa WEAKLEY¹, Samina RAHMAN², Catherine LUNA², Maureen SCHMITTER-EDGEcombe²

¹ University of California, Davis, Sacramento, United States, ² Washington State University, Pullman, United States



P326 Mediterranean Diet in Subjective Cognitive Decline: Cognitive, Mobility, and Neuroimaging Outcomes from a Randomized Cross-Over Trial

Presenter: Yu-Ruei Lin

Yu-Ruei LIN¹, Li-Ning PENG^{2,3}, Liang-Kung CHEN^{2,3,4}, Chih-Ping CHUNG^{1,5}

¹ Department of Neurology, Neurological Institute, Taipei Veterans General Hospital, Taipei City, Taiwan, République de China, ² Center for Geriatric and Gerontology, Taipei Veterans General Hospital, Taipei City, Taiwan, République de China, ³ Center for Healthy Longevity and Aging Sciences, National Yang Ming Chiao Tung University, Taipei City, Taiwan, République de China, ⁴ Taipei Municipal Gan-Dau Hospital Managed by Taipei Veterans General Hospital, Taipei City, Taiwan, République de China, ⁵ School of Medicine, National Yang Ming Chiao Tung University, Taipei City, Taiwan, République de China



P327 The Efficacy and Safety of Mobile-App-Based Metamemory Cognitive Training for Mild Cognitive Impairment: A Multicenter, Randomized Clinical Trial

Presenter: Sunyoung Kang

Sunyoung KANG^{1,2}, Jung-In LIM³, Lukas STENZEL⁴, Keun You KIM¹, Eosu KIM^{1,5,6}, Hong Jun JEON⁷, Doo-Heum PARK⁷, Hyun Kook LIM^{8,9}, Yongsoo SHIM¹⁰, Jae-Won JANG¹¹, Yesheon KIM¹¹, Kee Hyung PARK¹²

¹ Department of Psychiatry & Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea, ² Emocog Inc., Seoul, Republic of Korea, ³ Interdisciplinary Program in Cognitive Science, Seoul, Republic of Korea, ⁴ Cogthera GmbH, Munich, Germany, ⁵ Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea, ⁶ Metabolism-Dementia Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea, ⁷ Department of Psychiatry, Konkuk University Medical Center, Seoul, Republic of Korea, ⁸ Department of Psychiatry, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, ⁹ CMC Institute for Basic Medical Science, the Catholic Medical Center of The Catholic University of Korea, Seoul, Republic of Korea, ¹⁰ Department of Neurology, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, ¹¹ Department of Neurology, Kangwon National University Hospital, Kangwon National University College of Medicine, Chuncheon, Republic of Korea, ¹² Department of Neurology, College of Medicine, Gachon University, Gil Medical Center, Incheon, Republic of Korea

11 • COGNITIVE ASSESSMENT AND CLINICAL TRIALS

THURSDAY, DECEMBER 4 (7:15 A.M. – 5:00 P.M.)

P328 SGMA: Computational Phenotyping for the Rapid, Repeatable, and Reliable Longitudinal Assessments of Long-Term Memory Function in Clinical Trials

Presenter: Andrea Stocco

Andrea STOCOCCO¹, Holly HAKE², Anais CAPIK³, Thomas WILSCHUT³, Maarten VAN DER VELDE⁴, Michael ROSENBLOOM¹, Thomas GRABOWSKI¹, Hedderik VAN RIJN⁵

¹ University of Washington, Seattle, United States, ² MemoryLab Health, Seattle, United States, ³ MemoryLab Health, Groningen, Netherlands, ⁴ MemoryLab, Groningen, Netherlands, ⁵ University of Groningen, Seattle, Netherlands

P330 An integrated model of diagnosis, treatment, prevention and research: patient journeys at the Geneva Memory Center

Presenter: Federica Ribaldi

Federica RIBALDI, Augusto MENDES, Aurelien LATHUILIERE, Giovanni FRISONI
Geneva Memory Center, Geneva, Switzerland

P331 Preventing Cognitive Decline in Aging: A Network Meta-Analysis of Nutritional Supplement Trials in Cognitively Unimpaired Older Adults

Presenter: Federica Ribaldi

Augusto J. MENDES¹, Sophie MUTEL¹, Federica RIBALDI¹, Ozge SAYIN¹, Giorgi KHACHVANI¹, Roberta MULARGIA², Gabriele VOLPARA³, Giulia REMOLI⁴, Umberto NENCHA⁵, Stefano GIANONNI-LUZA⁶, Stefano CAPPÀ⁷, Giovanni FRISONI¹

¹ Laboratory of Neuroimaging of Aging LANVIE, University of Geneva, Geneva, Switzerland, ² Institute of Neurology, University of Cagliari, Cagliari, Italy, Cagliari, Italie, ³ Institute of Neurology, University of Cagliari, Cagliari, Italy, Pavia, Italie, ⁴ Institute of Neurology, University of Cagliari, Cagliari, Italy, Milano, Italie, ⁵ Geneva Memory Centre, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland, ⁶ Department of Translational Biomedicine and Neuroscience, University of Bari Aldo Moro, Bari, Italy, Bari, Italie, ⁷ ICoN Cognitive Neuroscience Centre, Institute for Advanced Studies, IUSS, Pavia, Italy, Pavia, Italie

P332 Speech measures enhance the prediction of Alzheimer's disease biomarkers

Presenter: Jessica Robin

Jessica ROBIN¹, Mengdan XU², Michael SPILKA², Francesca CORMACK³

¹ Cambridge Cognition, Vancouver, Canada, ² Cambridge Cognition, Toronto, Canada, ³ Cambridge Cognition, Cambridge, United Kingdom

P333 ERP biomarkers of cognitive dysfunction in Alzheimer's disease: Real-world evidence for translation into clinical trial endpoints

Presenter: Amir Meghdadi

Amir MEGHDADI¹, Natasha KOVACEVIC¹, Chris BERKA¹, Katy TARRIT MIRAKHORLI², Shay NAKAHIRA², Kirra BORRELLO², Janette BOW-KEOLA², Kylie YAMAUCHI², Enrique CARRAZANA², Janette ABRAMOWITZ², Qi ZHI³, Kore LIOW²

¹ Advanced Brain Monitoring, Carlsbad, United States, ² University of Hawaii, Honolulu, United States, ³ Hawaii Pacific Neuroscience, Honolulu, United States

P334 Integrating Plasma pTau-217 and Digital Cognitive Assessments for Early Detection in Alzheimer's Disease

Presenter: Casey Vanderlip

Casey VANDERLIP, Craig STARK
UC Irvine, Irvine, United States

P335 Combining plasma pTau217 and a remote digital cognitive assessment to predict cognitive decline in cognitively unimpaired older adults

Presenter: Hairin Kim

Hairin KIM¹, Daniel SOBERANES¹, Roos JUTTEN², Mark DUBBELMAN¹, Gad MARSHALL¹, Hyun-Sik YANG¹, Dorene RENTZ¹, Keith JOHNSON³, Reisa SPERLING³, Rebecca AMARIGLIO¹, Kathryn PAPP¹

¹ Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, Boston, United States, ² Department of Neurology, Amsterdam UMC location VUmc, Amsterdam, The Netherlands, Amsterdam, Netherlands, ³ Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, Boston, United States

P336 Speech-based digital cognitive assessments for scalable and cost-effective pre-screening of preclinical Alzheimer's Disease: Insights from the RETAIN study

Presenter: Anahita Kyani

Anahita KYANI ¹, Srinivasan VAIRAVAN ², Federico PARISI ³, Dzmitry KALIUKHOVICH ⁴, Macarena GARCIA VALDECASAS COLELL ⁵, Sara GALE ², Bahador MARZBAN ³, Nicklas LINZ ⁶, Johannes TRÖGER ⁶, Janna HERRMANN ⁶, David HENLEY ², Fiona ELWOOD ³, Tricia THORNTON-WELLS ³, Bryan HANSEN ⁷, Lennert STEUKERS ⁴

¹ Johnson & Johnson, La Jolla, United States, ² Johnson & Johnson, Titusville, United States, ³ Johnson & Johnson, Cambridge, United States, ⁴ Johnson & Johnson, Beerse, Belgium, ⁵ Johnson & Johnson, Basel, Switzerland, ⁶ ki elements GmbH, Saarbrücken, Germany, ⁷ Johnson & Johnson, Spring House, United States

P337 Electric Field of the Default Mode Network is Correlated with Effects of Transcranial Alternating Current Stimulation in Mild Alzheimer's Disease

Presenter: Yi Tang

Aonan LI, Yi XING, Yi TANG

Department of Neurology & Innovation Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, National Center for Neurological Disorders, Beijing, China

P338 The validation of the new Chinese Short Cognitive Performance Test (SKT)

Presenter: Mark Stemmler

Mark STEMLER ¹, Melina ARNOLD ¹, Liang CUI ², Qi-Hao GUO ²

¹ University of Erlangen-Nuremberg, Erlangen, Germany, ² Shanghai Jiao Tong University School of Medicine, Shanghai, China

P339 Subjective Cognitive Complaints and Stages of Objective Memory Impairment (SOMI) Predict Clinical Progression

Presenter: Priyanka Kumari

Priyanka KUMARI ¹, Richard LIPTON, B. ^{1,2}, Ellen GROBER ¹

¹ Albert Einstein College of Medicine, New York, United States, ² Montefiore Medical Center, Bronx, NY, USA

P340 The Digital Clock and Recall identifies eligible candidates for Alzheimer's disease-modifying treatment

Presenter: Ali Jannati

Ali JANNATI, Karl THOMPSON, Claudio TORO-SEREY, Connor HIGGINS, John SHOWALTER, David BATES, Alvaro PASCUAL-LEONE, Sean TOBYNE

Linus Health, Boston, United States

P342 Clinical Outcomes and Patient Experience of Subcutaneous Lecanemab Administration from an Alzheimer's Disease Treatment Center

Presenter: David Watson

David WATSON, Michael NEAM, Mark STAFFORD, Cynthia BOUCHARD, Venessa RANNEY, Sydney WERNER

Alzheimer's Research and Treatment Center, Wellington, United States

P343 Prediction of plasma p-tau217 status and Alzheimer's risk with the remote-ready digital assessment of cognition

Presenter: Ali Jannati

Ali JANNATI, Karl THOMPSON, Daniel SCHULMAN, David LIBON, Rod SWENSON, John SHOWALTER, David BATES, Alvaro PASCUAL-LEONE, Sean TOBYNE

Linus Health, Boston, United States



P344 Advancing Precision in Cognitive Impairment Research: The Role of the Institute for Cognitive Intervention

Presenter: Bon D. Ku

Bon D. KU ¹, Hong Mo KU ²

¹ Director of Neuroscience Center & Institute for Cognitive Intervention Department of Neurology, International St. Mary's Hospital Catholic Kwandong University College of Medicine, Incheon, Republic of Korea, ² Institute for Cognitive Intervention International St. Mary's Hospital, Incheon, Republic of Korea

P345 Interview Quality Matters: A Cross-Trial Analysis of CDR Administration Errors in Alzheimer's Disease Clinical Research

Presenter: Amanda Aedo

Amanda AEDO ¹, Gila BARBATI ¹, Sayaka MACHIZAWA ¹, Andrei IACOB ², Jessica STENCLIK ¹, Erica APPLEMAN ¹

¹ Signant Health, Blue Bell, United States, ² Signant Health, Iasi, Roumanie



P346 Linking the Mini-Mental State Examination and the 13-Item Version of Alzheimer's Disease Assessment Scale-Cognitive Subscale

Presenter: David Miller

David MILLER ¹, Alan KOTT ², Xingmei WANG ³

¹ Signant Health, Philadelphia, United States, ² Signant Health, Prague, Czech Republic, ³ Signant Health, Blue Bell, United States

P347 Development and preliminary findings of the MoCA-Cognitive Health Questionnaire

Presenter: Ziad Nasreddine

Laura KLAMING, Murray GILLIES, Ziad NASREDDINE

MoCA Cognition, Montreal, Canada

P348 Cognitive Trajectories in Alzheimer's Disease: Findings from the Multinational CICERO-AD Chart Review Study

Presenter: Diego Novick

Diego NOVICK ¹, Giuseppe BRUNO ², Grazie DELL'AGNELLO ³, Anthony ZAGAR ⁴, Agota SZENDE ⁵, Victor KIRI ⁶, Mercè BOADA ⁷, Mercè BOADA ⁸

¹ Eli Lilly and Company Ltd., Bracknell, United Kingdom, ² Department of Neurology and Psychiatry, University of Rome "Sapienza", Rome, Italie, ³ Eli Lilly Italia Spa, Sesto Fiorentino, Italie, ⁴ Eli Lilly and Company Ltd., Indianapolis, United States, ⁵ Fortrea, York, United Kingdom, ⁶ Fortrea, Maidenhead, United Kingdom, ⁷ Ace Alzheimer Center Barcelona. Universitat Internacional de Catalunya, Barcelona, Spain, ⁸ Networking Research Center on Neurodegenerative Diseases CIBERNED, Instituto de Salud Carlos III, Madrid, Spain

P349 Automated linguistic and acoustic metrics of a smartphone-captured cued narration and recall assessment for detecting early memory and biomarker changes in early Alzheimer's disease

Presenter: Thanneer Perumal

Raphael ULLMANN ¹, Arnaud WOLFER ¹, Kami KOSEK ², Monika ZBYTNIIEWSKA-MÉGRET ³, Thanneer PERUMAL ¹, Irma KURNIAWAN ¹, Kirsten TAYLOR ¹

¹ F. Hoffmann-La Roche Ltd., Basel, Switzerland, ² Roche Global IT Solution Center, Warsaw, Pologne, ³ CTC Resourcing Solutions AG, Basel, Switzerland

12 ● BEHAVIORAL DISORDERS AND CLINICAL TRIALS

THURSDAY, DECEMBER 4 (7:15 A.M. – 5:00 P.M.)

P350 Pain Severity Moderates Efficacy of Nabilone for Agitation in Alzheimer's Disease

Presenter: Oriel Feldman

Oriel FELDMAN ^{1, 2}, Myuri RUTHIRAKUHAN ³, Nathan HERRMANN ^{2, 4, 3}, Damien GALLAGHER ^{2, 4, 3}, Giovanni MAROTTA ^{2, 5}, Alex KISS ³, Sandra BLACK ^{3, 6}, Krista LANCTOT ^{1, 2, 4, 3}

¹ Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada, ² Geriatric Psychopharmacology Research Group, Sunnybrook Research Institute, Toronto, Canada, ³ Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Canada, ⁴ Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada, ⁵ Division of Geriatric Medicine, Sunnybrook Health Sciences Centre, Canada, ⁶ Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Canada

P351 Pharmacological Class and Dose Effects on Neuropsychiatric Symptoms and Disease Severity in Dementia: A Defined Daily Dose-Based Cohort Study

Presenter: Jong-Ling Fuh

Yu-Ruei LIN, Jong-Ling FUH

Taipei Veterans General Hospital, Taipei, Taiwan, République de China

P352 Evaluation of the Benefits of Benzgalantamine (ZUNVEYL®) Therapy on Sleep Quality and Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease Patients, and on Reduction of Care-Partner Burden: A Proposed Study Design.

Presenter: Denis Kay

Denis KAY ¹, Andrew WAHLERT ², Pavel SVINTOZELSKIY ², Michael MCFADDEN ², Kurt GRADY ²

¹ Alpha Cognition Inc, Vancouver, Bc, Canada, ² Alpha Cognition Inc, Grapevine, Tx, United States

13 ● HEALTH ECONOMICS AND CLINICAL TRIALS

THURSDAY, DECEMBER 4 (7:15 A.M. – 5:00 P.M.)

P355 Cost saving by plasma p-tau217 versus p-tau217/A β 42 ratio using two-step approach in the Japanese health care system

Presenter: Masanori Kurihara

Masanori KURIHARA ¹, Ryoko IHARA ¹, Kenichiro SATO ², Atsushi IWATA ¹

¹ Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, ² The University of Tokyo Hospital, Tokyo, Japan

P356 A Low-cost, Scalable Blood Biomarker Assay for Alzheimer's Disease Testing in Resource- Limited Settings

Presenter: Noah Elder

Robert LIN, Jason WAN, Noah ELDER, Hien NGUYEN, Paul HUNG

Taudia, San Carlos, United States

P357 Economic value of a blood test for Alzheimer's disease pathology in primary and specialty care in the U.S.

Presenter: Soeren Mattke

Soeren MATTKE ¹, Jiahe CHEN ¹, Mark HANSON ¹, Kim JOHNSON ², Cara LEAHY ³, David MERRILL ⁴, Victoria SHADA ⁵, Jorge RUIZ ⁶

¹ University of Southern California, Los Angeles, Ca, United States, ² Duke University, Durham, Nc, United States, ³ Memorial Healthcare Institute, Owosso, Mi, United States, ⁴ Pacific Brain Health Center, Santa Monica, Ca, United States, ⁵ Wake Forest School of Medicine, Winston-Salem, Nc, United States, ⁶ Memorial Healthcare System, Hollywood, Fl, United States

P358 Cost-Effectiveness Analysis of Initiating Novel Monoclonal Antibodies at Early Alzheimer's Disease Stages

Presenter: Minseon Chung

Minseon CHUNG ¹, Sean D. SULLIVAN ^{1,2}

¹ The CHOICE Institute, School of Pharmacy, University of Washington, Seattle, Wa, United States, ² Department of Health Policy, London School of Economics and Political Science, London, United Kingdom

P359 Neurologists' perceptions and experiences with Amyloid-targeting therapies in Alzheimer's disease in the United States: Baseline data

Presenter: Oralee Varnado

Oralee VARNADO ¹, Ann HARTRY ¹, Bridget GAGLIO ², Viviana NGUYEN ², Traci SCHILLING ¹

¹ Eli Lilly and Company, Indianapolis, In, United States, ² PPD Evidera Patient-Centered Research, Thermo Fisher Scientific, Wilmington, Nc, United States

P360 Enhancing Alzheimer's Disease Diagnostic Efficiency and Accuracy with Plasma-Based pTau217 Testing: A Comparative Analysis in Primary and Secondary Care

Presenter: Martin Guess

Sophie ROTH ¹, Martin GUESS ¹, Gustaf ORTSÄTER ²

¹ Roche Diagnostics International, Rotkreuz Zg, Switzerland, ² Quantify Research AB, Stockholm, Sweden

P361 Societal Cost and Efficiency Comparison of Subcutaneous vs Intravenous Lecanemab for Early Alzheimer's Disease in the United States

Presenter: Amir A. Tahami Monfared

Amir A. TAHAMI MONFARED^{1,2}, Stephanie BARROWS³, Lindsey FOX³, Brittney HERBEL³, William L. HERRING^{3,4}, Alisha KRUMBACH³, Quanwu ZHANG¹

¹ Eisai Inc., Nutley, United States, ² McGill University, Montreal, Canada, ³ RTI Health Solutions, Durham, United States, ⁴ Karolinska Institutet, Stockholm, Sweden

P362 Medication Adherence and Cost of Care for Comorbid Conditions in Patients with Early Alzheimer's Disease: A Retrospective Cohort Study Using the Axon Registry and Claims Data

Presenter: Abdalla Aly

Lei LV¹, Abdalla ALY¹, Caroline MCKAY¹, Paul MYSTKOWSKI¹, Shannon GALLAGHER², Kristian GARCIA², Heather E. MOSS³, Soeren MATTKE⁴

¹ Novo Nordisk Inc., Plainsboro, United States, ² Verana Health, New York, United States, ³ Department of Ophthalmology, Stanford University & Department of Neurology & Neurological Sciences, Stanford University, Stanford, United States, ⁴ University of Southern California, Los Angeles, United States

14 ● EPIDEMIOLOGY AND CLINICAL TRIALS

THURSDAY, DECEMBER 4 (7:15 A.M. – 5:00 P.M.)

P363 Higher DNA methylation-based intrinsic capacity reflects resilience against neurodegeneration in midlife: insights from the INSPIRE-T lifespan cohort

Presenter: Laure Rouch

Laure ROUCH¹, Sophie GUYONNET¹, Christelle CANTET¹, Matias FUENTEALBA², David FURMAN², Bruno VELLAS¹, Sandrine ANDRIEU¹
¹ IHU HealthAge CERPOP, Toulouse, France, ² Buck Institute for Research on Aging, Novato, United States

P364 Population-based reference values for Alzheimer blood biomarkers in France

Presenter: Sylvain Lehmann

Sylvain LEHMANN¹, Tahiana ANDRIAMBELOSOA¹, Mehdi MORCHIKH¹, Marion MORTAMAS¹, Marie DUCHIRON¹, Audrey GABELLE¹, Constance DELABY¹, Karim BENNYS¹, Catherine HELMER², Marie ZINS³, Thibault MURA¹
¹ Montpellier University, Montpellier, France, ² Bordeaux University, Montpellier, France, ³ Paris-Saclay University, Montpellier, France

P365 MCI Detection in Primary Care in the U.S.: Who is Finding the Cases?

Presenter: Ying Liu

Ying LIU, Wei YE, Andrew BECKER, Soeren MATTHE
University of Southern California, Los Angeles, United States

P366 Odor Identification and Tau Burden in Persons without Dementia: Insights from the Mayo Clinic Study of Aging

Presenter: Mohamed Y Elminawy

Mohamed Y ELMINAWY¹, Jeremiah A AAKRE², Jonathan GRAFF-RADFORD¹, Prashanthi VEMURI³, Christopher G. SCHWARZ³, Walter K. KREMERS², David S. KNOPMAN¹, Val J. LOWE³, Clifford R. JACK JR³, Ronald C. PETERSEN^{1,2}, Maria VASSILAKI²
¹ Department of Neurology, Mayo Clinic, Rochester, MN, Rochester, United States, ² Quantitative Health Sciences, Mayo Clinic, Rochester, MN, Rochester, United States, ³ Department of Radiology, Mayo Clinic, Rochester, MN, Rochester, United States

P367 Cross-Cohort Validation of Metabolomic Predictors of Global Cognition Using Elastic Net Regression

Presenter: Brandi Vollmer

Brandi VOLLMER¹, Amaryllis SKYFA², Christopher PAPANDREOU², Christian HABECK¹, Michal BEERI³, Yaakov STERN¹, Nikolaos SCARMEAS¹, Yian GU¹
¹ Columbia University, New York, United States, ² Hellenic Mediterranean University, Chania, United States, ³ Rutgers University, New Brunswick, United States

P368 Sex/gender differences in the associations between parental education and hippocampal volume in the oldest-old: The Life After 90 Study

Presenter: Batool Rizvi

Batool RIZVI¹, Paola GILSANZ², Pauline MAILLARD¹, Maria CORRADA³, Rachel WHITMER¹
¹ UC Davis, Davis, United States, ² Kaiser Permanente Northern California Division of Research, Pleasanton, United States, ³ UC Irvine, Irvine, United States

P369 Associations between epigenetic and inflammatory aging, cognitive function, and blood-based biomarkers of Alzheimer's disease: cross-sectional and longitudinal findings from the INSPIRE-T cohort

Presenter: Laure Rouch

Samuel THURIOT, Jason SHOURICK, David FURMAN, Jean Marc LEMAITRE, Sophie GUYONNET, Bruno VELLAS, Sandrine ANDRIEU, Laure ROUCH
IHU HealthAge, Toulouse, France

P370 Cardiorespiratory fitness and brain atrophy: Sex differences and potential vascular mechanisms.

Presenter: Adam J. Paulsen

Adam J. PAULSEN ^{1,2}, Ira DRISCOLL ^{1,2}, Brianne M. BREIDENBACH ^{1,2}, Matthew P. GLITTENBERG ^{1,2}, Sarah R. LOSE ^{1,2}, Yue MA ¹, Mark A. SAGER ¹, Catherine L. GALLAGHER ^{3,4}, Sanjay ASTHANA ^{1,2}, Sterling C. JOHNSON ^{1,2}, Bradley T. CHRISTIAN ⁵, Leonardo A. RIVERA-RIVERA ⁵, Oliver WIEBEN ^{5,6}, Dane B. COOK ^{7,8}, Ozioma C. OKONKWO ^{1,2}

¹ Wisconsin Alzheimer's Disease Research Center, Department of Medicine, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, United States, ² Wisconsin Alzheimer's Institute, Madison, United States, ³ Department of Neurology, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, United States, ⁴ Geriatric Research Education and Clinical Center, William S. Middleton VA Hospital, Madison, United States, ⁵ Department of Medical Physics, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, United States, ⁶ Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, United States, ⁷ William S. Middleton Memorial Veterans Hospital, Madison, United States, ⁸ Department of Kinesiology, University of Wisconsin School of Education, Madison, United States

P371 ABIDEing with automated cerebrospinal fluid assays; update of an MCI to dementia prediction model

Presenter: Pieter Van Der Veere

Pieter VAN DER VEERE ¹, Argonde VAN HARTEN ¹, Stefanie VOS ², Pieter Jelle VISSER ², Sterling JOHNSON ³, Erik STORMRUD ⁴, Oskar HANSSON ⁴, Sebastian PALMQVIST ⁴, Gerard PIÑOL-RIPOLL ⁵, Hans BERKHOF ¹, Wiesje VAN DER FLIER ¹

¹ Amsterdam UMC, Amsterdam, Netherlands, ² Maastricht University, Maastricht, Netherlands, ³ University of Wisconsin-Madison, Madison, United States, ⁴ Lund University, Malmö, Sweden, ⁵ Hospital Universitari Santa Maria, Lleida, Spain

P372 Real-world eligibility for lecanemab and donanemab based on Appropriate Use Recommendations in Korea

Presenter: So Yeon Jeon

So Yeon JEON ¹, Min Soo BYUN ², Hye Ji CHOI ³, Yoon Hee KIM ⁴, Chung Hee GWAG ⁵, Gijung JUNG ⁵, Dong Young LEE ⁵

¹ SMG-SNU Boramae Medical Center, Seoul, Republic of Korea, ² Seoul National University College of Medicine, Seoul, Republic of Korea, ³ Hallym University Dongtan Sacred Heart Hospital, Gyeonggi, Republic of Korea, ⁴ Seoul National University Hospital, Seoul, Republic of Korea, ⁵ Seoul National University Hospital - Seoul Korea, Republic of, Seoul, Republic of Korea

P373 The Alzheimer's Disease Sequencing Project Phenotype Harmonization Consortium

Presenter: Timothy Hohman

Timothy HOHMAN

Vanderbilt University Medical Center, Nashville, United States

P374 Equol-Producing Status is Associated with Greater Frontal Cortex Volume in Community-Dwelling Older Adults: Baseline findings from the ACE Trial

Presenter: Jiatong Li

Jiatong LI ¹, Mengyi LI ¹, Yueyang CHI ², Beth SNITZ ³, Yuefang CHANG ⁴, Cristina MURRAY-KREZAN ⁵, Howard AIZENSTEIN ^{2,6}, Shaolin YANG ^{2,6}, Minjie WU ^{2,6}, Whitney WHARTON ⁷, Timothy HUGHES ⁸, Akira SEKIKAWA ¹

¹ Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, United States, ² Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, United States, ³ Department of Neurology, School of Medicine, University of Pittsburgh, Pittsburgh, United States, ⁴ Department of Neurological Surgery, School of Medicine, University of Pittsburgh, Pittsburgh, United States, ⁵ Department of Medicine, Center for Research on Health Care, University of Pittsburgh, Pittsburgh, United States, ⁶ Department of Engineering, Swanson School of Engineering, University of Pittsburgh, Pittsburgh, United States, ⁷ Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, United States, ⁸ Department of Internal Medicine, Section on Gerontology and Geriatric Medicine, Wake Forest University School of Medicine, Winston-Salem, United States

P375 A MaChina Learning Approach to Predict Cognitive Decline Using Physical, Behavioral, and Blood Markers: Interpreting XGBoost with SHAP

Presenter: Jieun Yoon

Jieun YOON ¹, Kyohei SHIBUYA ¹, Namhoon LIM ¹, Kenji TSUNODA ¹, Tetsuaki ARAI ¹, Keisuke FUJII ², Jaehoon SEOL ¹, Tomohiro OKURA ¹

¹ University of Tsukuba, Tsukuba, Japan, ² Suzuka University of Medical Science, Suzuka, Japan

P376 Therapeutic Time Window of Disease-Modifying Therapy for Early Alzheimer's Disease in Japan

Presenter: Saki Nakashima

Saki NAKASHIMA ¹, Kenichiro SATO ², Yoshiki NIMI ², Wataru SATAKE ¹, Takeshi IWATSUBO ²

¹ Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ² Unit for Early and Exploratory Development, The University of Tokyo Hospital, Tokyo, Japan

P377 Caregiving and Economic Burden of Alzheimer's Disease in Japan

Presenter: Kavita Nair

Ran GAO¹, Kavita NAIR², Brien SMITH³, Babak HAJI¹, Raymond ZHANG¹, Noemi HUMMEL⁴, Dave MORTON⁵, Marta MARTINEZ⁶, Stephanie READ⁷, Quanwu ZHANG¹, Amir Abbas TAHAMI MONFARED¹

¹ Eisai, Nutley, United States, ² University of Colorado Anschutz Medical Campus, Aurora, United States, ³ Henry Ford Hospital, Detroit, United States, ⁴ Certara GmbH, Loerrach, Germany, ⁵ Certara, Princeton, United States, ⁶ Certara, Madrid, Spain, ⁷ Certara, Sheffield, United Kingdom

P378 High Eligibility of Frail Older Adults with Early AD for Lecanemab Treatment in Real-World Practice: Is There a Need for New Clinical Trials?

Presenter: Federico Bellelli

Federico BELLELLI, Sandrine SOURDET, Gaelle SORIANO, Bruno VELLAS, Davide ANGIONI

Centre Hospitalo-Universitaire de Toulouse, Toulouse, France

P379 Physician perception of treatment landscape and readiness in care delivery with anti-amyloid therapy for Alzheimer's disease in China

Presenter: Raymond Zhang

Amir Abbas TAHAMI MONFARED¹, Brien SMITH², Kavita NAIR³, Ran GAO¹, Raymond ZHANG¹, Babak HAJI¹, Noemi HUMMEL⁴, Agnieszka KOPIEC⁵, Marta MARTINEZ⁶, Stephanie READ⁷, Quanwu ZHANG¹

¹ Eisai, Nutley, United States, ² Henry Ford Hospital, Detroit, United States, ³ University of Colorado Anschutz Medical Campus, Aurora, United States, ⁴ Certara, Loerrach, Germany, ⁵ Certara, Krakow, Pologne, ⁶ Certara, Madrid, Spain, ⁷ Certara, Sheffield, United Kingdom

15 ● ANIMAL MODEL AND PRECLINICAL TRIALS IN AD

THURSDAY, DECEMBER 4 (7:15 A.M. – 5:00 P.M.)

P380 TRIM21 mediated clearance of intracellular protein pathologies

Presenter: Rakez Kaye

Rakez KAYE

University of Texas Medical Branch, Galveston, United States

P381 Fusing Transferrin Receptor Binders to the A β O-targeting Antibody Sabirnetug Achieves Increased Brain Penetration in Mice While Preserving Target Binding

Presenter: Elizabeth Johnson

Erika CLINE¹, Shunsuke IIZUKA², Mahiro KURODA², Elizabeth JOHNSON¹, Alex DAVIS¹, Martin KLEINSCHMIDT³, Oladayo OLADIRAN⁴, Jennifer GILLIES⁴, Jacob WOHLSTADTER⁴, Thomas LAVOIE¹, Liean SCHENCK¹, Mathias SCHMIDT², Hiroyuki SONODA², Jasna JERECIC¹, Paul SHUGHRUE¹

¹ Acumen Pharmaceuticals, Inc, Newton, Massachusetts, United States, ² JCR Pharmaceuticals Co., Ltd, Ashiya, Hyogo, Japan, ³ Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany, ⁴ Meso Scale Diagnostics, LLC, Rockville, Maryland, United States

P382 APOE-Targeted Microglia-Specific Epigenome Therapy for Alzheimer's Disease

Presenter: Ornit Chiba-Falek

Boris KANTOR, Bernadette O'DONOVAN, Joseph RITTINER, Ornit CHIBA-FALEK

Duke University, Durham, United States

P383 Passive Immunotherapy Targeting tau oligomeric strains reverses tauopathy phenotypes in aged in a mouse model sepecific manner

Presenter: Nemil Bhatt

Nemil BHATT, Alice BITTAR, Jia Yi LIEW, Twisha CHATTERJEE, Dhvani PANSURIYA, Nopparat SUTHPRASERTPORN, Ahmet BALCI, Rakez KAYE

University of Texas Medical Branch, Galveston, United States

P385 Lecanemab Ameliorates Alzheimer's Disease-Related Sleep Disorders via Modulating the Orexinergic System and Microglial Function: Evidence from Translational Models

Presenter: Hu Hao

Hu HAO¹, Yi QU², Lan TAN¹

¹ Qingdao Hospital Qingdao Municipal Hospital, Qingdao, China, ² University of Health and Rehabilitation Sciences, Qingdao, China

P386 Administration of benzgalantamine, a galantamine prodrug, reduces multiple forms of hyperphosphorylated Tau and mitigates neuropathology in two animal models of traumatic brain injury: potential implication for reduced dementia risk.

Presenter: Denis Kay

Denis KAY¹, Michael CHOPP², Haiyan PANG², Zheng Gang ZHANG², Ye XIONG², Abigail SCHINDLER³, David COOK³, James MEABON⁴

¹ Alpha Cognition Inc, Grapevine,tx, United States, ² Henry Ford Health, Detroit, Mi, United States, ³ VA Puget Sound, Seattle,wa, United States, ⁴ SIBCR, Seattle,wa, United States

P387 The APOE4 knock-in APPswe/PSEN1dE9/Tau-P301S triple transgenic (E4-3Tg) mouse model exhibited Tak1–NF- κ B-mediated astrocytic C3 overproduction, neurodegeneration and a severely reduced lifespan.

Presenter: Tatsuhiko Hisatsune

Chenxu LEI, Tatsuhiko HISATSUNE

The University of Tokyo, Kashiwa, Japan

P388 A conditionally activated siRNA (CASI) targeting APOE for the treatment of Alzheimer's Disease

Presenter: Anindya Bhattacharya

Maxine NELSON, Akila RAM, Priya PULYA, Anna BADNER, Marina KOVALIOV, Clara TOURINO, Priyanka SINGH, Shilpi MAHAJAN, Lisa SCHERER, Don BUTTON, Robert DUFF, Dee DATTA, Charles ALLERSON, Anindya BHATTACHARYA
Switch Therapeutics, San Francisco, United States

P389 A conditionally-activated siRNA targeting MAPT for the treatment of tauopathies

Presenter: Anindya Bhattacharya

Clara TOURINO, Marina KOVALIOV, Maxine NELSON, Priya PULYA, Shilpi MAHAJAN, Lisa SCHERER, Abhinav KUMAR, Don BUTTON, Robert DUFF, Dee DATTA, Charles Allerson CHARLES ALLERSON, Craig BLANCHETTE, Anindya BHATTACHARYA
Switch Therapeutics, San Francisco, United States

P390 Antibody effector function of the murine analogue of Etalanetug drives efficacy in an animal model of pathological tau seeding and spreading

Presenter: Malcolm Roberts

Jane GARTLON, Sonia TALMA, Kavita MISTRY, Malcolm ROBERTS
Eisai Ltd., Hatfield, United Kingdom

P391 SUVN-I6107, a True Positive Allosteric Modulator at Muscarinic M1 Receptor for Treatment of Cognitive Disorders, Update on the Development

Presenter: Vijay Benade

Vijay BENADE, Veera Raghava Chowdary PALACHARLA, Vinod Kumar GOYAL, Satish JETTA, Renny ABRAHAM, Rajeshbabu MEDAPATI, Ramkumar SUBRAMANIAN, Surendra PETLU, Anil SHINDE, Ilayaraja KALAIKADHIBAN, Ramakrishna NIROGI, Jasti VENKAT
Suven Life Sciences, Hyderabad, India

16 ● DIGITAL HEALTH/ E-TRIALS

THURSDAY, DECEMBER 4 (7:15 A.M. – 5:00 P.M.)

P392 Dementia Trials Accelerator: UK services for clinical trials in dementia and related disorders

Presenter: William Whiteley

William WHITELEY¹, Cornelia VAN DUIJN¹, Neil POSTLETHWAITE¹, Rhoswyn WALKER¹, Monika ZIMINSKA¹, Katie SMITH², Ivan KOYCHEV², Paresh MALHOTRA², Jonathan SCHOTT², Henrik ZETTERBERG², Amanda HESLEGRAVE², Graham BLAKOE³, Kimberley BENNET³, Andrew MORRIS¹, Siddharthan CHANDRAN²

¹ Health Data Research UK, London, United Kingdom, ² UK Dementia Research Institute, London, United Kingdom, ³ Imperial College London, London, United Kingdom

P393 QSP model for next-generation brainshuttle antibodies

Presenter: Lara Herriott

Lara HERRIOTT¹, Mark COLES¹, Eamonn GAFFNEY¹, Nicolas FOURNIER², Nicolas SANCHEZ³, Olivier SOL², Gunther STAFFLER², Andrea PFEIFER², Jonathan WAGG²

¹ University of Oxford, Oxford, United Kingdom, ² AC Immune SA, Lausanne, Switzerland, ³ Previously AC Immune SA, Lausanne, Switzerland

P394 Validating a Multi-Domain Digital Endpoint Platform (NeuLogiq) for Decentralized Alzheimer's Trials: Results from the CNS-101 Study

Presenter: Brian Murphy

Brian MURPHY¹, Alison BUICK², Shannon DIGGIN², Ruth MCKERNAN³, James B. ROWE⁴, Laura RUEDA-DELGADO¹

¹ Cumulus Neuroscience, Dublin, Ireland, ² Cumulus Neuroscience, Belfast, United Kingdom, ³ Dementia Discovery Fund, London, United Kingdom, ⁴ Cambridge University, Cambridge, United Kingdom

P395 Double XpressO: repeated online prescreening of cognitive impairment

Presenter: Willem Huijbers

Willem HUIJBERS¹, Hans-Aloys WISCHMANN², Kacylia PISTOIA³, Joana KRIEGER³, Johanna GRUBER³, Murray GILLIES¹, Ziad NASREDDINE³

¹ MoCA Cognition, Eindhoven, Netherlands, ² Charite, Berlin, Germany, ³ MoCA Cognition, Montreal, Canada

P396 Adherence to a multi-domain, person-centered, dementia risk factor management intervention to prevent cognitive decline (The BetterBrains Trial)

Presenter: Yen Ying Lim

Emily ROSENICH¹, Darshini AYTON¹, Stephanie PIROTTA¹, Hannah CUMMINS¹, Samantha DE ARAUGO¹, Amelia BEVINS¹, Catherine ROBB¹, Paul MARUFF², Yen Ying LIM¹

¹ Monash University, Melbourne, Australia, ² Cogstate Ltd., Melbourne, Australia

P397 A Holistic Approach for Understanding Alzheimer's Disease via Wearables, Speech, and eCOA

Presenter: Marissa Ballesteros

Kevin MACHADO GAMBOA¹, Brett MEYER², Paul O'DONOHUE¹, Marissa BALLESTEROS¹

¹ Medidata, London, United Kingdom, ² Medidata, Vermont, United Kingdom

P398 Impact of Telemedicine on Time and Process Measures Associated with Detection and Diagnosis of Alzheimer's Disease

Presenter: Eric Klein

Eric KLEIN¹, Eric ANDERSON², Chad PANNUCCI¹, Jiaying GUO¹, Aadrika AADRIKA¹, Bert VARGAS¹, Julie BEYRER¹

¹ Eli Lilly and Company, Indianapolis, United States, ² Syantpicure, Chicago, United States

P399 A Digital Olfactory Biomarker Platform for Prognostic Enrichment of Neurodegeneration

Presenter: Subhanjan Mondal

Subhanjan MONDAL¹, Sara MOUSTAFA², Levi MUYELA³, Anne GITERE³, Anne NYAMBURA³, Karen BLACKMON³, Farooq WAHEED¹, Mie RIZIG⁴, Mohamed SALAMA², Irene MEIER⁵, Vaibhav NARAYAN⁵

¹ Sensify Inc, New York, United States, ² Institute of Global health and Human Ecology, American University at Cairo, Egypt, Cairo, Égypte, ³ Brain and Mind Institute, Aga Khan University Nairobi, Kenya, Nairobi, Kenya, ⁴ UCL Queen Square Institute of Neurology, London, UK, London, United Kingdom, ⁵ Davos Alzheimer's Collaborative, Geneva, Switzerland, Geneva, Switzerland

P400 Technology and human support: a combined approach to improving quality of life in older adults living at home with cognitive impairments

Presenter: Achille Tchalla

Achille TCHALLA^{1,2}, Abdoul SAWADOGO¹, Clément RIMLAWI¹, Caroline GAYOT^{1,2}

¹ VieSanté laboratory UR²⁴¹³⁴, Limoges University, Limoges, France, ² Clinical Research and Innovation in Gerontology, Limoges Hospital Center, Limoges, France

P401 Assessing the validity of the MIND GamePack: A novel digital health technology (DHT) for the collection of supplementary cognitive data using games

Presenter: Steven Arnold

Jake GALLER¹, Liuqing YANG², Chao-Yi WU^{1,3}, Cathrine YOUNG¹, Edmarie GUZMÁN-VÉLEZ^{4,3}, Anthony BANNON², Hiroko DODGE^{1,3}, Jessica GERBER¹, Steven ARNOLD^{1,3}

¹ Department of Neurology, Massachusetts General Hospital, Boston, United States, ² AbbVie Inc., Chicago, United States, ³ Harvard Medical School, Boston, United States,

⁴ Department of Psychiatry, Massachusetts General Hospital, Boston, United States

P402 Association of Linguistic and Acoustic Digital Language Markers with CSF Biomarkers of Alzheimer's Disease

Presenter: S Ahmad Sajjadi

Pooyan MOBTAHEJ¹, Rojan JAVAHERI², Sam T. GOURON³, David SULTZER^{1,4}, Elizabeth HEAD^{1,5}, S Ahmad SAJJADI^{1,4}

¹ University of California , Irvine, Irvine, United States, ² Tufts University, School of Medicine, Boston, United States, ³ University of Colorado, School of Medicine, Aurora, United States, ⁴ The UC Irvine Institute for Memory Impairments and Neurological Disorders UCI MIND, Irvine, United States, ⁵ The UC Irvine Institute for Memory Impairments and Neurological Disorders UCI MIND , Irvine, United States

P403 Federated Data pilots for international collaboration in Alzheimer's disease and dementia research

Presenter: Eoghan Forde

Eoghan FORDE¹, Brenda BAUER², William WHITELEY², Jackie CALDWELL³, Robert WALLACE³, Ariel ONG⁴, Siegfried WAGNER⁴, Pearse KEANE⁴, Manjit BENNING⁴, Matthew CLEMENT⁵, Neil POSTLETHWAITE¹

¹ Health Data Research UK, London, United Kingdom, ² The University of Edinburgh, Edinburgh, United Kingdom, ³ Public Health Scotland, Edinburgh, United Kingdom, ⁴ INSIGHT Health Data Research Hub at Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom, ⁵ Alzheimer's Disease Data Initiative, Seattle, United States

P404 Protocol for SUPERBRAIN-BOOM Trial: A multicenter, randomized controlled feasibility study on SoUth Korean study to PrEvent cognitive impaiRment and protect BRAIN heath via Behavioral, Optimized, Organized Movement therapy in mild cognitive impairment

Presenter: Sun Min Lee

Sun Min LEE¹, Da Ae KIM¹, Kyunghwa SUN¹, Jung Yun SEO¹, Eun-Joo KIM², Hyun Sook KIM³, Soo Hyun CHO⁴, Yeshin KIM⁵, Sung Min KANG⁶, Jiwoo JEONG⁶, Sugyeong KIM⁶, Hang Rai KIM⁶, So Young MOON¹

¹ Department of Neurology, Ajou University School of Medicine, Suwon, Republic of Korea, ² Department of Neurology, Pusan National University Hospital, Pusan National University School of Medicine and Medical Research Institute, Busan, Republic of Korea, ³ Department of Neurology, CHA Bundang Medical Center, Seongnam, Republic of Korea, ⁴ Department of Neurology, Chonnam National University Hospital, Gwangju, Republic of Korea, ⁵ Department of Neurology, Kangwon National University Hospital, Chuncheon, Republic of Korea, ⁶ Rowan Inc., Seoul, Republic of Korea

P405 In-Air-Time during Drawing Tests as a Potential Predictor of Amyloid Positivity in Mild Cognitive Impairment Patients

Presenter: Ko Woon Kim

Ko Woon KIM^{1,2}, Byoung-Soo SHIN³

¹ Beth Israel Hospital, Harvard Medical School, Boston, United States, ² Jeonbuk National University Medical School and Hospital , Jeonju, Republic of Korea, ³ Jeonbuk National University Medical School and Hospital, Jeonju, Republic of Korea

P406 Real-World Care of Alzheimer's Disease Patients (n=2,358) in Germany: Insights from Registry of the Neurologists Network NeuroTransData (NTD) using the Physician/Patient Platform (DESTINY)

Presenter: Arnfin Bergmann

*Arnfin BERGMANN, Stefan BRAUNE, Oliver FASOLD, Niloofar TAVAKOLI, Ntd STUDY GROUP
NeuroTransData GmbH, NTD Study Group, Neuburg an der Donau, Neuburg, Germany*

P407 Leveraging the FTD Disorders Registry to Enhance Clinical Trial Recruitment in Frontotemporal Degeneration

Presenter: Shana Dodge

Mary KRAUSE¹, Carrie MILLIARD², Reinecker ROBERT³, Sweatha REDDY⁴, Shana DODGE⁵, Penny DACKS⁶

¹ FTD Disorders Registry, Norristown, United States, ² FTD Disorders Registry, Scarborough, United States, ³ FTD Disorders Registry, Myrtle Beach, United States, ⁴ FTD Disorders Registry, Jessup, United States, ⁵ Association for Frontotemporal Degeneration, Philadelphia, United States, ⁶ Association for Frontotemporal Degeneration, Brecksville, United States



P408 Exploring Persona-Based Large Language Model Simulation for Social Surveys on Dementia Treatment

Presenter: Kenichiro Sato

Kenichiro SATO¹, Yoshiki NIIMI¹, Saki NAKASHIMA¹, Ryoko IHARA², Kazushi SUZUKI³, Atsushi IWATA², Takeshi IWATSUBO¹

¹ The University of Tokyo Hospital, Tokyo, Japan, ² Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, ³ National Defense Medical College, Saitama, Japan

P409 Preliminary Efficacy of the Healthy Actions and Lifestyles to Avoid Dementia (HALT-AD) Program for Enhancing Dementia-Risk Knowledge, Self-Efficacy, and Diet Quality in Primary-Care Patients

Presenter: Sarah Banks

*Sarah BANKS, Sara MOUKARZEL, Ashley ROBLES, Ammar MANDVI, Breanna HOLLOWAY, Jordan STIVER
UC San Diego, San Diego, United States*

17 ● CLINICAL TRIALS EARLY CAREER INVESTIGATOR SHOWCASE

PEC001 Plasma p-tau181 levels are associated with cognitive and physical decline in a population of older adults meeting frailty criteria: longitudinal data from the CogFrail Study

Presenter: Daide Angioni

Daide ANGIONI, Julien DELRIEU, Christelle CANTET, Gaelle SORIANO, Federico BELLELLI, Bruno VELLAS, Sandrine ANDRIEU, Sandrine SOUDET

IHU HealthAge, Toulouse, France

PEC002 Effects of escitalopram on Neuropsychiatric Symptoms in Alzheimer's Disease: a secondary analysis from the S-CitAD Study

Presenter: Emily Clark

Emily CLARK¹, Jamie PERIN², D.P. DEVANAND³, Prasad PADALA⁴, David SHADE⁵, Constantine LYKETSOS⁶, Anton PORSTEINSSON¹

¹ Department of Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, United States, ² Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, United States, ³ Department of Psychiatry, New York State Psychiatric Institute and Columbia University Irving Medical Center, New York, United States, ⁴ Central Arkansas Veterans Healthcare System, Baptist Health-University of Arkansas for Medical Sciences, Little Rock, United States, ⁵ Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, United States, ⁶ Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine and Johns Hopkins Bayview Medical Center, Baltimore, United States

PEC003 Plasma and CSF proteomic signatures of lifestyle activities: a search for biomarkers of cognitive reserve in the Stanford Aging and Memory Study (SAMS)

Presenter: Irina Skylar-Scott

Olivia LU¹, Patricia MORAN LOSADA¹, Amelia FARINAS¹, Veronica BOT¹, Daisy DING¹, Zihuai HE¹, Valerie CARR², Hillary VOSSLER¹, Jennifer PARK³, Sharon SHA³, Tony WYSS-CORAY³, Elizabeth MORMINO³, Anthony WAGNER³, Irina SKYLAR-SCOTT³

¹ Stanford University, Palo Alto, United States, ² San Jose State University, San Jose, United States, ³ Stanford University, Palo Alto, United States

PEC004 Testing and Tailoring Group Cognitive Behavioral Therapy for Insomnia (CBTi) with Persons with Early-Stage Alzheimer's disease and their Care Partners.

Presenter: Inga Antonsdottir

Inga ANTONSDOTTIR, Molly ATWOOD, Constantine LYKETSOS

Johns Hopkins School of Medicine, Baltimore, United States

PEC005 MRI utilization for ARIA response in patients receiving lecanemab

Presenter: Giovanna Pilonieta

Giovanna PILONIETA^{1,2}, Karen FAHNESTOCK¹, Christina MAMAEVA¹, Laurie MORRISON¹, Danielle WILLS¹, Maria PISU^{3,4}, David GELDMACHER^{1,5}

¹ Division of Cognitive and Behavioral Neurology, Birmingham, United States, ² Alzheimer's Disease Center - Birmingham United States, Birmingham, United States, ³ Division of General Internal Medicine & Population Science, Birmingham, United States, ⁴ Alzheimer's Disease Center, Birmingham, United States, ⁵ Alzheimer's Disease Center, Birmingham, United States

PEC006 Feasibility and accuracy of the LILA app: Pilot study of a fully remote, self-administered, verbal list learning task for community cognitive screening

Presenter: Karra D Harrington

Karra D HARRINGTON¹, Jess SEGURA¹, Shannon ARCHER¹, Laura MILLER¹, Ruth RAY¹, Najeeba FAROUK¹, Anders NORDBLOM², Sophia LERDAHL², Kaycee M SINK¹, Pam VENTOLA¹

¹ Cogstate Ltd, New Haven, United States, ² Asteroidea Ventures LLC, DBA Formative, Seattle, United States

PEC007 A preliminary study on the effectiveness of therapeutic agricultural programs for healthy individuals and patients with dementia

Presenter: Bon D. Ku

Bon D. KU¹, Boram KIM², Nayeon LEE², Hong Mo KU³, Jeon YESEO⁴

¹ Department of Neurology, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon, Republic of Korea, ² GyeYang Mubicipal Dementia Daycare Center, Incheon, Republic of Korea, ³ Institute for Cognitive Intervention, International St. Mary's Hospital, Incheon, Republic of Korea, ⁴ Incheon Metropolitan City Agricultural Technology Center, Incheon, Republic of Korea

PEC008 Broad Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus in Alzheimer's Disease: A Rationale, Study Design, and Preliminary Open-Label Data

Presenter: Michael Leuchter

Michael LEUCHTER¹, Hanadi OUGHLI¹, Kelly DURBIN¹, Nicholas JACKSON¹, David ELASHOFF¹, Timothy CHANG¹, Juliana CORLIER¹, Cole MATTHEWS¹, Julia SUN¹, Darice WONG¹, Brent FOGEL¹, Andrew LEUCHTER¹, Keith VOSSEL¹, Nanthia SUTHANA²

¹ UCLA, Los Angeles, United States, ² Duke, Durham, United States

● BIOTECH SHOWCASE SESSIONS

FLASH PRESENTATIONS DURING COFFEE BREAKS

As part of a new initiative at CTAD 2025, we are hosting dedicated Biotech Showcase Sessions — dynamic flash presentation slots where selected biotech companies will:

- Present their work in 3-minute / 3-slides lightning talks
- Engage in 3 minutes of live Q&A with moderators and attendees
- Gain expert feedback and investor attention
- Build high-value connections with leaders in AD clinical trials

Tuesday, December 2nd – 10:30 a.m. to 11:00 a.m.

Session 1 – Artificial Intelligence and Digital Innovation

Focus: AI platforms, digital biomarkers, virtual and mobile cognitive assessment.

Moderators: Sandrine Andrieu, IHU HealthAge, Toulouse (France) and Lefkos Middleton, Imperial College London – London (United Kingdom)

1. **Prima Mente – AI neuroscience integrating data generation and clinical translation**
Ravi Solanki, Prima Mente - San Francisco, CA (United States)
2. **Tolion Health – AI-driven brain health and longevity guidance app**
Ondřej Lerch, Tolion Health - Prague (Czech Republic)
3. **Unlearn.AI – Digital twin platform for modern Alzheimer’s trials**
Kwame Marfo, Unlearn AI - San Francisco, CA (United States)
4. **Indivi AG – Adaptive cognitive assessments with dynamic difficulty adjustment**
Shibeshih Belachew, Indivi AG - Basel (Switzerland)

Tuesday, December 2nd – 3:50 p.m. to 4:20 p.m.

Session 2 – Digital and Neurotechnology-Based Biomarkers and Therapeutics

Focus: novel neurotech and at-home stimulation tools.

Moderator: Michael Weiner, UCSF – San Francisco (United States)

1. **Nuuron GmbH – Ultra-high-frequency visual stimulation for memory enhancement**
Fabian Queisner, Nuuron GmbH - Berlin (Germany)
2. **Clarity Health Technologies – VR-integrated 40Hz sensory stimulation**
Carolina Reis, Clarity Health Technologies - Delaware (United States)
3. **REGENLIFE – Photomedical neurotechnology for brain–gut stimulation**
Guillaume Blivet, REGENLIFE - Paris (France)
4. **Cumulus Neuroscience – Remote digital biomarkers for trial efficiency**
Brian Murphy, Cumulus Neuroscience - Dublin (Ireland)

BIOTECH SHOWCASE SESSIONS

FLASH PRESENTATIONS DURING COFFEE BREAKS

Wednesday, December 3rd – 10:55 a.m. to 11:25 a.m.

Session 3 – Blood-Based Diagnostics and Biomarkers

Focus: plasma and proteomic biomarker innovation.

Moderators: Robert Rissman, ATRI – USC – San Diego, CA (United States)

1. **Diadem Inc. – AlzoSure® Predict plasma test (unfolded p53)**
Shmuel Agus, Diadem Inc - Palo Alto (United States)
2. **Veravas – VeraBIND Tau plasma assay for active tau pathology**
Josh Soldo, Veravas Inc - Austin (United States)
3. **betaSENSE GmbH – Immuno-infrared sensor detecting misfolded proteins**
Klaus Gerwert, betaSENSE GmbH - Bochum (Germany)
4. **Taudia – Detection of low-abundance biomarkers for patient screening**
Noah Elder, Taudia - San Carlos (United States)

Wednesday, December 3rd – 3:50 p.m. to 4:20 p.m.

Session 4 – Multiomics and Precision Diagnostics

Focus: Omics-based platforms and biomarker qualification.

Moderators: Miranda Orr, Washington University in St. Louis – St Louis, MO (United States) and Howard Feldman, UCSD – San Diego, CA (United States)

1. **Agent – Multiomics blood biomarkers for Alzheimer’s drug development**
Jérôme Braudeau, Agent - Evry (France)
2. **Washington University in St. Louis – Proteomic classifier for precision diagnosis**
Carlos Cruchaga, Department of Psychiatry, NeuroGenomics and Informatics Center, Washington University School of Medicine - St Louis (United States)
3. **Fujirebio/ADx NeuroSciences – ADxPLOTTER qualified assays for early biomarker access**
Charlotte Lambrechts, ADx NeuroSciences - Ghent (Belgium)
4. **Ricoh Biosciences – iPSC neuron panel for biomarker discovery**
Marama Diaz-Asper, Ricoh Biosciences - Baltimore (United States)

BIOTECH SHOWCASE SESSIONS

FLASH PRESENTATIONS DURING COFFEE BREAKS

Thursday, December 4th– 10:30 a.m. to 11:00 a.m.

Session 5 – Next-Generation Therapeutics

Focus: novel small molecules, peptides, and new treatment modalities.

Moderators: Jeffrey Cummings, UNLV – Las Vegas, NV (United States) and Bruno Vellas, IHU HealthAge – Toulouse (France)

1. **ProNeurogen Inc. – PNA5 first-in-class therapy for vascular dementia**
Meredith Hay, ProNeurogen, Inc - Tucson (United States)
2. **Galimedix Therapeutics – GAL-101 Phase 1 oral small molecule**
Alexander Gebauer, Galimedix Therapeutics Inc. - Kensington (United States)
3. **ChainGen Bio – BrainPortal peptides for blood–brain barrier transport**
Hao Wu, ChainGen Bio - Shanghai (China)
4. **Anavex Life Sciences – Oral Blarcamesine Phase IIb/III trial results**
David Gould, Anavex Life Sciences - New York (United States)

Thursday, December 4th – 3:55 p.m. to 4:30 p.m.

Session 6 – Late-Stage Biotech and Industry Innovations

Focus: advanced clinical programs and scalable biomarker platforms.

Moderators: Laura Nisenbaum, Alzheimer's Drug Discovery Foundation, New York, NY (United States) and Jacques Touchon, University of Montpellier – Montpellier (France)

1. **AriBio Co. Ltd. – AR1001 Phase 3 neurodegeneration program (POLARIS-AD)**
Fred Kim, AriBio Co., Ltd. - San Diego (United States)
2. **Beckman Coulter Inc. – Blood-based biomarker solutions for AD diagnostics**
Kinal Bhatt, Beckman Coulter, Inc. - Chaska, Mn (United States)
3. **Advanced Brain Monitoring – BEAM™ mobile EEG/ERP platform for cognitive assessment**
Chris Berka, Advanced Brain Monitoring - Carlsbad (United States)
4. **Sunbird Bio – EV-based plasma assay platform for non-invasive detection of modified α Syn species**
Vijay Parthasarathy, Sunbird Bio - Cambridge (United States)

● EARLY CAREER INVESTIGATOR SHOWCASE

FLASH PRESENTATIONS DURING COFFEE BREAKS

Tuesday, December 2nd – 10:25 a.m. to 11:00 a.m.

Category 1 – Translational Therapeutics and Clinical Innovation

Moderators: Rema Raman, USC-ATRI, San Diego (United States) and Michael Rafii, ATRI – USC, San Diego (United States)

1. **Michael Leuchter (UCLA)** – Broad Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus in Alzheimer’s Disease – **Poster PEC008**

Exploring large-coil rTMS targeting the precuneus to improve brain network function and memory in Alzheimer’s disease through a two-stage feasibility trial.

2. **Emily Clark (University of Rochester)** – Effects of Escitalopram on Neuropsychiatric Symptoms in Alzheimer’s Disease: S-CitAD Secondary Analysis – **Poster PEC002**

Analyzing escitalopram’s effect on mood and caregiver distress, suggesting potential antidepressant and behavioral benefits in Alzheimer’s care.

3. **Melissa Wong (University of Toronto / Sunnybrook Research Institute)** – Cerebral Blood Flow Ratio of the Default Mode Network to the Central Executive Network as a Predictor of Executive Function Following N-acetylcysteine Supplementation in Vascular Mild Cognitive Impairment – **Poster P162**

Examining whether cerebral blood flow ratios can predict treatment response to N-acetylcysteine in vascular MCI, highlighting personalized neurovascular biomarkers for intervention response.

Tuesday, December 2nd – 3:50 p.m. to 4:20 p.m.

Category 2 – Biomarkers and Mechanisms of Frailty and Cognitive Decline

Moderators: Robert Rissman, ATRI – USC – San Diego, CA (United States) and Mark Espeland, Wake Forest University – Winston Salem, NC (United States)

1. **Davide Angioni (IHU HealthAge, Toulouse)** – Plasma p-tau181 Levels and Cognitive & Physical Decline in Frail Older Adults (CogFrail Study) – **Poster PEC001**

Linking elevated plasma p-tau181 to both cognitive and physical decline, identifying a shared biological pathway for frailty and neurodegeneration.

2. **Irina Skylar-Scott (Stanford University)** – Proteomic Signatures of Lifestyle Activities and Cognitive Reserve – **Poster PEC 003**

Identifying plasma and CSF proteins associated with physical and cognitive activity, suggesting molecular pathways underlying resilience and cognitive reserve.

- 3. Lara Herriott (University of Oxford / AC Immune SA) – Modeling Brain Exposure and Efficacy of Next-Generation Brainshuttle Antibodies – Poster P393**

Developing a quantitative systems pharmacology model to predict brain exposure and efficacy of receptor-mediated transcytosis antibodies such as trontinemab, offering insights into amyloid clearance mechanisms.

Wednesday December 3rd – 10:55 a.m. to 11:25 a.m.

Category 3: Digital Health and New Tools for Early Detection

Moderators: Charlotte Teunissen, VUMC – Amsterdam (The Netherlands) and Anton Porsteinsson, University of Rochester Medical Center, New York, NY (United States)

- 1. Karra D. Harrington (Cogstate Ltd) – Feasibility and Accuracy of the LILA App for Community Cognitive Screening – Poster PEC006**

Demonstrating the feasibility of a fully remote, AI-based verbal learning test for large-scale cognitive screening via smartphone.

- 2. Giovanna Pilonieta (University of Alabama at Birmingham) – MRI Utilization for ARIA Response in Lecanemab-treated Patients – Poster PEC005**

Investigating MRI monitoring practices in amyloid therapy, highlighting the clinical and economic implications of ARIA management.

- 3. Marina Ritchie (ATRI, University of Southern California – San Diego) – Characterizing Enrollment Patterns in a Preclinical Alzheimer's Disease Trial – Poster P006**

Analyzing enrollment dynamics and demographic factors influencing participation in a preclinical Alzheimer's disease trial, providing insights to optimize recruitment strategies and improve trial diversity.

Wednesday December 3rd – 3:50 p.m. to 4:20 p.m.

Category 4: Non-Pharmacological and Lifestyle Interventions

Moderators: Laura Baker, Wake Forest Alzheimer's Disease Research Center, Winston-Salem, NC (United States) and Joshua Grill, University of California, Irvine – Irvine, CA (United States)

- 1. Bon D. Ku (Catholic Kwandong University – South Korea) – Therapeutic Agriculture for Cognitive and Emotional Well-being – Poster P344**

Evaluating gardening-based interventions as a novel, low-cost therapy to improve mood and executive function in older adults and dementia patients

- 2. Inga Antonsdottir (Johns Hopkins University – United States) – Group Cognitive Behavioral Therapy for Insomnia (CBTi) in Dementia Dyads – Poster PEC004**

Testing the feasibility of group CBTi tailored for persons with early Alzheimer's and their care partners, aiming to enhance sleep and reduce frailty.

CTAD would like to thank its 2025 privileged partners for their continued support.

ULTIMATE SPONSOR




Alzheimer's
Drug Discovery
Foundation

PLATINUM SPONSORS



GOLD SPONSORS





i PRACTICAL DETAILS

CONFERENCE VENUE

Hilton San Diego Bayfront
1 Park Boulevard, San Diego, CA 92101



The Hilton is located just 3 miles (5km) from San Diego International Airport, easily accessible by taxi or Uber.

REGISTRATION DESK & BADGES PICK-UP



Sapphire Foyer - Level 4

Opening Hours

- Mon, Dec 1: **9:00 a.m. - 6:00 p.m.**
- Tue-Thu, Dec 2-4: **7:30 a.m. - 6:00 p.m.**

*Badge required for all sessions and breaks.
No reprints available.*

HIGHLIGHTS

Early Career Investigators Showcase

Short Flash talks during Coffee Breaks
(see details p.90)

NEW Biotech Showcase Sessions

3-min talks by emerging biotech companies,
Q&A, and networking (see details p.87)

Wi-Fi

Network & Password: CTAD2025

LUNCH OPTIONS

Lunch not included. Nearby restaurants listed
in the app and at the registration desk.

CTAD WELCOME RECEPTION WITH THE SUPPORT OF THE ALZHEIMER'S ASSOCIATION

Monday, December 1 from 6:45 p.m. to
7:45 p.m. in the Sapphire Ballroom
(Level 4).



PARKING

Both valet and self-parking are available
on-site at the Hilton.

- Self-Parking: \$50.00 per day
- Valet Parking: \$65.00 per day

ROOM LOCATOR



LEVEL 5 - COBALT
Sponsors Meeting Rooms



LEVEL 4 - SAPPHIRE
Registration Desk
Conference Room (All sessions)



LEVEL 3 - AQUA
Sponsors Meeting Rooms



LEVEL 2 - INDIGO
Coffee Breaks
Posters
Showcases
Business Suites
Sponsors Meeting Rooms



LEVEL 1 - PROMENADE
Meeting Room: The Pointe

[illegible]

KEEP IN TOUCH!

Visit our brand new website

Follow us on Social Media



Subscribe to our newsletter

SAVE THE DATE

A photograph of the Boston skyline, featuring numerous skyscrapers and buildings along the waterfront, reflected in the water below. The image serves as the background for the top half of the poster.

CTAD

2026

Clinical Trials on Alzheimer's Disease

**November
16-19, 2026
Boston, MA (USA)**

www.ctad-alzheimer.com

Email: ctad@ant-congres.com

JPAD
THE JOURNAL
OF PREVENTION
OF ALZHEIMER'S
DISEASE

